0001607062-17-000161.txt : 20170428 0001607062-17-000161.hdr.sgml : 20170428 20170428161128 ACCESSION NUMBER: 0001607062-17-000161 CONFORMED SUBMISSION TYPE: 10-Q/A PUBLIC DOCUMENT COUNT: 54 CONFORMED PERIOD OF REPORT: 20150630 FILED AS OF DATE: 20170428 DATE AS OF CHANGE: 20170428 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Regen BioPharma Inc CENTRAL INDEX KEY: 0001589150 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 455192997 STATE OF INCORPORATION: NV FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q/A SEC ACT: 1934 Act SEC FILE NUMBER: 333-191725 FILM NUMBER: 17795651 BUSINESS ADDRESS: STREET 1: 4700 SPRING ST #304 CITY: LA MESA STATE: CA ZIP: 91942 BUSINESS PHONE: 619-702-1404 MAIL ADDRESS: STREET 1: 4700 SPRING ST #304 CITY: LA MESA STATE: CA ZIP: 91942 10-Q/A 1 rgbp063015form10qa2.htm FORM 10-Q/A

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q/A

Amendment No. 2

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2015

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

Commission File No. 333-191725

REGEN BIOPHARMA, INC.

(Exact name of small business issuer as specified in its charter)

Nevada		45-5192997
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

4700 Spring Street, St 304, La Mesa, California 91942

(Address of Principal Executive Offices)

619 702 1404

(Issuer’s telephone number)

None

(Former name, address and fiscal year, if changed since last report)

Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “non-accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

☐ Large accelerated filer	☐ Accelerated filer
☐ Non-accelerated filer	☒ Smaller reporting company

APPLICABLE ONLY TO CORPORATE ISSUERS:

As of July 1 , 2015 there were 113,937,338 shares of common stock issued and outstanding.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):

Yes ☐ No ☒

EXPLANATORY NOTE:

THIS AMENDMENT NO.2 TO REGEN BIOPHARMA, INC’S (THE “COMPANY”) FORM 10-Q FOR THE PERIOD ENDED JUNE 30, 2015 (“(“ORIGINAL FILING”) IS BEING FILED SOLELY TO AMEND THE FOLLOWING PORTIONS OF AMENDMENT NO.1 OF THE ORIGINAL FILING (“AMENDMENT NO.1”).

PART 1, ITEM 4

THE COMPANY HAS NOT MODIFIED OR UPDATED DISCLOSURES PRESENTED IN AMENDMENT NO.1 OR THE ORIGINAL FILING, EXCEPT AS INDICATED ABOVE. ACCORDINGLY, THIS AMENDMENT DOES NOT REFLECT EVENTS OCCURRING AFTER THE DATE OF THE ORIGINAL FILING AND DOES NOT MODIFY OR UPDATE THOSE DISCLOSURES AFFECTED BY SUBSEQUENT EVENTS, EXCEPT AS SPECIFICALLY REFERENCED HEREIN. INFORMATION NOT AFFECTED BY THE ABOVE AMENDMENTS IS UNCHANGED AND REFLECTS THE DISCLOSURES MADE AT THE TIME OF THE ORIGINAL FILING.

PART I - FINANCIAL INFORMATION

Item 1. - Financial Statements

REGEN BIOPHARMA , INC.
BALANCE SHEET

	As of			As of
	June 30, 2015			September 30, 2014
	(unaudited)
	restated
ASSETS
CURRENT ASSETS
Cash		208,582			0
Note Receivable		12,051			10,422
Prepaid Expenses		6,289
Accrued Interest Receivable		1,081			233
Total Current Assets		228,003			10,655


TOTAL ASSETS		228,003			10,655

LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Bank Overdraft		0			6,137
Accounts payable		1,190			3,305
Notes Payable		103,751			120,169
Accrued payroll taxes		6,692			8,463
Accrued Interest		18,147			2,212
Accrued Rent		5,000
Accrued Payroll		10,501
Total Current Liabilities		145,281			140,286
Total Liabilities		145,281			140,286

STOCKHOLDERS' EQUITY (DEFICIT)
Common Stock ($.0001 par value) 500,000,000 shares authorized; 113,525,096 issued and outstanding as of June 30, 2015 and 51,907,917 shares issued and outstanding September 30, 2014		11,353			5,191
Preferred Stock, 0.0001 par value, 100,000,000 authorized and Five Million authorized as of June 30, 2015 and September 30, 2014 respectively
Series A Preferred 90,000,000 Authorized and 0 authorized, 60,548,364 and 0 outstanding as of June 30, 2105 and September 30, 2014 respectively		6,055
Series AA Preferred $0.0001 par value 600,000 authorized and 30, 000 and 0 outstanding as of June 30, 2015 and September 30, 2014 respectively		3			0
Additional Paid in capital		2,300,262			485,097
Contributed Capital		728,658			658,658
Retained Earnings (Deficit) accumulated during the development stage		(2,963,609	)		(1,278,577	)
Total Stockholders' Equity (Deficit)		82,722			(129,631	)

TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)		228,003			10,655

The Accompanying Notes are an Integral Part of These Financial Statements

REGEN BIOPHARMA , INC.
STATEMENT OF OPERATIONS


	Three months ended		Three months ended		Nine Months Ended		Nine Months Ended
	June 30, 2015		June 30, 2014		June 30, 2015		June 30, 2014
	(unaudited)		(unaudited)		(unaudited)		(unaudited)
	restated				restated
REVENUES	0		0		0		0

COST AND EXPENSES
Research and Development	68,081		0		93,287		13,867
General and Administrative	463,765		127,580		906,754		389,961
Consulting and Professional Fees	73,364		30,287		413,125		109,917
Rent	16,200		0		43,071		0
Total Costs and Expenses	621,410		157,867		1,456,238		513,745

OPERATING LOSS	(621,410	)	(157,867	)	(1,456,238	)	(513,745	)

OTHER INCOME & (EXPENSES)
Interest Income	297		14		848		14
Refunds of amounts previously paid	0		490		0		490
Interest Expense	(3,512	)	0		(18,742	)	0
Capital contribution to parent	0		(8,658	)	0		(48,510	)
Loss on issuance of common shares for less than fair value	(207,425	)	0		(207,425	)	0
Preferred shares issued pursuant to contractual obligations	(321	)	0		(3,475	)	0

TOTAL OTHER INCOME (EXPENSE)	(210,961	)	(8,154	)	(228,794	)	(48,006	)

NET INCOME (LOSS)	(832,371	)	(166,021	)	(1,685,032	)	(561,751	)
BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE	(0.0075	)	(0.0032	)	(0.0212	)	(0.0152	)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	110,648,054		51,909,907		79,454,728		37,082,956

The Accompanying Notes are an Integral Part of These Financial Statements

REGEN BIOPHARMA , INC.
STATEMENT OF CASH FLOWS
(unaudited)

	Nine Months Ended			Nine Months Ended
	June 30, 2015			June 30, 2014
	restated
CASH FLOWS FROM OPERATING ACTIVITIES

Net Income (loss)	$	(1,685,032	)	$	(561,751	)
Adjustments to reconcile net Income to net cash

Preferred Stock issued for Expenses		100
Preferred Stock issued for interest		891
Common Stock issued for expenses
Preferred Stock issued pursuant to contractual obligations		3,475
Common Stock issued to Consultants		226,177
Preferred Stock issued to Consultants		440
Changes in operating assets and liabilities:
Increase (Decrease) in Accounts Payable		(2,115	)		117
(Increase) Decrease in Notes Receivable		(1,629	)		(2,222	)
(Increase) Decrease in Interest Receivable		(848	)		(14	)
Increase ( Decrease) in Bank Overdraft		(6,137	)
Increase (Decrease) in accrued Expenses		29,665			7,343
Increase in issuance of stock below fair value		207,425
(Increase) Decrease in Prepaid Expenses		(6,289	)
Increase in Additional Paid in Capital		380,191
Net Cash Provided by (Used in) Operating Activities		(853,686	)		(556,527	)
CASH FLOWS FROM FINANCING ACTIVITIES
Common Stock issued for Cash		0			300,000
Increase in Contributed Capital		70,000			140,000
Increase ( Decrease) in Notes Payable		19,582			50,000
Increase in Convertible Notes payable		972,686
Net Cash Provided by (Used in) Financing Activities		1,062,268			490,000

Net Increase (Decrease) in Cash	$	208,582		$	(66,527	)

Cash at Beginning of Period		0			115,922

Cash at End of Period	$	208,582		$	49,395


Supplemental Disclosure of Noncash investing and financing activities:
Common Shares Issued for Debt	$	1,002,686
Preferred Shares issued for Debt	$	6,000

The Accompanying Notes are an Integral Part of These Financial Statements

REGEN BIOPHARMA, INC.

Notes to Financial Statements

As of June 30, 2015

The accompanying unaudited interim condensed consolidated financial statements of Regen Biopharma , Inc. (“Regen” or “the Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the United States Securities and Exchange Commission (“SEC”), and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s annual report filed with the SEC on Form 10-K for the year ended September 30, 2014. In general, interim disclosures do not repeat those contained in the annual statements. In the opinion of management, all adjustments consisting of normal recurring adjustments necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year.

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company was organized April 24, 2012 under the laws of the State of Nevada. The Company is a majority owned subsidiary of Bio-Matrix Scientific Group, Inc, a Delaware corporation.

The Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials

A. BASIS OF ACCOUNTING

The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.

B. USE OF ESTIMATES

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

C. CASH EQUIVALENTS

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

D. PROPERTY AND EQUIPMENT

Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized.

E. FAIR VALUE OF FINANCIAL INSTRUMENTS

Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:

Level 1: Quoted prices in active markets for identical assets or liabilities

Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

F. INCOME TAXES

The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.

The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of June 30, 2015 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.

The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established.

Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

G. BASIC EARNINGS (LOSS) PER SHARE

The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception.

Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.

H. ADVERTISING

Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the three months ended June 30, 2015 and $0 for the three months ended June 30, 2014.

NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS

In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as "Development Stage Entities" (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity's financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard.

The following accounting standards updates were recently issued and have not yet been adopted by us. These standards are currently under review to determine their impact on our consolidated financial position, results of operations, or cash flows.

In May 2014, FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers. The revenue recognition standard affects all entities that have contracts with customers, except for certain items. The new revenue recognition standard eliminates the transaction-and industry-specific revenue recognition guidance under current GAAP and replaces it with a principle-based approach for determining revenue recognition. Public entities are required to adopt the revenue recognition standard for reporting periods beginning after December 15, 2016, and interim and annual reporting periods thereafter. Early adoption is not permitted for public entities. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements.

In June 2014, FASB issued Accounting Standards Update (ASU) No. 2014-12 Compensation — Stock Compensation (Topic 718), Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. A performance target in a share-based payment that affects vesting and that could be achieved after the requisite service period should be accounted for as a performance condition under Accounting Standards Codification (ASC) 718, Compensation — Stock Compensation. As a result, the target is not reflected in the estimation of the award's grant date fair value. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective for annual periods beginning after 15 December 2015 and interim periods within those annual periods. Early adoption is permitted. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements.

In August2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity's liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity's liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity's liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity's ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met the conditions which would subject these financial statements for additional disclosure.

On January 31, 2013, the FASB issued Accounting Standards Update [ASU] 2013-01, entitled Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities. The guidance in ASU 2013-01 amends the requirements in the FASB Accounting Standards Codification [FASB ASC] Topic 210, entitled Balance Sheet. The ASU 2013-01 amendments to FASB ASC 210 clarify that ordinary trade receivables and receivables in general are not within the scope of ASU 2011-11, entitled Disclosure about Offsetting Assets and Liabilities, where that ASU amended the guidance in FASB ASC 210. As those disclosures now are modified with the ASU 2013-01 amendments, the FASB ASC 210 balance sheet offsetting disclosures now clearly are applicable only where reporting entities are involved with bifurcated embedded derivatives, repurchase agreements, reverse repurchase agreements, and securities borrowing and lending transactions that either are offset using the FASB ASC 210 or 815 requirements, or that are subject to enforceable master netting arrangements or similar agreements. ASU 2013-01 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. The adoption of this ASU is not expected to have a material impact on our financial statements.

On February 28, 2013, the FASB issued Accounting Standards Update [ASU] 2013-04, entitled Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date. The ASU 2013-04 amendments add to the guidance in FASB Accounting Standards Codification [FASB ASC] Topic 405, entitled Liabilities and require reporting entities to measure obligations resulting from certain joint and several liability arrangements where the total amount of the obligation is fixed as of the reporting date, as the sum of the following:

The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors.

Any additional amounts the reporting entity expects to pay on behalf of its co-obligors.

While early adoption of the amended guidance is permitted, for public companies, the guidance is required to be implemented in fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments need to be implemented retrospectively to all prior periods presented for obligations resulting from joint and several liability arrangements that exist at the beginning of the year of adoption. The adoption of ASU 2013-04 is not expected to have a material effect on the Company’s operating results or financial position.

On April 22, 2013, the FASB issued Accounting Standards Update [ASU] 2013-07, entitled Liquidation Basis of Accounting. With ASU 2013-07, the FASB amends the guidance in the FASB Accounting Standards Codification [FASB ASC] Topic 205, entitled Presentation of Financial Statements. The amendments serve to clarify when and how reporting entities should apply the liquidation basis of accounting. The guidance is applicable to all reporting entities, whether they are public or private companies or not-for-profit entities. The guidance also provides principles for the recognition of assets and liabilities and disclosures, as well as related financial statement presentation requirements. The requirements in ASU 2013-07 are effective for annual reporting periods beginning after December 15, 2013, and interim reporting periods within those annual periods. Reporting entities are required to apply the requirements in ASU 2013-07 prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of ASU 2013-07 is not expected to have a material effect on the Company’s operating results or financial position.

A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, the Company’s management has not determined whether implementation of such standards would be material to its financial statements.

NOTE 3. GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $ 2,963,609 during the period from April 24, 2012 (inception) through June 30, 2015. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Management plans to raise additional funds by offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise. During the quarter ended March 31, 2015 the Company raised $775,000 through the issuance of convertible debt and during the quarter ended June 30, 2015 the Company raised $90,000 through the issuance of convertible debt ( Note 4).

NOTE 4. NOTES PAYABLE AND CONVERTIBLE NOTES PAYABLE

	June 30, 2015		September 30, 2014
Bio Matrix Scientific Group, Inc. (Note 7)		19,701		90,000
David Koos ( Notes7)		50		30,168
Bio Technology Partners Business Trust		84,000		0
Notes payable	$	103,751	$	120,168

$19,701 lent to the Company by Bio Matrix Scientific Group, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.

$50 lent to the Company by David Koos. is due and payable at the demand of the holder and bear simple interest at a rate of 15% per annum.

$84,000 lent to the Company by Bio Technology Partners Business Trust. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.

CONVERTIBLE NOTES PAYABLE

During the quarter ended March 31, 2015 the Company issued Convertible Notes ( “Notes”) with an aggregate face value of $882,686 . Consideration for these Notes consisted of:

(a)

$775,000 cash and

(b)

Satisfaction of $107,686 of existing indebtedness:

Each Note becomes due and payable at the demand of the Lender at any time after one year subsequent to the issuance date and bears simple interest at 10% per annum payable quarterly at the demand of the Lender.

All or part of the principal and accrued but unpaid interest is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to a 65% discount to the lowest Trading Price (as defined below) for the Common Shares during the thirty (30) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the conversion date. “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by Regen and the Lender. “Trading Day” shall mean any day on which the Common Shares are tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Shares are then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by Regen relating to the Lender’s securities. Principal and interest may be prepaid in part or in full by Regen on not less than three Trading Days prior written notice to the Lender.

Upon expiration of the six month holding specified in Rule 144(d) promulgated under the Securities Act of 1933, Regen , at the request of the Lender, shale remove sale restrictions on one sixth (1/6) of the shares that resulted from conversions made through the issuance of this Note , each month, for a period of six months, with all restrictions being removed by the Company by the expiration of the six month subsequent to expiration of the aforementioned Rule 144 holding period.

If the Lender converts principal into Common Stock of Regen on or prior to 180 days from the issuance of the Note the Lender shall receive one share of Preferred Series “A” Stock of the Company for each share of Common Stock received through conversion.

All Notes were fully converted during the quarter ended March 31, 2015. 31,539,262 common shares of Regen were issued to the Convertible Noteholders in satisfaction of the convertible indebtedness. 31,538,862 of the Company’s Series A Preferred shares were issued to Noteholders pursuant to the terms and conditions of the Notes.

The Company analyzed the conversion feature of the Notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change.

The Company values the embedded derivative using the Black-Scholes pricing model and an aggregate derivative liability of $2,368,685 was recognized by the Company. This liability was eliminated prior to the end of the Company’s second quarter as a result of the full conversion of all Notes prior to the end of the Company’s second quarter.

During the quarter ended June 30, 2015 the Company issued Convertible Notes ( “Notes”) with an aggregate face value of $90,000 . Consideration for these Notes consisted of $90,000.

All or part of the principal and accrued but unpaid interest is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent the lower of (1) a 65% discount to the lowest Trading Price (as defined below) for the Common Shares during the thirty (30) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the conversion date. “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by Regen and the Lender. “Trading Day” shall mean any day on which the Common Shares are tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Shares are then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by Regen relating to the Lender’s securities.

(2) $0.03 per share

Principal and interest may be prepaid in part or in full by Regen on not less than three Trading Days prior written notice to the Lender.

During the quarter ended June 30, 2015 the Company issued 3,214,285 of its common shares in satisfaction of the abovementioned convertible notes and 3,214,285 shares of its Series A Preferred stock in accordance with the terms and conditions of abovementioned convertible notes. ..

The Company values the embedded derivative using the Black-Scholes pricing model and an aggregate derivative liability of $350,666 was recognized by the Company in connection with $90,000 of convertible notes payable issued during the quarter ended June 30, 2015. This liability was eliminated prior to the end of the Company’s third quarter as a result of the full conversion of these convertible noted prior to the end of the Company’s third quarter.

NOTE 5. NOTES RECEIVABLE

	June 30, 2015		September 30, 2014
Entest Biomedical, Inc. (Note 7)	$	12,051	$	10,422

Notes Receivable	$	12,051	$	10,422

$12,051 lent by the Company to Entest Biomedical, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.

NOTE 6. INCOME TAXES

As of June 30, 2015

Deferred tax assets:
Net operating tax carry forwards	$	1,007,627
Other		-0-
Gross deferred tax assets		1,007,627
Valuation allowance		(1,007,627	)
Net deferred tax assets	$	-0-

As of June 30, 2015 the Company has a Deferred Tax Asset of $1,007,627 completely attributable to net operating loss carry forwards of approximately $2,963,609 (which expire 20 years from the date the loss was incurred).

Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry forwards are expected to be available to reduce taxable income. The achievement of required future taxable income is uncertain. As a result, the Company has the Company recorded a valuation allowance reducing all deferred tax assets to 0.

Income tax is calculated at the 34% Federal Corporate Rate.

NOTE 7. RELATED PARTY TRANSACTIONS

As of June 30, 2015 the Company has received capital contributions from Bio Matrix Scientific Group, Inc (“BMSN”) , a corporation under common control with the Company and which possesses the majority of the voting power of the shares outstanding of the company, totaling $728,658 and has issued 50,010,000 common shares to BMSN for aggregate consideration of $20,090. The Company also utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 subleased to the Company by Entest BioMedical, Inc. on a month to month basis beginning October 1, 2014. The Chief Executive Officer of Entest Biomedical Inc. is David R. Koos who also serves as the Chief Executive Officer of the Company’s parent and the Company. The sublease is on a month to month basis and rent payable to Entest Biomedical, Inc. by Regen Biopharma Inc is equal to $5,000 per month.

As of June 30, 2015 Entest Biomedical Inc. is indebted to the Company in the amount of $12,051. $12,051 lent by the Company to Entest Biomedical, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.

As of June 30, 2015 the Company is indebted to BMSN in the amount of $19,701. $19,701 lent to the Company by Bio Matrix Scientific Group, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.

As of June 30, 2015 the Company is indebted to David R. Koos in the amount of $50. $50 lent to the Company by Koos is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.

NOTE 8. COMMITMENTS AND CONTINGENCIES

The Company utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 subleased to the Company by Entest BioMedical, Inc. on a month to month basis beginning October 1, 2014. The Chief Executive Officer of Entest Biomedical Inc. is David R. Koos who also serves as the Chief Executive Officer of the Company’s parent and the Company. The sublease is on a month to month basis and rent payable to Entest Biomedical, Inc. by Regen Biopharma Inc is equal to $5,000 per month.

On March 20, 2015 Regen Biopharma, Inc. agreed to sublease 199 square feet of laboratory space located at 5310 Eastgate Mall, San Diego, CA 92121 from Human BioMolecular Research Institute (“Sublease Agreement”). Pursuant to the terms of the Sublease Agreement Regen Biopharma, Inc. will pay rent of $400 per month to Human BioMolecular Research Institute (“HBRI”) . The term of the sublease shall be from March 9, 2015 to September 8, 2015 (a period of 6 months) and will automatically renew thereafter for the same 6 month term unless written notice is received by HBRI within 60 days prior to renewal. On June 1, 2015 Regen Biopharma, Inc. terminated its sublease with Human BioMolecular Research Institute

On March 20, 2015 Regen Biopharma, Inc entered into a Research Agreement with HBRI wherein HBRI agreed to provide a variety of professional, scientific and technical services for the proper conduct of research by Regen Biopharma, Inc. and also to make available certain research equipment to Regen Biopharma, Inc. The term of the agreement shall be from March 9, 2015 to September 8, 2015 (a period of 6 months) and will automatically renew thereafter for the same 6 month term unless written notice is received by HBRI within 60 days prior to renewal. As consideration Regen Biopharma, Inc shall pay a monthly fee of $2,700 to HBRI over the term of the agreement. On June 1, 2015 Regen Biopharma, Inc. terminated the aforementioned agreement with Human BioMolecular Research Institute

NOTE 9. STOCKHOLDERS' EQUITY

The stockholders' equity section of the Company contains the following classes of capital stock as June 30, 2015:

Common stock, $ 0.0001 par value; 500,000,000 shares authorized: 113,525,096 shares issued and outstanding.

With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1).

On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation.

Preferred Stock, $0.0001 par value, 100,000,000 shares authorized of which 600,000 is designated as Series AA Preferred Stock: 30,000 shares issued and outstanding as of June 30, 2015 and 90,000,000 is designated Series A Preferred Stock of which 60,548,364 shares are outstanding as of June 30, 2015.

The abovementioned shares authorized pursuant to the Company’s certificate of incorporation may be issued from time to time without prior approval of the shareholders. The Board of Directors of the Company shall have the full authority permitted by law to establish one or more series and the number of shares constituting each such series and to fix by resolution full or limited, multiple or fractional, or no voting rights, and such designations, preferences, qualifications, restrictions, options, conversion rights and other special or relative rights of any series of the Stock that may be desired.

Series AA Preferred Stock

On September 15, 2014 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series AA Preferred Stock” (hereinafter referred to as “Series AA Preferred Stock”).

The Board of Directors of the Company have authorized 600,000 shares of the Series AA Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times ten thousand (10,000). Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series AA Preferred Stock shall vote as a single class on all matters submitted to the stockholders.

Series A Preferred Stock

On January 15, 2015 the Company filed a CERTIFICATE OF DESIGNATION ("Certificate of Designations") with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as "Series A Preferred Stock" (hereinafter referred to as "Series A Preferred Stock").

The Board of Directors of the Company have authorized 90,000,000 shares of the Series A Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series A Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series A Preferred Stock owned by such holder times one . Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series A Preferred Stock shall vote as a single class on all matters submitted to the stockholders.

Holders of the Series A Preferred Stock will be entitled to receive, when, as and if declared by the board of directors of the Company (the “Board”) out of funds legally available therefore, non-cumulative cash dividends of $0.01 per quarter. In the event any dividends are declared or paid or any other distribution is made on or with respect to the Common Stock , the holders of Series A Preferred Stock as of the record date established by the Board for such dividend or distribution on the

Common Stock shall be entitled to receive, as additional dividends (the “Additional Dividends”) an amount (whether in the form of cash, securities or other property) equal to the amount (and in the form) of the dividends or distribution that such holder would have received had each share of the Series A Preferred Stock been one share of the Common Stock, such Additional Dividends to be payable on the same payment date as the payment date for the Common Stock.

Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (collectively, a “Liquidation”), before any distribution or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series A Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal to $0.01 per share of Series A Preferred (the “Liquidation Amount”) plus all declared and unpaid dividends thereon, for each share of Series A Preferred held by them.

If, upon any Liquidation, the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full to all holders of Series A Preferred, then the entire net assets of the Company shall be distributed among the holders of the Series A Preferred, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions may be made in cash or in property taken at its fair value (as determined in good faith by the Board), or both, at the election of the Board.

NOTE 10. STOCK TRANSACTIONS

Common Stock

On April 14, 2015 the Company issued 1,428, 571 of its common shares in satisfaction of $40,000 of convertible indebtedness.

On May 12, 2015 the Company issued 500,000 of its common shares in satisfaction of $15,000 of indebtedness.

On May 18, 2015 the Company issued 500,000 of its common shares in satisfaction of $15,000 of indebtedness.

On May 19, 2015 the Company issued 1,785,714 of its common shares in satisfaction of $50,000 of convertible indebtedness.

Series A Preferred Stock

On April 14, 2015 the Company issued 1,428, 571 of its shares of Series A Preferred Stock in accordance with the terms and conditions of a $40,000 face value convertible note issued by the Company.

On May 19, 2015 the Company issued 200,000 of its shares of Series A Preferred Stock as consideration for services rendered by nonemployees.

On May 19, 2015 the Company issued 1,785,714 of its shares of Series A Preferred Stock in accordance with the terms and conditions of a $50,000 face value convertible note issued by the Company.

NOTE 11. RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS

Subsequent to the original issuance of Regen’s quarterly financial statements for the three month period ended June 30, 2015 the Company determined that $730,000 of expenses recognized during the quarter ended June 30, 2015 resulting from the issuance for less than fair value of common shares in satisfactions of convertible notes issued by the Company should not have been recognized.

The following tables reflect the corrections:

REGEN BIOPHARMA , INC.
BALANCE SHEET

	As of			adjustments			As of
	June 30, 2015						June 30, 2015
	(unaudited)						(unaudited)
							restated
ASSETS
CURRENT ASSETS
Cash		208,582						208,582
Note Receivable		12,051						12,051
Prepaid Expenses		6,289						6,289
Accrued Interest Receivable		1,081						1,081
Total Current Assets		228,003						228,003


TOTAL ASSETS		228,003						228,003

LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable		1,190						1,190
Notes Payable		103,751						103,751
Accrued payroll taxes		6,692						6,692
Accrued Interest		18,147						18,147
Accrued Rent		5,000						5,000
Accrued Payroll		10,501						10,501
Total Current Liabilities		145,281						145,281
Total Liabilities		145,281						145,281

STOCKHOLDERS' EQUITY (DEFICIT)
Common Stock ($.0001 par value) 500,000,000 shares authorized; 113,525,096 issued and outstanding as of June 30, 2015 and 51,907,917 shares issued and outstanding September 30, 2014		11,353						11,353
Preferred Stock, 0.0001 par value, 100,000,000 authorized and Five Million authorized as of June 30, 2015 and September 30, 2014 respectively
Series A Preferred 90,000,000 Authorized and 0 authorized, 60,548,364 and 0 outstanding as of June 30, 2105 and September 30, 2014 respectively		6,055						6,055
Series AA Preferred $0.0001 par value 600,000 authorized and 30, 000 and 0 outstanding as of June 30, 2015 and September 30, 2014 respectively		3						3
Additional Paid in capital		11,209,694			(8,909,432	)		2,300,262
Contributed Capital		728,658						728,658
Retained Earnings (Deficit) accumulated during the development stage		(11,873,041	)		8,909,432			(2,963,609	)
Total Stockholders' Equity (Deficit)		82,722						82,722

TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)		228,003						228,003

REGEN BIOPHARMA , INC.
STATEMENT OF OPERATIONS

	Three months ended		adjustments	Three months ended		Nine Months Ended		adjustments	Nine Months Ended
	June 30, 2015			June 30, 2015		June 30, 2015			June 30, 2015
	(unaudited)			(unaudited)		(unaudited)			(unaudited)
				(as restated)					(as restated)
REVENUES	0			0		0			0

COST AND EXPENSES
Research and Development	68,081			68,081		93,287			93,287
General and Administrative	463,765			463,765		906,754			906,754
Consulting and Professional Fees	73,364			73,364		413,125			413,125
Rent	16,200			16,200		43,071			43,071
Total Costs and Expenses	621,410			621,410		1,456,238			1,456,238

OPERATING LOSS	(621,410	)		(621,410	)	(1,456,238	)		(1,456,238	)

OTHER INCOME & (EXPENSES)
Interest Income	297			297		848			848
Refunds of amounts previously paid
Interest Expense	(3,512	)		(3,512	)	(18,742	)		(18,742	)
Capital contribution tp parent	0			0		0			0
Loss on issuance of common shares for
less than fair value	(937,425	)	730,000	(207,425	)	(9,116,857	)	8,909,432	(207,425	)
Preferred shares issued pursuant to
contractual obligations	(321	)		(321	)	(3,475	)		(3,475	)

TOTAL OTHER INCOME (EXPENSE)	(940,961	)		(210,961	)	(9,138,226	)		(228,794	)

NET INCOME (LOSS)	(1,562,371	)		(832,371	)	(10,594,463	)		(1,685,032	)
BASIC AND FULLY DILUTED
EARNINGS (LOSS) PER SHARE	(0.0141	)		(0.0075	)	(0.1333	)		(0.0212	)
WEIGHTED AVERAGE NUMBER OF COMMON	110,648,054			110,648,054		79,454,728			79,454,728
SHARES OUTSTANDING


REGEN BIOPHARMA , INC.
STATEMENT OF CASH FLOWS
(unaudited)

	Nine Months Ended			Adjustments			Nine Months Ended
	June 30, 2015						June 30, 2015
							Restated
CASH FLOWS FROM OPERATING ACTIVITIES

Net Income (loss)	$	(10,594,463	)		8,909,432			(1,685,032	)
Adjustments to reconcile net Income to net cash

Preferred Stock issued for Expenses	$	100						100
Predrred Stock issued for interest	$	891						891
Common Stock issued for expenses
Preferred Stock issued pursuant to contractual obligations	$	3,475						3,475
Common Stock issued to Consultants	$	226,177						226,177
Preferred Stock issued to Consultants	$	440						440
Changes in operating assets and liabilities:
Increase (Decrease) in Accounts Payable	$	(2,115	)					(2,115	)
(Increase) Decrease in Notes Receivable	$	(1,629	)					(1,629	)
(Increase) Decrease in Interest Receivable	$	(848	)					(848	)
Increase ( Decrease) in Bank Overdraft	$	(6,137	)					(6,137	)
Increase (Decrease) in accrued Expenses	$	29,665						29,665
(Increase) Decrease in Prepaid Expenses	$	(6,289	)					(6,289	)
Increase in issuance of stock below fair value	$	9,116,857			(8,909,432	)		207,425
Increase in Additional Paid in Capital	$	380,191						380,191
Net Cash Provided by (Used in) Operating Acitivities	$	(853,686	)					(853,685	)
CASH FLOWS FROM FINANCING ACTIVITIES
Common Stock issued for Cash		0						0
Increase in Contributed Capital		70,000						70,000
Increase ( Decrease) in Notes Payable		19,582						19,582
Increase in Convertible Notes payable		972,686						972,686
Net Cash Provided by (Used in) Financing Activities		1,062,268						1,062,268

Net Increase (Decrease) in Cash	$	208,582						208,583

Cash at Beginning of Period		0						0

Cash at End of Period	$	208,582						208,583


Supplemental Disclosure of Noncash investing and financing activities:
Common Shares Issued for Debt	$	1,002,686
Preferred Shares issued for Debt	$	6,000

The Accompanying Notes are an Integral Part of These Financial Statements

NOTE 12. SUBSEQUENT EVENTS

On July 1, 2015 the Company issued 412,242 of its shares of common stock as consideration for services rendered by a nonemployee.

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

CERTAIN FORWARD-LOOKING INFORMATION

Information provided in this Quarterly report on Form 10Q may contain forward-looking statements within the meaning of Section 21E or Securities Exchange Act of 1934 that are not historical facts and information. These statements represent the Company's expectations or beliefs, including, but not limited to, statements concerning future and operating results, statements concerning industry performance, the Company's operations, economic performance, financial conditions, margins and growth in sales of the Company's products, capital expenditures, financing needs, as well assumptions related to the forgoing. For this purpose, any statements contained in this Quarterly Report that are not statement of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based on current expectations and involve various risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. The Company's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by the Company with the Securities and Exchange Commission. All references to” We”, “Us”, “Company” or the “Company” refer to Regen BioPharma, Inc.

Material Changes in Financial Condition

As of June 30, 2015, we had Cash on Hand of $ 208,582 and as of September 30, 2014 we had Cash on Hand of $0.

The increase in Cash on Hand of 100 % is primarily attributable to :

(a)

$25, 650 lent to the Company by David Koos, the Company’s Chief Executive Officer, during the six months ended March 31, 2015

(b)

$164, 000 lent to the Company by Bio Technology Partners Business Trust during the six months ended March 31, 2015

(c)

$775,000 paid to the Company as a result of issuance of convertible notes during the six months ended March 31, 2015

(d) $90,000 paid to the Company as a result of issuance of convertible notes during the three months ended June 30, 2015

Offset by $60,425 of debt repaid to the Company’s parent, Bio Matrix Scientific Group, Inc. and funds expended in the operation of the Company’s business during the six months ended March 31, 2015.

As of June 30, 2015 we had Prepaid Expenses of $6,289 and as of September 30, 2014 we had Prepaid Expenses of $0.

The increase in Prepaid Expenses is attributable to:

$5,000 in salary prepaid to the company’s Chief Scientific Officer

$1,289 prepaid to an employee of the Company

As of June 30, 2015, we had Notes Receivable of $ 12,051 and as of September 30, 2014 we had Notes Receivable of $10,422 .

The increase in Notes Receivable of approximately 16 % is attributable to overpayment of $1,629 of rental charges to Entest Biomedical, Inc. by the Company which the parties have agreed shall be due and payable to the Company by Entest Biomedical, Inc and which shall bear simple interest at 10% per annum.

As of June 30, 2015 we had Accrued Interest Receivable of $1,081 and as of September 30, 2014 we had Accrued Interest Receivable of $233.

The increase in of Accrued Interest Receivable of approximately 364% is attributable to interest accrued but unpaid during the nine months ended June 30 , 2015 resulting from amounts due to the Company by Entest Bio-Medical, Inc.

As of June 30, 2015 we had Bank Overdraft of $0 and as of September 30, 2014 we had Bank Overdraft of $6,137.

The decrease in Bank Overdraft of 100% is attributable to loans made to the Company during the quarter ended December 31, 2014.

As of June 30, 2015 we had Accounts Payable of $1,190 and as of September 30, 2014 we had Accounts payable of $3,305.

The decrease in Accounts Payable of approximately 64% is primarily attributable to the payment of outstanding obligations of the Company in the course of business.

As of June 30,2015 we had Notes Payable of $103,751 and as of September 30, 2014 we had Notes Payable of $120,169.

The increase in Notes Payable of approximately 14% is attributable to:

(a)

$25, 650 lent to the Company by the Company’s Chief Executive Officer during the six months ended March 31, 2015

(b)

$164,000 lent to the Company by a third party lender during the quarter ended December 31, 2014.

(c)

$8,500 of company expenses paid by Bio Matrix Scientific Group, Inc. on the Company’s behalf during the quarter ended December 31, 2014.

Offset by:

(a)

$48,051 of principal debt repaid in cash to Bio Matrix Scientific Group, Inc. during the six months ended March 31, 2015

(a)

$6,000 of principal debt owed to Bio Matrix Scientific Group, Inc satisfied through the issuance of the Company’s Series AA Preferred stock

	(c)	$105,768 of principal indebtedness satisfied through the issuance of convertible notes to the creditors.

	(d)	$30,000 of principal indebtedness satisfied through the issuance of common shares.

As of June 30, 2105 we had Accrued Payroll Taxes of $6,692 and as of September 30, 2014 we had Accrued Payroll Taxes of $8,463.

The decrease in Accrued Payroll Taxes of approximately 20% is attributable to payment by the Company of employer tax obligations incurred in prior periods.

As of June 30, 2105 we had Accrued Interest of $18,147 and as of September 30, 2014 we had Accrued Interest of $2,212.

The increase in Accrued Interest of approximately 720% is attributable to interest expense on Notes Payable and Convertible Notes Payable incurred during the six months ended March 31 , 2015 but not yet paid offset by $1,918 of accrued interest owed to the company’s Chief Executive Officer satisfied by the issuance of a convertible note to the Officer as well as $890 of accrued interest on convertible notes satisfied through the issuance of common stock.

As of June 30, 2105 we had Accrued Rent of $5,000 and as of September 30, 2014 we had Accrued Rent of $0.

The increase in Accrued Rent is attributable to rental expense incurred but not paid for the month of June 2015.

As of June 30, 2015 we had Accrued Salaries of $10,501 and as of September 30, 2014 we had Accrued Salaries of $0.

The increase is attributable to $6,750 of salary accrued during the quarter ended March 31, 2015 but not yet paid due to the Company’s Chief Financial Officer and $3,751 of salary accrued during the nine months ended June 30, 2015 but not yet paid due to an employee.

Material Changes in Results of Operations

Revenues from operations were $0 for the three months ended June 30, 2015 and -0- for the three months ended June 30 , 2014. Net Losses were $832,371 for the three months ended June 30, 2015 and $166,021 for the same period ended 2014.

The increase in Net Losses of approximately 401% is primarily attributable to the recognition of $16,000 of rental expenses during the quarter ended June 30, 2015, the recognition of $3,512 of interest expense during the quarter ended June 30, 2015, as well as an increase in expenses related to General and Administrative, Research and Development, and consulting and professional Fees incurred during the quarter ended June 30, 2015 as compared to the same quarter ended 2014.

Revenues from operations were $0 for the nine months ended June 30, 2015 and -0- for the nine months ended June 30, 2014. Net Losses were $1,685,032 for the nine months ended June 30, 2015 and $561,471 for the same period ended 2014.

The increase in Net Losses of approximately 200% is primarily attributable to increases in expenses attributable to Research and Development , General and Administrative, Consulting, and Rents recognized incurred during the nine months ended June 30, 2015 as compared to the same period ended 2014.

Liquidity and Capital Resources

As of June 30, 2015 we had $208,582 cash on hand and current liabilities of $145,281 such liabilities consisting of Accounts Payable, Notes Payable and Accrued Expenses. We feel we will not be able to satisfy our cash requirements over the next twelve months and shall be required to seek additional financing.

The Company plans to meet cash needs through applying for governmental and non-governmental grants as well as selling its securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the

Company will raise. There is no guarantee that the Company will be able to raise any capital through any type of offerings. Management can give no assurance that any governmental or non-governmental grant will be obtained by the Company despite the Company’s best efforts. As of February 19, 2014 The Company has identified the National Heart Lung and Blood Institute Clinical Trial Pilot Studies (R34) grant which provides up to $450,000 in funding over a period of three years as well as the Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications administered by the Small Business Innovation Research (SBIR) program of the National Institute of Health as grants for which the Company intends to apply.

We cannot assure that we will be successful in obtaining additional financing necessary to implement our business plan. We have not received any commitment or expression of interest from any financing source that has given us any assurance that we will obtain the amount of additional financing in the future that we currently anticipate. For these and other reasons, we are not able to assure that we will obtain any additional financing or, if we are successful, that we can obtain any such financing on terms that may be reasonable in light of our current circumstances. Management plans to raise additional funds by offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise. During the nine months ended June 30, 2015 the Company raised $865,000 through the issuance of convertible debt. All principal convertible debt issued by the Company has been converted into equity as of June 30, 2015.

As of June 30, 2015 the Company was not party to any binding agreements which would commit Regen to any material capital expenditures.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company, as defined by Rule 229.10(f) (1) of Regulation S-K, we are not required to provide the information required by this Item. We have chosen to disclose, however, that we have not engaged in any transactions, issued or bought any financial instruments or entered into any contracts that are required to be disclosed in response to this item.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, the Company carried out an evaluation, under the supervision and with the participation of David Koos, who is the Company's Principal Executive Officer and Todd S. Caven who is the Company’s Chief Financial Officer and Principal Financial Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures. The Company's disclosure controls and procedures are designed to provide a reasonable level of assurance of achieving the Company's disclosure control objectives. The Company's Principal Executive Officer and Principal Financial Officer have concluded that the Company's disclosure controls and procedures are not effective at this reasonable assurance level as of the period covered solely because of the material weakness in our internal control over financial reporting described below.

The Company’s internal control over financial reporting is a process designed under the supervision of the Company’s management to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company’s financial statements for external purposes in accordance with U.S. generally accepted accounting principles.

In designing and evaluating our disclosure controls and procedures, our management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only a reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met.

The Company’s management assessed the effectiveness of its internal control over financial reporting as of June 30, 2015 based on the framework in 2013 Committee of Sponsoring Organizations of the Treadway Commission, or COSO, framework. Based on its assessment, management believes that, as of June 30, 2015, the Company’s internal control over financial reporting is not effective.

Management identified a material weakness in internal control over financial reporting as of June 30, 2015. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

We did not design and maintain effective internal control over the accounting for issuances of equity securities of the Company for cash consideration and issuances of equity securities of the Company for conversion of convertible securities. This control deficiency resulted in the improper recognition of $730,000 of expenses recognized during the quarter ended June 30, 2015 resulting from the issuance for less than fair value of common shares in satisfactions of convertible notes issued by the Company which should not have been recognized ( See Note 11 of Notes to Financial Statements.)

Remediation

Plan for Material Weakness in Internal Control over Financial Reporting

The Company’s management has begun to design and implement certain remediation measures to address the above-described material weakness and enhance the Company’s internal control over financial reporting. We will take the following actions to improve the design and operating effectiveness of our internal control in order to remediate this material weakness:

Institute an additional review of any and all issuances of capital stock to ensure the event is recognized in accordance with United States GAAP.

Management's report was not subject to attestation by the Company's registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit the company to provide only management's report in this annual report. This exemption for smaller reporting companies provided under the temporary rules referenced above has been made permanent under Section 989G of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

Changes in Internal Controls over Financial Reporting

In connection with the evaluation of the Company's internal controls during the period commencing on April 1, 2015 and ending on June 30, 2015, David Koos and Todd S. Caven , who serve as the Company's Principal Executive Officer and Principal Financial Officer respectively, have determined that, other than as described above, there were no changes to the Company's internal controls over financial reporting that have been materially affected, or is reasonably likely to materially effect, the Company's internal controls over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

There are no material pending legal proceedings to which the Company is a party or of which any of the Company’s property is the subject.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

CONVERTIBLE NOTES

On April 6, 2015 Regen issued a $40,000 face value Convertible Promissory Note ( “Note”) to joint individual investors (“Lender”) for consideration of $40,000. The Note becomes due and payable at the demand of the Lender at any time after March 6, 2016 and bears simple interest at 10% per annum payable quarterly at the demand of the Lender.

All or part of the principal and accrued but unpaid interest is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent the lower of (1) a 65% discount to the lowest Trading Price (as defined below) for the Common Shares during the thirty (30) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the conversion date. “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by Regen and the Lender. “Trading Day” shall mean any day on which the Common Shares are tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Shares are then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by Regen relating to the Lender’s securities.

(2) $0.03 per share

Principal and interest may be prepaid in part or in full by Regen on not less than three Trading Days prior written notice to the Lender.

The Note was issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended (the “Act”). No underwriters were retained to serve as placement agents for the sale. The Note was sold directly through our management. No commission or other consideration was paid in connection with the sale of the Note. There was no advertisement or general solicitation made in connection with this Offer and Sale of the Note. A legend was placed on the Note stating that the Note has not been registered under the Act and setting forth or referring to the restrictions on transferability and sale of the Note. Cash proceeds received from the Note will be utilized by Regen for general corporate purposes. On April 14, 2015 1,428,571 Common Shares of Regen were issued in satisfaction of the abovementioned convertible note. On April 14, 2015 the Company issued 1,428,571 shares of its Series A Preferred Stock in accordance with the terms and conditions of abovementioned convertible note

On May 18, 2015 Regen issued a $50,000 face value Convertible Promissory Note ( “Note”) to an individual investor (“Lender”) for consideration of $50,000. The Note becomes due and payable at the demand of the Lender at any time after May 7, 2016 and bears simple interest at 10% per annum payable quarterly at the demand of the Lender.

All or part of the principal and accrued but unpaid interest is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent the lower of (1) a 65% discount to the lowest Trading Price (as defined below) for the Common Shares during the thirty (30) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the conversion date. “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by Regen and the Lender. “Trading Day” shall mean any day on which the Common Shares are tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Shares are then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by Regen relating to the Lender’s securities.

(2) $0.03 per share

Principal and interest may be prepaid in part or in full by Regen on not less than three Trading Days prior written notice to the Lender.

The Note was issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended (the “Act”). No underwriters were retained to serve as placement agents for the sale. The Note was sold directly through our management. No commission or other consideration was paid in connection with the sale of the Note. There was no advertisement or general solicitation made in connection with this Offer and Sale of the Note. A legend was placed on the Note stating that the Note has not been registered under the Act and setting forth or referring to the restrictions on transferability and sale of the Note. Cash proceeds received from the Note will be utilized by Regen for general corporate purposes. On May 19, 2015 1,785,714 Common Shares of Regen were issued in satisfaction of the abovementioned convertible note. On May 19, 2015 the Company issued 1,785,714 shares of its Series A Preferred Stock in accordance with the terms and conditions of abovementioned convertible note

COMMON SHARES

On April 14, 2015 the Company issued 1,428, 571 of its common shares (“Shares”) in satisfaction of $40,000 of convertible indebtedness.

The Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended (the “Act”). No underwriters were retained to serve as placement agents for the sale. The shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares. A legend was placed on the certificate that evidences the Shares stating that the Shares have not been registered under the Act and setting forth or referring to the restrictions on transferability and sale of the Shares.

On May 12, 2015 the Company issued 500,000 of its common shares (“Shares”) in satisfaction of $15,000 of indebtedness.

On May 18, 2015 the Company issued 500,000 of its common shares (“Shares”) in satisfaction of $15,000 of indebtedness.

On May 19, 2015 the Company issued 1,785,714 of its common shares (“Shares”) in satisfaction of $50,000 of convertible indebtedness.

On July 1, 2015 the company issued 206,121 common shares ( “Shares”) to a consultant for services.

Series A Preferred Stock:

On April 14, 2015 the Company issued 1,428, 571 of its shares of Series A Preferred Stock (“Shares”) in accordance with the terms and conditions of a $40,000 face value convertible note issued by the Company.

On May 19, 2015 the Company issued 200,000 of its shares of Series A Preferred Stock (“Shares”) as consideration for services rendered by nonemployees.

On May 19, 2015 the Company issued 1,785,714 of its shares of Series A Preferred Stock (“Shares”) in accordance with the terms and conditions of a $50,000 face value convertible note issued by the Company.

Item 3. DEFAULTS UPON SENIOR SECURITIES

None.

Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.

Item 5. OTHER INFORMATION

None

Item 6. EXHIBITS

31.1 Certification of Chief Executive Officer

31.2 Certification of Acting Chief Financial Officer

32.1 Certification of Chief Executive Officer under Section 906 of the Sarbanes-Oxley Act of 2002.

32.2 Certification of Acting Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002.

10.1 Form of Convertible Note (c)

10.2 AGREEMENT BY AND BETWEEN REGEN BIOPHARMA, INC. AND ZANDER THERAPEUTICS, INC. (a)

10.3 AGREEMENT BY AND BETWEEN REGEN BIOPHARMA, INC. AND SANTOSH KESARI (b)

	(a)	Incorporated by reference to Exhibit 10.1 of that Form 8-K filed by the Company dated June 25, 2015
	(b)	Incorporated by reference to Exhibit 10.1 of that Form 8-K filed by the Company dated June 10, 2015
	(c)	Filed previously as Exhibit 10.1 with the Company’s Form 10-Q for the period ended June 30, 2015

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Regen Biopharma, Inc.

Dated: 04/28/2017	By: /s/ David Koos
	David Koos
	Chief Executive Officer


Dated: 04/28/2017	By: /s/ Todd S. Caven
	Todd S. Caven
	Chief Financial Officer

EX-31.1 2 ex31_1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David Koos, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Regen BioPharma, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: 04/28/2017	By:	/s/ David R. Koos
		David R. Koos Chief Executive Officer

EX-31.2 3 ex31_2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION OF ACTING CHIEF FINANCIAL OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Todd S. Caven, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Regen BioPharma, Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: 04/28/2017	By:	/s/ Todd S. Caven
		Todd S. Caven Acting Chief Financial Officer

EX-32.1 4 ex32_1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly report of Regen BioPharma, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: 04/28/2017	By:	/s/ David R. Koos
		David R. Koos Chief Executive Officer

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002, or other document authentications, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Regen BioPharma, Inc. and will be retained by Regen BioPharma, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 ex32_2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly report of Regen BioPharma, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to her knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: 04/28/2017	By:	/s/ Todd S. Caven
		Todd S. Caven Acting Chief Financial Officer

EX-101.INS 6 rgbp-20150630.xml XBRL INSTANCE FILE 0001589150 2014-10-01 2015-06-30 0001589150 2015-06-30 0001589150 2014-09-30 0001589150 2015-04-01 2015-06-30 0001589150 2014-04-01 2014-06-30 0001589150 2013-10-01 2014-06-30 0001589150 2013-09-30 0001589150 2014-06-30 0001589150 2012-04-24 2015-06-30 0001589150 2012-07-21 2015-06-30 0001589150 2015-03-20 0001589150 2015-07-01 0001589150 us-gaap:SeriesAPreferredStockMember us-gaap:ScenarioActualMember 2015-06-30 0001589150 us-gaap:SeriesAPreferredStockMember 2014-09-30 0001589150 RGBP:SeriesAAPreferredStockMember us-gaap:ScenarioActualMember 2015-06-30 0001589150 RGBP:SeriesAAPreferredStockMember 2014-09-30 0001589150 2015-01-01 2015-03-31 0001589150 RGBP:BioMatrixScientificGroupMember 2015-04-01 2015-06-30 0001589150 RGBP:BioMatrixScientificGroupMember 2015-06-30 0001589150 RGBP:DavidKoosMember 2015-04-01 2015-06-30 0001589150 RGBP:DavidKoosMember 2015-06-30 0001589150 RGBP:BioTechnologyPartnersBusinessTrustMember 2015-04-01 2015-06-30 0001589150 RGBP:BioTechnologyPartnersBusinessTrustMember 2015-06-30 0001589150 us-gaap:SeriesAPreferredStockMember 2015-04-01 2015-06-30 0001589150 us-gaap:CommonStockMember 2015-04-14 0001589150 us-gaap:CommonStockMember 2015-05-12 0001589150 us-gaap:CommonStockMember 2015-05-18 0001589150 us-gaap:CommonStockMember 2015-05-19 0001589150 us-gaap:SeriesAPreferredStockMember 2015-04-14 0001589150 us-gaap:SeriesAPreferredStockMember 2015-05-19 0001589150 2015-06-29 2015-07-01 0001589150 us-gaap:ScenarioActualMember 2014-10-01 2015-06-30 0001589150 us-gaap:ScenarioActualMember 2015-06-30 0001589150 us-gaap:ScenarioActualMember 2015-04-01 2015-06-30 0001589150 us-gaap:ScenarioActualMember 2014-09-30 0001589150 us-gaap:RestatementAdjustmentMember 2015-06-30 0001589150 us-gaap:RestatementAdjustmentMember 2015-04-01 2015-06-30 0001589150 us-gaap:RestatementAdjustmentMember 2014-10-01 2015-06-30 0001589150 us-gaap:ScenarioPreviouslyReportedMember 2015-06-30 0001589150 us-gaap:ScenarioPreviouslyReportedMember 2014-10-01 2015-06-30 0001589150 us-gaap:ScenarioPreviouslyReportedMember 2015-04-01 2015-06-30 0001589150 us-gaap:ScenarioPreviouslyReportedMember 2014-09-30 0001589150 us-gaap:SeriesAPreferredStockMember 2015-06-30 0001589150 us-gaap:SeriesAPreferredStockMember us-gaap:ScenarioPreviouslyReportedMember 2015-06-30 0001589150 RGBP:SeriesAAPreferredStockMember us-gaap:ScenarioPreviouslyReportedMember 2015-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure Regen BioPharma Inc 0001589150 10-Q/A 2015-06-30 true --09-30 No No Yes Smaller Reporting Company Q3 2015 113937338

208582

10422

12051

233

1081

10655

228003

10655

228003

6137

3305

1190

120169

103751

8463

6692

2212

18147

0 5000 5000

10501

140286

145281

140286

145281

5191

11353

485097

2300262

-8909432

11209694

658658

728658

-1278577

-2963609

8909432

-11873041

-129631

6055

82722

10655

6055

228003

0.0001

500000000

113525096

51907917

109310811

51907917

13867

93287

68081

93287

68081

127580

389961

906754

463765

906754

463765

30287

109917

413125

73364

413125

73364

43071

16200

43071

16200

157867

513745

1456238

621410

1456238

621410

-157867

-513745

-1456238

-621410

-1456238

-621410

848

297

848

297

18742

3512

18742

3512

8658 48510 0 0 0 0 0 207425 207425 730000 8909432 -9116857 -937425 0 0 -3475 -321 -3475 -321

-8154

-48006

-228794

-210961

-9138226

-940961

-166021

-561751

-11873041

-8812901

-1685032

-832371

8909432

-10594463

-1562371

-.0032

-.0152

-0.0212

-0.0075

-0.1333

-0.0141

51909907

37082956

79454728

110648054

79454728

110648054

100 100 891 891 3475 3475

226177

440 440

117

-2115

-2222

-1629

-14

-848

7343

29665

-556527

-853686

50000

19582

380191

490000

1062268

-66527

208582

115922

49395

208582

1002686 1002686 6000 6000

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   The Company was organized April 24, 2012 under the laws of the State of Nevada. The Company is a majority owned subsidiary of Bio-Matrix Scientific Group, Inc, a Delaware corporation.   The Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials   A. BASIS OF ACCOUNTING   The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.   B. USE OF ESTIMATES   The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.   C. CASH EQUIVALENTS   The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.     D. PROPERTY AND EQUIPMENT   Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized.   E. FAIR VALUE OF FINANCIAL INSTRUMENTS   Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.  A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:   Level 1:  Quoted prices in active markets for identical assets or liabilities   Level 2:  Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.   Level 3:  Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.   F. INCOME TAXES   The Company accounts for income taxes using the liability method prescribed by ASC 740, Income Taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.   The Company applied the provisions of ASC 740-10-50, Accounting For Uncertainty In Income Taxes, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Companys liability for income taxes. Any such adjustment could be material to the Companys results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of June 30, 2015 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.   The Company generated a deferred tax credit through net operating loss carry forward.  However, a valuation allowance of 100% has been established.   Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.   G.  BASIC EARNINGS (LOSS) PER SHARE   The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception.   Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.   H. ADVERTISING   Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the three months ended June 30, 2015 and $0 for the three months ended June 30, 2014.

NOTE 2.  RECENT ACCOUNTING PRONOUNCEMENTS   In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as "Development Stage Entities" (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity's financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard.   The following accounting standards updates were recently issued and have not yet been adopted by us. These standards are currently under review to determine their impact on our consolidated financial position, results of operations, or cash flows.   In May 2014, FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers. The revenue recognition standard affects all entities that have contracts with customers, except for certain items. The new revenue recognition standard eliminates the transaction-and industry-specific revenue recognition guidance under current GAAP and replaces it with a principle-based approach for determining revenue recognition. Public entities are required to adopt the revenue recognition standard for reporting periods beginning after December 15, 2016, and interim and annual reporting periods thereafter. Early adoption is not permitted for public entities. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements. In June 2014, FASB issued Accounting Standards Update (ASU) No. 2014-12 Compensation Stock Compensation (Topic 718), Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. A performance target in a share-based payment that affects vesting and that could be achieved after the requisite service period should be accounted for as a performance condition under Accounting Standards Codification (ASC) 718, Compensation Stock Compensation. As a result, the target is not reflected in the estimation of the award's grant date fair value. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective for annual periods beginning after 15 December 2015 and interim periods within those annual periods. Early adoption is permitted. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements. In August2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity's liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity's liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial StatementsLiquidation Basis of Accounting. Even when an entity's liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity's ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met the conditions which would subject these financial statements for additional disclosure.   On January 31, 2013, the FASB issued Accounting Standards Update [ASU] 2013-01, entitled Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities. The guidance in ASU 2013-01 amends the requirements in the FASB Accounting Standards Codification [FASB ASC] Topic 210, entitled Balance Sheet. The ASU 2013-01 amendments to FASB ASC 210 clarify that ordinary trade receivables and receivables in general are not within the scope of ASU 2011-11, entitled Disclosure about Offsetting Assets and Liabilities, where that ASU amended the guidance in FASB ASC 210. As those disclosures now are modified with the ASU 2013-01 amendments, the FASB ASC 210 balance sheet offsetting disclosures now clearly are applicable only where reporting entities are involved with bifurcated embedded derivatives, repurchase agreements, reverse repurchase agreements, and securities borrowing and lending transactions that either are offset using the FASB ASC 210 or 815 requirements, or that are subject to enforceable master netting arrangements or similar agreements. ASU 2013-01 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. The adoption of this ASU is not expected to have a material impact on our financial statements.   On February 28, 2013, the FASB issued Accounting Standards Update [ASU] 2013-04, entitled Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date. The ASU 2013-04 amendments add to the guidance in FASB Accounting Standards Codification [FASB ASC] Topic 405, entitled Liabilities and require reporting entities to measure obligations resulting from certain joint and several liability arrangements where the total amount of the obligation is fixed as of the reporting date, as the sum of the following:   The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors.   Any additional amounts the reporting entity expects to pay on behalf of its co-obligors.   While early adoption of the amended guidance is permitted, for public companies, the guidance is required to be implemented in fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments need to be implemented retrospectively to all prior periods presented for obligations resulting from joint and several liability arrangements that exist at the beginning of the year of adoption. The adoption of ASU 2013-04 is not expected to have a material effect on the Companys operating results or financial position.   On April 22, 2013, the FASB issued Accounting Standards Update [ASU] 2013-07, entitled Liquidation Basis of Accounting. With ASU 2013-07, the FASB amends the guidance in the FASB Accounting Standards Codification [FASB ASC] Topic 205, entitled Presentation of Financial Statements. The amendments serve to clarify when and how reporting entities should apply the liquidation basis of accounting. The guidance is applicable to all reporting entities, whether they are public or private companies or not-for-profit entities. The guidance also provides principles for the recognition of assets and liabilities and disclosures, as well as related financial statement presentation requirements. The requirements in ASU 2013-07 are effective for annual reporting periods beginning after December 15, 2013, and interim reporting periods within those annual periods. Reporting entities are required to apply the requirements in ASU 2013-07 prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of ASU 2013-07 is not expected to have a material effect on the Companys operating results or financial position. A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies.  Due to the tentative and preliminary nature of those proposed standards, the Companys management has not determined whether implementation of such standards would be material to its financial statements.

NOTE 3. GOING CONCERN   The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $ 11,873,041 during the period from April 24, 2012 (inception) through June 30, 2015. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.   Management plans to raise additional funds by offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise. During the quarter ended March 31, 2015 the Company raised $775,000 through the issuance of convertible debt and during the quarter ended June 30, 2015 the Company raised $90,000 through the issuance of convertible debt ( Note 4).

NOTE 4. NOTES PAYABLE AND CONVERTIBLE NOTES PAYABLE   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"> </td> <td> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">June 30, 2015</td> <td> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">September 30, 2014</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 60%; padding-left: 20pt; text-align: justify; text-indent: -0.25in">Bio Matrix Scientific Group, Inc. (Note 7)</td> <td style="width: 8%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">19,701</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">90,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 20pt; text-align: justify; text-indent: -0.25in">David Koos ( Notes7) </td> <td> </td> <td> </td> <td style="text-align: right">50</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">30,168</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 20pt; text-align: justify; text-indent: -0.25in">Bio Technology Partners Business Trust</td> <td style="font-size: 12pt"> </td> <td style="font-size: 12pt"> </td> <td style="text-align: right">84,000</td> <td style="font-size: 12pt"> </td> <td style="font-size: 12pt"> </td> <td style="font-size: 12pt"> </td> <td style="text-align: right">0</td> <td style="font-size: 12pt"> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 20pt; text-indent: -0.25in">Notes payable</td> <td> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">103,751</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">120,168</td> <td> </td></tr> </table>    $19,701 lent to the Company by Bio Matrix Scientific Group, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.   $50 lent to the Company by David Koos. is due and payable at the demand of the holder and bear simple interest at a rate of 15% per annum.   $84,000 lent to the Company by Bio Technology Partners Business Trust. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.   CONVERTIBLE NOTES PAYABLE   During the quarter ended March 31, 2015 the Company issued Convertible Notes ( Notes) with an aggregate face value of $882,686 . Consideration for these Notes consisted of:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="vertical-align: top"> <td style="width: 27px"> </td> <td style="width: 24px">(a)</td> <td style="text-align: justify">$775,000 cash and</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="vertical-align: top"> <td style="width: 27px"> </td> <td style="width: 24px">(b)</td> <td style="text-align: justify">Satisfaction of $107,686 of existing indebtedness:</td></tr> </table>   Each Note becomes due and payable at the demand of the Lender at any time after one year subsequent to the issuance date and bears simple interest at 10% per annum payable quarterly at the demand of the Lender.   All or part of the principal and accrued but unpaid interest is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( Conversion Price) equivalent to a 65% discount to the lowest Trading Price (as defined below) for the Common Shares during the thirty (30) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the conversion date. Trading Price means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the OTCQB) as reported by a reliable reporting service (Reporting Service) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the pink sheets by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by Regen and the Lender. Trading Day shall mean any day on which the Common Shares are tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Shares are then being traded. Trading Volume shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by Regen relating to the Lenders securities. Principal and interest may be prepaid in part or in full by Regen on not less than three Trading Days prior written notice to the Lender.   Upon expiration of the six month holding specified in Rule 144(d) promulgated under the Securities Act of 1933, Regen , at the request of the Lender, shale remove sale restrictions on one sixth (1/6) of the shares that resulted from conversions made through the issuance of this Note , each month, for a period of six months, with all restrictions being removed by the Company by the expiration of the six month subsequent to expiration of the aforementioned Rule 144 holding period.   If the Lender converts principal into Common Stock of Regen on or prior to 180 days from the issuance of the Note the Lender shall receive one share of Preferred Series A Stock of the Company for each share of Common Stock received through conversion.   All Notes were fully converted during the quarter ended March 31, 2015. 31,539,262 common shares of Regen were issued to the Convertible Noteholders in satisfaction of the convertible indebtedness. 31,538,862 of the Companys Series A Preferred shares were issued to Noteholders pursuant to the terms and conditions of the Notes.   The Company analyzed the conversion feature of the Notes for derivative accounting consideration under ASC 815-15 Derivatives and Hedging and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Companys convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change.   The Company values the embedded derivative using the Black-Scholes pricing model and an aggregate derivative liability of $2,368,685 was recognized by the Company. This liability was eliminated prior to the end of the Companys second quarter as a result of the full conversion of all Notes prior to the end of the Companys second quarter.   During the quarter ended June 30, 2015 the Company issued Convertible Notes ( Notes) with an aggregate face value of $90,000 . Consideration for these Notes consisted of $90,000. All or part of the principal and accrued but unpaid interest is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( Conversion Price) equivalent the lower of (1) a 65% discount to the lowest Trading Price (as defined below) for the Common Shares during the thirty (30) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the conversion date. Trading Price means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the OTCQB) as reported by a reliable reporting service (Reporting Service) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the pink sheets by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by Regen and the Lender. Trading Day shall mean any day on which the Common Shares are tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Shares are then being traded. Trading Volume shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by Regen relating to the Lenders securities.       Or       (2) $0.03 per share       Principal and interest may be prepaid in part or in full by Regen on not less than three Trading Days prior written notice to the Lender.   Upon expiration of the six month holding specified in Rule 144(d) promulgated under the Securities Act of 1933, Regen , at the request of the Lender, shale remove sale restrictions on one sixth (1/6) of the shares that resulted from conversions made through the issuance of this Note , each month, for a period of six months, with all restrictions being removed by the Company by the expiration of the six month subsequent to expiration of the aforementioned Rule 144 holding period.   If the Lender converts principal into Common Stock of Regen on or prior to 180 days from the issuance of the Note the Lender shall receive one share of Preferred Series A Stock of the Company for each share of Common Stock received through conversion.   During the quarter ended June 30, 2015 the Company issued 3,214,285 of its common shares in satisfaction of the abovementioned convertible notes and 3,214,285 shares of its Series A Preferred stock in accordance with the terms and conditions of abovementioned convertible notes. .   The Company values the embedded derivative using the Black-Scholes pricing model and an aggregate derivative liability of $350,666 was recognized by the Company in connection with $90,000 of convertible notes payable issued during the quarter ended June 30, 2015. This liability was eliminated prior to the end of the Companys third quarter as a result of the full conversion of these convertible noted prior to the end of the Companys third quarter.

NOTE 5. NOTES RECEIVABLE   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">June 30, 2015</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">September 30, 2014</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 58%; padding-left: 20pt; text-align: justify; text-indent: -0.25in">Entest Biomedical, Inc. (Note 7)</td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">12,051</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">10,422</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 20pt; text-align: justify; text-indent: -0.25in"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-bottom: 1pt; padding-left: 20pt; text-indent: -0.25in">Notes Receivable</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">12,051</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">10,422</td> <td style="padding-bottom: 1pt"> </td></tr> </table>    $12,051 lent by the Company to Entest Biomedical, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.

NOTE 6. INCOME TAXES   As of June 30, 2015   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-right: 0.8pt; text-align: justify">Deferred tax assets:</td> <td style="padding-right: 0.8pt; text-align: justify"> </td> <td colspan="2" style="padding-right: 1.8pt; text-align: center"> </td> <td style="padding-right: 0.8pt; text-align: justify"> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 91%; padding-right: 0.8pt; text-align: justify">Net operating tax carry forwards</td> <td style="width: 1%; padding-right: 0.8pt; text-align: justify"> </td> <td style="width: 1%; padding-right: 0.8pt; text-align: center">$</td> <td style="width: 5%; padding-right: 0.8pt; font-size: 12pt; text-align: center">4,036,834</td> <td style="width: 2%; padding-right: 0.8pt; text-align: justify"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-right: 0.8pt; text-align: justify">Other</td> <td style="padding-right: 0.8pt; text-align: justify"> </td> <td style="border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center">-0-</td> <td style="padding-right: 0.8pt; text-align: justify"> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-right: 0.8pt; text-align: justify">Gross deferred tax assets</td> <td style="padding-right: 0.8pt; text-align: justify"> </td> <td style="padding-right: 0.8pt; font-size: 12pt; text-align: center"> </td> <td style="padding-right: 0.8pt; font-size: 12pt; text-align: center">4,036,834</td> <td style="padding-right: 0.8pt; text-align: justify"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-right: 0.8pt; text-align: justify">Valuation allowance</td> <td style="padding-right: 0.8pt; text-align: justify"> </td> <td style="border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center">(4,036,834</td> <td style="padding-right: 0.8pt; text-align: justify">)</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-right: 0.8pt; text-align: justify">Net deferred tax assets</td> <td style="padding-right: 0.8pt; text-align: justify"> </td> <td style="border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center">$</td> <td style="border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center">-0-</td> <td style="padding-right: 0.8pt; text-align: justify"> </td></tr> </table>   As of June 30, 2015 the Company has a Deferred Tax Asset of $4,036,834 completely attributable to net operating loss carry forwards of approximately $11,873,041 (which expire 20 years from the date the loss was incurred).   Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry forwards are expected to be available to reduce taxable income. The achievement of required future taxable income is uncertain. As a result, the Company has the Company recorded a valuation allowance reducing all deferred tax assets to 0.   Income tax is calculated at the 34% Federal Corporate Rate.

NOTE 7. RELATED PARTY TRANSACTIONS   As of June 30, 2015 the Company has received capital contributions from Bio Matrix Scientific Group, Inc (BMSN) , a corporation under common control with the Company and which possesses the majority of the voting power of the shares outstanding of the company, totaling $728,658 and has issued 50,010,000 common shares to BMSN for aggregate consideration of $20,090. The Company also utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 subleased to the Company by Entest BioMedical, Inc. on a month to month basis beginning October 1, 2014. The Chief Executive Officer of Entest Biomedical Inc. is David R. Koos who also serves as the Chief Executive Officer of the Companys parent and the Company. The sublease is on a month to month basis and rent payable to Entest Biomedical, Inc. by Regen Biopharma Inc is equal to $5,000 per month.   As of June 30, 2015 Entest Biomedical Inc. is indebted to the Company in the amount of $12,051. $12,051 lent by the Company to Entest Biomedical, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.   As of June 30, 2015 the Company is indebted to BMSN in the amount of $19,701. $19,701 lent to the Company by Bio Matrix Scientific Group, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.   As of June 30, 2015 the Company is indebted to David R. Koos in the amount of $50. $50 lent to the Company by Koos is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.

NOTE 8. COMMITMENTS AND CONTINGENCIES   The Company utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 subleased to the Company by Entest BioMedical, Inc. on a month to month basis beginning October 1, 2014. The Chief Executive Officer of Entest Biomedical Inc. is David R. Koos who also serves as the Chief Executive Officer of the Companys parent and the Company. The sublease is on a month to month basis and rent payable to Entest Biomedical, Inc. by Regen Biopharma Inc is equal to $5,000 per month.   On March 20, 2015 Regen Biopharma, Inc. agreed to sublease 199 square feet of laboratory space located at 5310 Eastgate Mall, San Diego, CA 92121 from Human BioMolecular Research Institute (Sublease Agreement). Pursuant to the terms of the Sublease Agreement Regen Biopharma, Inc. will pay rent of $400 per month to Human BioMolecular Research Institute (HBRI) . The term of the sublease shall be from March 9, 2015 to September 8, 2015 (a period of 6 months) and will automatically renew thereafter for the same 6 month term unless written notice is received by HBRI within 60 days prior to renewal. On June 1, 2015 Regen Biopharma, Inc. terminated its sublease with Human BioMolecular Research Institute   On March 20, 2015 Regen Biopharma, Inc entered into a Research Agreement with HBRI wherein HBRI agreed to provide a variety of professional, scientific and technical services for the proper conduct of research by Regen Biopharma, Inc. and also to make available certain research equipment to Regen Biopharma, Inc. The term of the agreement shall be from March 9, 2015 to September 8, 2015 (a period of 6 months) and will automatically renew thereafter for the same 6 month term unless written notice is received by HBRI within 60 days prior to renewal. As consideration Regen Biopharma, Inc shall pay a monthly fee of $2,700 to HBRI over the term of the agreement. On June 1, 2015 Regen Biopharma, Inc. terminated the aforementioned agreement with Human BioMolecular Research Institute

NOTE 9. STOCKHOLDERS' EQUITY   The stockholders' equity section of the Company contains the following classes of capital stock as June 30, 2015:   Common stock, $ 0.0001 par value; 500,000,000 shares authorized: 113,525,096 shares issued and outstanding. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1). On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation. Preferred Stock, $0.0001 par value, 100,000,000 shares authorized of which 600,000 is designated as Series AA Preferred Stock: 30,000 shares issued and outstanding as of June 30, 2015 and 90,000,000 is designated Series A Preferred Stock of which 60,548,364 shares are outstanding as of June 30, 2015. The abovementioned shares authorized pursuant to the Companys certificate of incorporation may be issued from time to time without prior approval of the shareholders. The Board of Directors of the Company shall have the full authority permitted by law to establish one or more series and the number of shares constituting each such series and to fix by resolution full or limited, multiple or fractional, or no voting rights, and such designations, preferences, qualifications, restrictions, options, conversion rights and other special or relative rights of any series of the Stock that may be desired.   Series AA Preferred Stock   On September 15, 2014 the Company filed a CERTIFICATE OF DESIGNATION (Certificate of Designations) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as Series AA Preferred Stock (hereinafter referred to as Series AA Preferred Stock).   The Board of Directors of the Company have authorized 600,000 shares of the Series AA Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times ten thousand (10,000). Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series AA Preferred Stock shall vote as a single class on all matters submitted to the stockholders.   Series A Preferred Stock   On January 15, 2015 the Company filed a CERTIFICATE OF DESIGNATION ("Certificate of Designations") with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as "Series A Preferred Stock" (hereinafter referred to as "Series A Preferred Stock"). The Board of Directors of the Company have authorized 90,000,000 shares of the Series A Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series A Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series A Preferred Stock owned by such holder times one . Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series A Preferred Stock shall vote as a single class on all matters submitted to the stockholders. Holders of the Series A Preferred Stock will be entitled to receive, when, as and if declared by the board of directors of the Company (the Board) out of funds legally available therefore, non-cumulative cash dividends of $0.01 per quarter. In the event any dividends are declared or paid or any other distribution is made on or with respect to the Common Stock , the holders of Series A Preferred Stock as of the record date established by the Board for such dividend or distribution on the <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr> <td style="width: 100%; font: 12pt Times New Roman, Times, Serif; text-align: center"> </td></tr> <tr> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"> </td></tr> </table> Common Stock shall be entitled to receive, as additional dividends (the Additional Dividends) an amount (whether in the form of cash, securities or other property) equal to the amount (and in the form) of the dividends or distribution that such holder would have received had each share of the Series A Preferred Stock been one share of the Common Stock, such Additional Dividends to be payable on the same payment date as the payment date for the Common Stock. Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (collectively, a Liquidation), before any distribution or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series A Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal to $0.01 per share of Series A Preferred (the Liquidation Amount) plus all declared and unpaid dividends thereon, for each share of Series A Preferred held by them. If, upon any Liquidation, the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full to all holders of Series A Preferred, then the entire net assets of the Company shall be distributed among the holders of the Series A Preferred, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions may be made in cash or in property taken at its fair value (as determined in good faith by the Board), or both, at the election of the Board.

NOTE 10. STOCK TRANSACTIONS   Common Stock   On April 14, 2015 the Company issued 1,428, 571 of its common shares in satisfaction of $40,000 of convertible indebtedness. On May 12, 2015 the Company issued 500,000 of its common shares in satisfaction of $15,000 of indebtedness. On May 18, 2015 the Company issued 500,000 of its common shares in satisfaction of $15,000 of indebtedness. On May 19, 2015 the Company issued 1,785,714 of its common shares in satisfaction of $50,000 of convertible indebtedness.   Series A Preferred Stock   On April 14, 2015 the Company issued 1,428, 571 of its shares of Series A Preferred Stock in accordance with the terms and conditions of a $40,000 face value convertible note issued by the Company.   On May 19, 2015 the Company issued 200,000 of its shares of Series A Preferred Stock as consideration for services rendered by nonemployees.   On May 19, 2015 the Company issued 1,785,714 of its shares of Series A Preferred Stock in accordance with the terms and conditions of a $50,000 face value convertible note issued by the Company.

NOTE 11. SUBSEQUENT EVENTS   On July 1, 2015 the Company issued 412,242 of its shares of common stock as consideration for services rendered by a nonemployee.

A. BASIS OF ACCOUNTING   The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.

B. USE OF ESTIMATES   The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

C. CASH EQUIVALENTS   The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

D. PROPERTY AND EQUIPMENT   Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized.

E. FAIR VALUE OF FINANCIAL INSTRUMENTS   Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.  A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:   Level 1:  Quoted prices in active markets for identical assets or liabilities   Level 2:  Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.   Level 3:  Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

F. INCOME TAXES   The Company accounts for income taxes using the liability method prescribed by ASC 740, Income Taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.   The Company applied the provisions of ASC 740-10-50, Accounting For Uncertainty In Income Taxes, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Companys liability for income taxes. Any such adjustment could be material to the Companys results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of June 30, 2015 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.   The Company generated a deferred tax credit through net operating loss carry forward.  However, a valuation allowance of 100% has been established.   Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

G.  BASIC EARNINGS (LOSS) PER SHARE   The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception.   Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.

H. ADVERTISING   Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the three months ended June 30, 2015 and $0 for the three months ended June 30, 2014.

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"> </td> <td> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">June 30, 2015</td> <td> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">September 30, 2014</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 60%; padding-left: 20pt; text-align: justify; text-indent: -0.25in">Bio Matrix Scientific Group, Inc. (Note 7)</td> <td style="width: 8%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">19,701</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">90,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 20pt; text-align: justify; text-indent: -0.25in">David Koos ( Notes7) </td> <td> </td> <td> </td> <td style="text-align: right">50</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">30,168</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 20pt; text-align: justify; text-indent: -0.25in">Bio Technology Partners Business Trust</td> <td style="font-size: 12pt"> </td> <td style="font-size: 12pt"> </td> <td style="text-align: right">84,000</td> <td style="font-size: 12pt"> </td> <td style="font-size: 12pt"> </td> <td style="font-size: 12pt"> </td> <td style="text-align: right">0</td> <td style="font-size: 12pt"> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 20pt; text-indent: -0.25in">Notes payable</td> <td> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">103,751</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">120,168</td> <td> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">June 30, 2015</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">September 30, 2014</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 58%; padding-left: 20pt; text-align: justify; text-indent: -0.25in">Entest Biomedical, Inc. (Note 7)</td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">12,051</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">10,422</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 20pt; text-align: justify; text-indent: -0.25in"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-bottom: 1pt; padding-left: 20pt; text-indent: -0.25in">Notes Receivable</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">12,051</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">10,422</td> <td style="padding-bottom: 1pt"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-right: 0.8pt; text-align: justify">Deferred tax assets:</td> <td style="padding-right: 0.8pt; text-align: justify"> </td> <td colspan="2" style="padding-right: 1.8pt; text-align: center"> </td> <td style="padding-right: 0.8pt; text-align: justify"> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 91%; padding-right: 0.8pt; text-align: justify">Net operating tax carry forwards</td> <td style="width: 1%; padding-right: 0.8pt; text-align: justify"> </td> <td style="width: 1%; padding-right: 0.8pt; text-align: center">$</td> <td style="width: 5%; padding-right: 0.8pt; font-size: 12pt; text-align: center">4,036,834</td> <td style="width: 2%; padding-right: 0.8pt; text-align: justify"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-right: 0.8pt; text-align: justify">Other</td> <td style="padding-right: 0.8pt; text-align: justify"> </td> <td style="border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center">-0-</td> <td style="padding-right: 0.8pt; text-align: justify"> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-right: 0.8pt; text-align: justify">Gross deferred tax assets</td> <td style="padding-right: 0.8pt; text-align: justify"> </td> <td style="padding-right: 0.8pt; font-size: 12pt; text-align: center"> </td> <td style="padding-right: 0.8pt; font-size: 12pt; text-align: center">4,036,834</td> <td style="padding-right: 0.8pt; text-align: justify"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-right: 0.8pt; text-align: justify">Valuation allowance</td> <td style="padding-right: 0.8pt; text-align: justify"> </td> <td style="border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center">(4,036,834</td> <td style="padding-right: 0.8pt; text-align: justify">)</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-right: 0.8pt; text-align: justify">Net deferred tax assets</td> <td style="padding-right: 0.8pt; text-align: justify"> </td> <td style="border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center">$</td> <td style="border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center">-0-</td> <td style="padding-right: 0.8pt; text-align: justify"> </td></tr> </table>

19701

90000

19701

30168

84000

103751

120168

882686

775000

90000

775000

107686

31539262

31538862

2368685

12051

10422

12051

10422

4036834

11873041

728658

50010000 20090 5000

12052

40000 15000 15000 50000 40000 50000

400

0.0001

.0001

0.0001

100000000

5000000

600000

90000000

6289

60548364

30000

60548364

-490 -490

-6289

1.00

140000

70000

972686 972686

300000

-6137

0.10

0.15

0.10

0.65

90000

.03

3214285

350666

0.10

0.34

5000

2700

412242

.01

1428571 500000 500000 1785714 1428571 1785714 200000

-561751

-1685032

EXPLANATORY NOTE: THIS AMENDMENT NO.2 TO REGEN BIOPHARMA, INC’S (THE “COMPANY”) FORM 10-Q FOR THE PERIOD ENDED JUNE 30, 2015 (“(“ORIGINAL FILING”) IS BEING FILED SOLELY TO AMEND THE FOLLOWING PORTIONS OF AMENDMENT NO.1 OF THE ORIGINAL FILING (“AMENDMENT NO.1”).     PART 1, ITEM 4   THE COMPANY HAS NOT MODIFIED OR UPDATED DISCLOSURES PRESENTED IN AMENDMENT NO.1 OR THE ORIGINAL FILING, EXCEPT AS INDICATED ABOVE. ACCORDINGLY, THIS AMENDMENT DOES NOT REFLECT EVENTS OCCURRING AFTER THE DATE OF THE ORIGINAL FILING AND DOES NOT MODIFY OR UPDATE THOSE DISCLOSURES AFFECTED BY SUBSEQUENT EVENTS, EXCEPT AS SPECIFICALLY REFERENCED HEREIN. INFORMATION NOT AFFECTED BY THE ABOVE AMENDMENTS IS UNCHANGED AND REFLECTS THE DISCLOSURES MADE AT THE TIME OF THE ORIGINAL FILING.

NOTE 11. RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS   Subsequent to the original issuance of Regen’s quarterly financial statements for the three month period ended June 30, 2015 the Company determined that $730,000 of expenses recognized during the quarter ended June 30, 2015 resulting from the issuance for less than fair value of common shares in satisfactions of convertible notes issued by the Company should not have been recognized.   The following tables reflect the corrections:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2">REGEN BIOPHARMA , INC.</td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2">BALANCE SHEET</td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom"> </td> <td> </td></tr> <tr> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; text-align: center">As of</td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; text-align: center">adjustments</td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; text-align: center">As of</td> <td> </td></tr> <tr> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; text-align: center">June 30, 2015</td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; text-align: center">June 30, 2015</td> <td> </td></tr> <tr> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; text-align: center">(unaudited)</td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; text-align: center">(unaudited)</td> <td> </td></tr> <tr> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; text-align: center">restated</td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom">ASSETS</td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom">CURRENT ASSETS</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; width: 46%; padding-left: 10pt">Cash</td> <td style="vertical-align: bottom; width: 5%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 11%; text-align: right">208,582</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 5%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 11%; text-align: right"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 5%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 11%; text-align: right">208,582</td> <td style="vertical-align: bottom; width: 1%"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">Note Receivable</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">12,051</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">12,051</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">Prepaid Expenses</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">6,289</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">6,289</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">Accrued Interest Receivable</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1,081</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1,081</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">     Total Current Assets</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">228,003</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">228,003</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom">TOTAL ASSETS</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">228,003</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">228,003</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">LIABILITIES AND STOCKHOLDERS' EQUITY</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">Current Liabilities:</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">Accounts payable</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1,190</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1,190</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">Notes Payable</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">103,751</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">103,751</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">Accrued payroll taxes</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">6,692</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">6,692</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">Accrued Interest</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">18,147</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">18,147</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">Accrued Rent</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">5,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">5,000</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">Accrued Payroll</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">10,501</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">10,501</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">Total Current Liabilities</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">145,281</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">145,281</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">Total Liabilities</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">145,281</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">145,281</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom">STOCKHOLDERS' EQUITY (DEFICIT)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">Common Stock ($.0001 par value) 500,000,000 shares authorized; 113,525,096 issued and outstanding as of  June 30, 2015 and 51,907,917 shares issued and outstanding September  30, 2014</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">11,353</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">11,353</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">Preferred Stock, 0.0001 par value, 100,000,000 authorized and Five Million authorized as of June 30, 2015 and September 30, 2014 respectively</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">Series A Preferred 90,000,000 Authorized and 0 authorized, 60,548,364 and 0 outstanding as of  June 30, 2105 and September 30, 2014 respectively</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">6,055</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">6,055</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">Series AA Preferred $0.0001 par value 600,000 authorized and 30, 000  and 0 outstanding as of June 30, 2015 and September 30, 2014 respectively</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">3</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">3</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">Additional Paid in capital</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">11,209,694</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(8,909,432</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">2,300,262</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">Contributed Capital</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">728,658</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">728,658</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">Retained Earnings (Deficit) accumulated during the development stage</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(11,873,041</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">8,909,432</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(2,963,609</td> <td style="vertical-align: bottom">)</td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">Total Stockholders' Equity (Deficit)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">82,722</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">82,722</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom">TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">228,003</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">228,003</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="7">REGEN BIOPHARMA , INC.</td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="7">STATEMENT OF OPERATIONS</td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom"> </td> <td> </td></tr> <tr> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: center">Three months ended </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center">adjustments</td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center">Three months ended </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center">Nine Months Ended </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center">adjustments</td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center">Nine Months Ended </td> <td style="vertical-align: bottom; text-align: center"> </td> <td> </td></tr> <tr> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center">June 30, 2015</td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center">June 30, 2015</td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center">June 30, 2015</td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center">June 30, 2015</td> <td style="vertical-align: bottom; text-align: center"> </td> <td> </td></tr> <tr> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center">(unaudited)</td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center">(unaudited)</td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center">(unaudited)</td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center">(unaudited)</td> <td style="vertical-align: bottom; text-align: center"> </td> <td> </td></tr> <tr> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center">(as restated)</td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center">(as restated)</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; width: 40%">REVENUES</td> <td style="vertical-align: bottom; width: 2%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 6%; text-align: right">0</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 2%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 6%; text-align: right"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 2%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 6%; text-align: right">0</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 2%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 6%; text-align: right">0</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 2%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 6%; text-align: right"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 2%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 6%; text-align: right">0</td> <td style="vertical-align: bottom; width: 1%"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom">COST AND EXPENSES</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">Research and Development</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">68,081</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">68,081</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">93,287</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">93,287</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">General and Administrative</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">463,765</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">463,765</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">906,754</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">906,754</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">Consulting and Professional Fees</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">73,364</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">73,364</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">413,125</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">413,125</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">Rent</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">16,200</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">16,200</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">43,071</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">43,071</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">Total Costs and Expenses</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">621,410</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">621,410</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1,456,238</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1,456,238</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom">OPERATING LOSS</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(621,410</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(621,410</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(1,456,238</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(1,456,238</td> <td style="vertical-align: bottom">)</td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom">OTHER INCOME & (EXPENSES)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">Interest Income</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">297</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">297</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">848</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">848</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">Refunds of amounts previously paid</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">Interest Expense</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(3,512</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(3,512</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(18,742</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(18,742</td> <td style="vertical-align: bottom">)</td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">Capital contribution tp parent</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">0</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">0</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">0</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">0</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">Loss on issuance of common shares for</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">less than fair value</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(937,425</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">730,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(207,425</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(9,116,857</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">8,909,432</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(207,425</td> <td style="vertical-align: bottom">)</td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">Preferred shares issued pursuant to</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">contractual obligations</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(321</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(321</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(3,475</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(3,475</td> <td style="vertical-align: bottom">)</td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom">TOTAL OTHER INCOME (EXPENSE)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(940,961</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(210,961</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(9,138,226</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(228,794</td> <td style="vertical-align: bottom">)</td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom">NET INCOME (LOSS)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(1,562,371</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(832,371</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(10,594,463</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(1,685,032</td> <td style="vertical-align: bottom">)</td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom">BASIC AND FULLY DILUTED</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom">EARNINGS (LOSS) PER SHARE</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(0.0141</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(0.0075</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(0.1333</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(0.0212</td> <td style="vertical-align: bottom">)</td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom">WEIGHTED AVERAGE NUMBER OF COMMON</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">110,648,054</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">110,648,054</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">79,454,728</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">79,454,728</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom">SHARES OUTSTANDING</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom"> <td>REGEN BIOPHARMA , INC.</td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom"> <td>STATEMENT OF CASH FLOWS</td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom"> <td>(unaudited)</td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3" style="text-align: center">Nine  Months Ended</td> <td style="text-align: center"> </td> <td colspan="3" style="text-align: center">Adjustments</td> <td style="text-align: center"> </td> <td colspan="3" style="text-align: center">Nine  Months Ended</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="3" style="text-align: center">June 30, 2015</td> <td style="text-align: center"> </td> <td colspan="3" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="3" style="text-align: center">June 30, 2015</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="3" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="3" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="3" style="text-align: center">Restated</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td>CASH FLOWS FROM OPERATING ACTIVITIES</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 46%">Net Income (loss)</td> <td style="width: 5%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">(10,594,463</td> <td style="width: 1%">)</td> <td style="width: 5%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">8909432</td> <td style="width: 1%"> </td> <td style="width: 5%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">(1,685,032</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Adjustments to reconcile net Income to net cash</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Preferred Stock issued for Expenses</td> <td> </td> <td>$</td> <td style="text-align: right">100</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">100</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 10pt">Predrred Stock issued for interest</td> <td> </td> <td>$</td> <td style="text-align: right">891</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">891</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Common Stock issued for expenses</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 10pt">Preferred Stock issued pursuant to contractual obligations</td> <td> </td> <td>$</td> <td style="text-align: right">3,475</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,475</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Common Stock issued to Consultants</td> <td> </td> <td>$</td> <td style="text-align: right">226,177</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">226,177</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 10pt">Preferred Stock issued to Consultants</td> <td> </td> <td>$</td> <td style="text-align: right">440</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">440</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Changes in operating assets and liabilities:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 10pt">Increase (Decrease) in Accounts Payable</td> <td> </td> <td>$</td> <td style="text-align: right">(2,115</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(2,115</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">(Increase) Decrease in Notes Receivable</td> <td> </td> <td>$</td> <td style="text-align: right">(1,629</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(1,629</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 10pt">(Increase) Decrease in Interest  Receivable</td> <td> </td> <td>$</td> <td style="text-align: right">(848</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(848</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Increase ( Decrease) in Bank Overdraft</td> <td> </td> <td>$</td> <td style="text-align: right">(6,137</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(6,137</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 10pt">Increase (Decrease) in accrued Expenses</td> <td> </td> <td>$</td> <td style="text-align: right">29,665</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">29,665</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">(Increase) Decrease in Prepaid Expenses</td> <td> </td> <td>$</td> <td style="text-align: right">(6,289</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(6,289</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 10pt">Increase in issuance of stock below fair value</td> <td> </td> <td>$</td> <td style="text-align: right">9,116,857</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(8,909,432</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">207,425</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Increase in Additional Paid in Capital</td> <td> </td> <td>$</td> <td style="text-align: right">380,191</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">380,191</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td>Net Cash Provided by (Used in) Operating Acitivities</td> <td> </td> <td>$</td> <td style="text-align: right">(853,686</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(853,685</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>CASH FLOWS FROM FINANCING ACTIVITIES</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 20pt">Common Stock issued for Cash</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 20pt">Increase in Contributed Capital</td> <td> </td> <td> </td> <td style="text-align: right">70,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">70,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 20pt">Increase ( Decrease)  in Notes Payable</td> <td> </td> <td> </td> <td style="text-align: right">19,582</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">19,582</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 20pt">Increase in Convertible Notes payable</td> <td> </td> <td> </td> <td style="text-align: right">972,686</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">972,686</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td>Net Cash Provided by (Used in) Financing Activities</td> <td> </td> <td> </td> <td style="text-align: right">1,062,268</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,062,268</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td>Net Increase (Decrease) in Cash</td> <td> </td> <td>$</td> <td style="text-align: right">208,582</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">208,583</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td>Cash at Beginning of Period</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td>Cash at End of Period</td> <td> </td> <td>$</td> <td style="text-align: right">208,582</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">208,583</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Supplemental Disclosure of Noncash investing and financing activities:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td>Common Shares Issued for Debt</td> <td> </td> <td>$</td> <td style="text-align: right">1,002,686</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Preferred Shares issued for Debt</td> <td> </td> <td>$</td> <td style="text-align: right">6,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td colspan="13" style="padding-left: 20pt; text-align: center">The Accompanying Notes are an Integral Part of These Financial Statements</td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2">REGEN BIOPHARMA , INC.</td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2">BALANCE SHEET</td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom"> </td> <td> </td></tr> <tr> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; text-align: center">As of</td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; text-align: center">adjustments</td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; text-align: center">As of</td> <td> </td></tr> <tr> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; text-align: center">June 30, 2015</td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; text-align: center">June 30, 2015</td> <td> </td></tr> <tr> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; text-align: center">(unaudited)</td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; text-align: center">(unaudited)</td> <td> </td></tr> <tr> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; text-align: center">restated</td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom">ASSETS</td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom">CURRENT ASSETS</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; width: 46%; padding-left: 10pt">Cash</td> <td style="vertical-align: bottom; width: 5%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 11%; text-align: right">208,582</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 5%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 11%; text-align: right"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 5%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 11%; text-align: right">208,582</td> <td style="vertical-align: bottom; width: 1%"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">Note Receivable</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">12,051</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">12,051</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">Prepaid Expenses</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">6,289</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">6,289</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">Accrued Interest Receivable</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1,081</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1,081</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">     Total Current Assets</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">228,003</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">228,003</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom">TOTAL ASSETS</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">228,003</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">228,003</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">LIABILITIES AND STOCKHOLDERS' EQUITY</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">Current Liabilities:</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">Accounts payable</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1,190</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1,190</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">Notes Payable</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">103,751</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">103,751</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">Accrued payroll taxes</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">6,692</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">6,692</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">Accrued Interest</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">18,147</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">18,147</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">Accrued Rent</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">5,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">5,000</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">Accrued Payroll</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">10,501</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">10,501</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">Total Current Liabilities</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">145,281</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">145,281</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">Total Liabilities</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">145,281</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">145,281</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom">STOCKHOLDERS' EQUITY (DEFICIT)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">Common Stock ($.0001 par value) 500,000,000 shares authorized; 113,525,096 issued and outstanding as of  June 30, 2015 and 51,907,917 shares issued and outstanding September  30, 2014</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">11,353</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">11,353</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">Preferred Stock, 0.0001 par value, 100,000,000 authorized and Five Million authorized as of June 30, 2015 and September 30, 2014 respectively</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">Series A Preferred 90,000,000 Authorized and 0 authorized, 60,548,364 and 0 outstanding as of  June 30, 2105 and September 30, 2014 respectively</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">6,055</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">6,055</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">Series AA Preferred $0.0001 par value 600,000 authorized and 30, 000  and 0 outstanding as of June 30, 2015 and September 30, 2014 respectively</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">3</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">3</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">Additional Paid in capital</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">11,209,694</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(8,909,432</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">2,300,262</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">Contributed Capital</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">728,658</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">728,658</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">Retained Earnings (Deficit) accumulated during the development stage</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(11,873,041</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">8,909,432</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(2,963,609</td> <td style="vertical-align: bottom">)</td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">Total Stockholders' Equity (Deficit)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">82,722</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">82,722</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom">TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">228,003</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">228,003</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="7">REGEN BIOPHARMA , INC.</td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="7">STATEMENT OF OPERATIONS</td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom"> </td> <td> </td></tr> <tr> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: center">Three months ended </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center">adjustments</td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center">Three months ended </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center">Nine Months Ended </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center">adjustments</td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center">Nine Months Ended </td> <td style="vertical-align: bottom; text-align: center"> </td> <td> </td></tr> <tr> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center">June 30, 2015</td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center">June 30, 2015</td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center">June 30, 2015</td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center">June 30, 2015</td> <td style="vertical-align: bottom; text-align: center"> </td> <td> </td></tr> <tr> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center">(unaudited)</td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center">(unaudited)</td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center">(unaudited)</td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center">(unaudited)</td> <td style="vertical-align: bottom; text-align: center"> </td> <td> </td></tr> <tr> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center">(as restated)</td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center">(as restated)</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; width: 40%">REVENUES</td> <td style="vertical-align: bottom; width: 2%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 6%; text-align: right">0</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 2%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 6%; text-align: right"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 2%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 6%; text-align: right">0</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 2%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 6%; text-align: right">0</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 2%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 6%; text-align: right"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 2%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 6%; text-align: right">0</td> <td style="vertical-align: bottom; width: 1%"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom">COST AND EXPENSES</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">Research and Development</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">68,081</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">68,081</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">93,287</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">93,287</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">General and Administrative</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">463,765</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">463,765</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">906,754</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">906,754</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">Consulting and Professional Fees</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">73,364</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">73,364</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">413,125</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">413,125</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">Rent</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">16,200</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">16,200</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">43,071</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">43,071</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">Total Costs and Expenses</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">621,410</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">621,410</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1,456,238</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1,456,238</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom">OPERATING LOSS</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(621,410</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(621,410</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(1,456,238</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(1,456,238</td> <td style="vertical-align: bottom">)</td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom">OTHER INCOME & (EXPENSES)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">Interest Income</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">297</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">297</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">848</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">848</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">Refunds of amounts previously paid</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">Interest Expense</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(3,512</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(3,512</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(18,742</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(18,742</td> <td style="vertical-align: bottom">)</td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">Capital contribution tp parent</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">0</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">0</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">0</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">0</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">Loss on issuance of common shares for</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">less than fair value</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(937,425</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">730,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(207,425</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(9,116,857</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">8,909,432</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(207,425</td> <td style="vertical-align: bottom">)</td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-left: 10pt">Preferred shares issued pursuant to</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom; padding-left: 10pt">contractual obligations</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(321</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(321</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(3,475</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(3,475</td> <td style="vertical-align: bottom">)</td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom">TOTAL OTHER INCOME (EXPENSE)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(940,961</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(210,961</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(9,138,226</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(228,794</td> <td style="vertical-align: bottom">)</td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom">NET INCOME (LOSS)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(1,562,371</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(832,371</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(10,594,463</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(1,685,032</td> <td style="vertical-align: bottom">)</td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom">BASIC AND FULLY DILUTED</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom">EARNINGS (LOSS) PER SHARE</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(0.0141</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(0.0075</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(0.1333</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(0.0212</td> <td style="vertical-align: bottom">)</td> <td> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom">WEIGHTED AVERAGE NUMBER OF COMMON</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">110,648,054</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">110,648,054</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">79,454,728</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">79,454,728</td> <td style="vertical-align: bottom"> </td> <td> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: bottom">SHARES OUTSTANDING</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td> </td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom"> <td>REGEN BIOPHARMA , INC.</td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom"> <td>STATEMENT OF CASH FLOWS</td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom"> <td>(unaudited)</td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3" style="text-align: center">Nine  Months Ended</td> <td style="text-align: center"> </td> <td colspan="3" style="text-align: center">Adjustments</td> <td style="text-align: center"> </td> <td colspan="3" style="text-align: center">Nine  Months Ended</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="3" style="text-align: center">June 30, 2015</td> <td style="text-align: center"> </td> <td colspan="3" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="3" style="text-align: center">June 30, 2015</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="3" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="3" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="3" style="text-align: center">Restated</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td>CASH FLOWS FROM OPERATING ACTIVITIES</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 46%">Net Income (loss)</td> <td style="width: 5%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">(10,594,463</td> <td style="width: 1%">)</td> <td style="width: 5%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">8909432</td> <td style="width: 1%"> </td> <td style="width: 5%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">(1,685,032</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Adjustments to reconcile net Income to net cash</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Preferred Stock issued for Expenses</td> <td> </td> <td>$</td> <td style="text-align: right">100</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">100</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 10pt">Predrred Stock issued for interest</td> <td> </td> <td>$</td> <td style="text-align: right">891</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">891</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Common Stock issued for expenses</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 10pt">Preferred Stock issued pursuant to contractual obligations</td> <td> </td> <td>$</td> <td style="text-align: right">3,475</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,475</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Common Stock issued to Consultants</td> <td> </td> <td>$</td> <td style="text-align: right">226,177</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">226,177</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 10pt">Preferred Stock issued to Consultants</td> <td> </td> <td>$</td> <td style="text-align: right">440</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">440</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Changes in operating assets and liabilities:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 10pt">Increase (Decrease) in Accounts Payable</td> <td> </td> <td>$</td> <td style="text-align: right">(2,115</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(2,115</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">(Increase) Decrease in Notes Receivable</td> <td> </td> <td>$</td> <td style="text-align: right">(1,629</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(1,629</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 10pt">(Increase) Decrease in Interest  Receivable</td> <td> </td> <td>$</td> <td style="text-align: right">(848</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(848</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Increase ( Decrease) in Bank Overdraft</td> <td> </td> <td>$</td> <td style="text-align: right">(6,137</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(6,137</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 10pt">Increase (Decrease) in accrued Expenses</td> <td> </td> <td>$</td> <td style="text-align: right">29,665</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">29,665</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">(Increase) Decrease in Prepaid Expenses</td> <td> </td> <td>$</td> <td style="text-align: right">(6,289</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(6,289</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 10pt">Increase in issuance of stock below fair value</td> <td> </td> <td>$</td> <td style="text-align: right">9,116,857</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(8,909,432</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">207,425</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Increase in Additional Paid in Capital</td> <td> </td> <td>$</td> <td style="text-align: right">380,191</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">380,191</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td>Net Cash Provided by (Used in) Operating Acitivities</td> <td> </td> <td>$</td> <td style="text-align: right">(853,686</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(853,685</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>CASH FLOWS FROM FINANCING ACTIVITIES</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 20pt">Common Stock issued for Cash</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 20pt">Increase in Contributed Capital</td> <td> </td> <td> </td> <td style="text-align: right">70,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">70,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 20pt">Increase ( Decrease)  in Notes Payable</td> <td> </td> <td> </td> <td style="text-align: right">19,582</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">19,582</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 20pt">Increase in Convertible Notes payable</td> <td> </td> <td> </td> <td style="text-align: right">972,686</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">972,686</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td>Net Cash Provided by (Used in) Financing Activities</td> <td> </td> <td> </td> <td style="text-align: right">1,062,268</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,062,268</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td>Net Increase (Decrease) in Cash</td> <td> </td> <td>$</td> <td style="text-align: right">208,582</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">208,583</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td>Cash at Beginning of Period</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td>Cash at End of Period</td> <td> </td> <td>$</td> <td style="text-align: right">208,582</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">208,583</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Supplemental Disclosure of Noncash investing and financing activities:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td>Common Shares Issued for Debt</td> <td> </td> <td>$</td> <td style="text-align: right">1,002,686</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Preferred Shares issued for Debt</td> <td> </td> <td>$</td> <td style="text-align: right">6,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td colspan="13" style="padding-left: 20pt; text-align: center">The Accompanying Notes are an Integral Part of These Financial Statements</td></tr> </table> -6137 -6137 0 0 70000 70000

6055

EX-101.SCH 7 rgbp-20150630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Balance Sheet (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Balance Sheet (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Statement of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Statement of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - Organization and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Notes Payable and Convertible Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Notes Receivable link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Stockholders Equity link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Stock Transactions link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Restatement of Previously Issued Financial Statements link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Notes Payable and Convertible Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Notes Receivable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Restatement of Previously Issued Financial Statements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Notes Payable and Convertible Notes Payable - Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Notes Payable and Convertible Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Notes Receivable - Notes Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Notes Receivable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Income Taxes - Deferred tax assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Stockholders Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Stock Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Restatement of Balance Sheets (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Restatment of Statements of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Restatement of Cashflows (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 rgbp-20150630_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 rgbp-20150630_def.xml XBRL DEFINITION FILE EX-101.LAB 10 rgbp-20150630_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series A Preferred Stock Adjustments for Error Corrections [Axis] Restated Series AA Preferred Stock Debt Instrument [Axis] Bio Matrix Scientific Group, Inc David Koos Bio Technology Partners Business Trust Common Stock Adjustments Original Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Amendment Description Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement [Table] Statement [Line Items] ASSETS CURRENT ASSETS Cash Note Receivable Prepaid Expenses Accrued Interest Receivable Total Current Assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS EQUITY Current Liabilities: Bank Overdraft Accounts payable Notes Payable Accrued payroll taxes Accrued Interest Accrued Rent Accrued Payroll Total Current Liabilities Total Liabilities STOCKHOLDERS EQUITY (DEFICIT) Common Stock, ($0.0001 par value) 500,000,000 shares authorized, 113,525,096 issued and outstanding as of June 30, 2015 and 51,907,917 shares issued and outstanding as of September 30, 2014 Preferred Stock, 0.0001 par value, 100,000,000 authorized and Five Million authorized as of June 30, 2015 and September 30, 2014 respectively Additional Paid in capital Contributed Capital Retained Earnings (Deficit) accumulated during the development stage Total Stockholders' Equity (Deficit) TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT) Common stock, par value (in dollars per share) Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding REVENUES COST AND EXPENSES Research and Development General and Administrative Consulting and Professional Fees Rent Total Costs and Expenses OPERATING LOSS OTHER INCOME & (EXPENSES) Interest Income Refunds of amounts previously paid Interest Expense Capital contribution to parent Loss on issuance of common shares for less than fair value Preferred shares issued pursuant to contractual obligations TOTAL OTHER INCOME (EXPENSE) NET INCOME (LOSS) BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING CASH FLOWS FROM OPERATING ACTIVITIES Net Income (loss) Adjustments to reconcile net Income to net cash Preferred Stock issued for Expenses Preferred Stock issued for interest Common Stock issued for expenses Preferred Stock issued pursuant to contractual obligations Common Stock issued to Consultants Preferred Stock issued to Consultants Changes in operating assets and liabilities: Increase (Decrease) in Accounts Payable (Increase) Decrease in Notes Receivable (Increase) Decrease in Interest Receivable Increase (Decrease) in Bank Overdraft Increase (Decrease) in Accrued Expenses Increase in issuance of stock below fair value (Increase) Decrease in Prepaid Expenses Net Cash Provided by (Used in) Operating Activities CASH FLOWS FROM FINANCING ACTIVITIES Common Stock issued for Cash Increase in Contributed Capital Increase (Decrease) in Notes Payable Increase in Convertible Notes Payable Net Cash Provided by (Used in) Financing Activities Net Increase (Decrease) in Cash Cash at Beginning of Period Cash at End of Period Supplemental Disclosure of Noncash investing and financing activities: Common shares Issued for Debt Preferred Shares Issued for Debt Accounting Policies [Abstract] Organization and Summary of Significant Accounting Policies Accounting Changes and Error Corrections [Abstract] Recent Accounting Pronouncements Organization, Consolidation and Presentation of Financial Statements [Abstract] Going Concern Debt Disclosure [Abstract] Notes Payable and Convertible Notes Payable Receivables [Abstract] Notes Receivable Income Tax Disclosure [Abstract] Income Taxes Related Party Transactions [Abstract] Related Party Transactions Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Equity [Abstract] Stockholders Equity Notes to Financial Statements Stock Transactions Restatement of Previously Issued Financial Statements Subsequent Events [Abstract] Subsequent Events BASIS OF ACCOUNTING USE OF ESTIMATES CASH EQUIVALENTS PROPERTY AND EQUIPMENT FAIR VALUE OF FINANCIAL INSTRUMENTS INCOME TAXES BASIC EARNINGS (LOSS) PER SHARE ADVERTISING Notes Payable Notes Receivable Deferred tax assets Restatement of Consolidated Balance Sheeet Restatement of Statement of Operations Restatement of Statment of Cashflows Advertising expenses Valuation allowance Net loss since inception Issuance of convertible debt Bio Matrix Scientific Group, Inc. (Note 7) David Koos ( Notes7) Bio Technology Partners Business Trust Notes payable Lent by Bio Matrix Scientific Group, Inc. Interest rate per annum Lent by David Koos Lent by Bio Technology Partners Business Trust Face value of convertible notes issued Cash consideration for issued notes Satisfaction of existing indebtedness Interest rate per annum payable quarerly Discount to lowest trading price Common shares issued upon conversion of notes payable Series A preferred shares issued upon conversion of notes payable Derivative liability Convertible notes, aggregate face value Price per share Shares issued in satisfaction of convertible notes payable Aggregate derivative liability (Black-Scholes pricing) Entest Biomedical, Inc. (Note 7) Note Receivable Entest Biomedical note receivable Interest rate on note receivable Deferred tax assets: Net operating tax carry forwards Other Gross deferred tax assets Valuation allowance Net deferred tax assets Deferred Tax Asset Net operating loss carry forwards Federal corporate rate Capital contributions from related party Common shares issued to BMSN Value of shares issued to BMSN Monthly rent payable to Entest Amount due from related party (ENTB) Amount payable to related party (BMSN) Amount due to company CEO EX-101.PRE 11 rgbp-20150630_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Jun. 30, 2015	Jul. 01, 2015
Document And Entity Information
Entity Registrant Name	Regen BioPharma Inc
Entity Central Index Key	0001589150
Document Type	10-Q/A
Document Period End Date	Jun. 30, 2015
Amendment Flag	true
Amendment Description	EXPLANATORY NOTE: THIS AMENDMENT NO.2 TO REGEN BIOPHARMA, INC’S (THE “COMPANY”) FORM 10-Q FOR THE PERIOD ENDED JUNE 30, 2015 (“(“ORIGINAL FILING”) IS BEING FILED SOLELY TO AMEND THE FOLLOWING PORTIONS OF AMENDMENT NO.1 OF THE ORIGINAL FILING (“AMENDMENT NO.1”). PART 1, ITEM 4 THE COMPANY HAS NOT MODIFIED OR UPDATED DISCLOSURES PRESENTED IN AMENDMENT NO.1 OR THE ORIGINAL FILING, EXCEPT AS INDICATED ABOVE. ACCORDINGLY, THIS AMENDMENT DOES NOT REFLECT EVENTS OCCURRING AFTER THE DATE OF THE ORIGINAL FILING AND DOES NOT MODIFY OR UPDATE THOSE DISCLOSURES AFFECTED BY SUBSEQUENT EVENTS, EXCEPT AS SPECIFICALLY REFERENCED HEREIN. INFORMATION NOT AFFECTED BY THE ABOVE AMENDMENTS IS UNCHANGED AND REFLECTS THE DISCLOSURES MADE AT THE TIME OF THE ORIGINAL FILING.
Current Fiscal Year End Date	--09-30
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		113,937,338
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2015

XML 13 R2.htm IDEA: XBRL DOCUMENT

Balance Sheet (Unaudited) - USD ($)	Jun. 30, 2015	Sep. 30, 2014
CURRENT ASSETS
Cash		$ 0
Note Receivable		10,422
Prepaid Expenses		0
Accrued Interest Receivable		233
Total Current Assets		10,655
TOTAL ASSETS		10,655
Current Liabilities:
Bank Overdraft		6,137
Accounts payable		3,305
Notes Payable		120,169
Accrued payroll taxes		8,463
Accrued Interest		2,212
Accrued Rent		0
Accrued Payroll		0
Total Current Liabilities		140,286
Total Liabilities		140,286
STOCKHOLDERS EQUITY (DEFICIT)
Common Stock, ($0.0001 par value) 500,000,000 shares authorized, 113,525,096 issued and outstanding as of June 30, 2015 and 51,907,917 shares issued and outstanding as of September 30, 2014		5,191
Preferred Stock, 0.0001 par value, 100,000,000 authorized and Five Million authorized as of June 30, 2015 and September 30, 2014 respectively
Additional Paid in capital		485,097
Contributed Capital		658,658
Retained Earnings (Deficit) accumulated during the development stage		(1,278,577)
Total Stockholders' Equity (Deficit)		(129,631)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)		10,655
Series A Preferred Stock
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock, 0.0001 par value, 100,000,000 authorized and Five Million authorized as of June 30, 2015 and September 30, 2014 respectively
Series AA Preferred Stock
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock, 0.0001 par value, 100,000,000 authorized and Five Million authorized as of June 30, 2015 and September 30, 2014 respectively
Restated
CURRENT ASSETS
Cash	$ 208,582
Note Receivable	12,051
Prepaid Expenses	6,289
Accrued Interest Receivable	1,081
Total Current Assets	228,003
TOTAL ASSETS	228,003
Current Liabilities:
Bank Overdraft	0
Accounts payable	1,190
Notes Payable	103,751
Accrued payroll taxes	6,692
Accrued Interest	18,147
Accrued Rent	5,000
Accrued Payroll	10,501
Total Current Liabilities	145,281
Total Liabilities	145,281
STOCKHOLDERS EQUITY (DEFICIT)
Common Stock, ($0.0001 par value) 500,000,000 shares authorized, 113,525,096 issued and outstanding as of June 30, 2015 and 51,907,917 shares issued and outstanding as of September 30, 2014	11,353
Preferred Stock, 0.0001 par value, 100,000,000 authorized and Five Million authorized as of June 30, 2015 and September 30, 2014 respectively
Additional Paid in capital	2,300,262
Contributed Capital	728,658
Retained Earnings (Deficit) accumulated during the development stage	(2,963,609)
Total Stockholders' Equity (Deficit)	82,722
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	228,003
Restated \| Series A Preferred Stock
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock, 0.0001 par value, 100,000,000 authorized and Five Million authorized as of June 30, 2015 and September 30, 2014 respectively	6,055
Total Stockholders' Equity (Deficit)	6,055
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	6,055
Restated \| Series AA Preferred Stock
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock, 0.0001 par value, 100,000,000 authorized and Five Million authorized as of June 30, 2015 and September 30, 2014 respectively	3
Total Stockholders' Equity (Deficit)	3
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$ 3

XML 14 R3.htm IDEA: XBRL DOCUMENT

Balance Sheet (Parenthetical) - $ / shares	Jun. 30, 2015	Sep. 30, 2014
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	113,525,096	51,907,917
Common stock, shares outstanding	109,310,811	51,907,917
Preferred stock, par value	$ 0.0001	$ .0001
Preferred stock, shares authorized	100,000,000	5,000,000
Series A Preferred Stock
Preferred stock, par value	$ 0.0001
Preferred stock, shares authorized	90,000,000	0
Preferred stock, shares issued		0
Preferred stock, shares outstanding	60,548,364	0
Series A Preferred Stock \| Restated
Preferred stock, shares issued	60,548,364
Series AA Preferred Stock
Preferred stock, par value		$ 0.0001
Preferred stock, shares authorized		600,000
Preferred stock, shares issued		0
Preferred stock, shares outstanding		0
Series AA Preferred Stock \| Restated
Preferred stock, par value	$ 0.0001
Preferred stock, shares authorized	600,000
Preferred stock, shares issued	30,000
Preferred stock, shares outstanding	30,000

XML 15 R4.htm IDEA: XBRL DOCUMENT

Statement of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
Statement of Operations (Unaudited) - USD ($)	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
REVENUES		$ 0		$ 0
COST AND EXPENSES
Research and Development		0		13,867
General and Administrative		127,580		389,961
Consulting and Professional Fees		30,287		109,917
Rent		0		0
Total Costs and Expenses		157,867		513,745
OPERATING LOSS		(157,867)		(513,745)
OTHER INCOME & (EXPENSES)
Interest Income		14		14
Refunds of amounts previously paid		490		490
Interest Expense		0		0
Capital contribution to parent		(8,658)		(48,510)
Loss on issuance of common shares for less than fair value		0
Preferred shares issued pursuant to contractual obligations		0		0
TOTAL OTHER INCOME (EXPENSE)		(8,154)		(48,006)
NET INCOME (LOSS)		$ (166,021)		$ (561,751)
BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE		$ (.0032)		$ (.0152)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING		51,909,907		37,082,956
Restated
REVENUES	$ 0		$ 0
COST AND EXPENSES
Research and Development	68,081		93,287
General and Administrative	463,765		906,754
Consulting and Professional Fees	73,364		413,125
Rent	16,200		43,071
Total Costs and Expenses	621,410		1,456,238
OPERATING LOSS	(621,410)		(1,456,238)
OTHER INCOME & (EXPENSES)
Interest Income	297		848
Refunds of amounts previously paid
Interest Expense	(3,512)		(18,742)
Capital contribution to parent	0		0
Loss on issuance of common shares for less than fair value	(207,425)		(207,425)
Preferred shares issued pursuant to contractual obligations	(321)		(3,475)
TOTAL OTHER INCOME (EXPENSE)	(210,961)		(228,794)
NET INCOME (LOSS)	$ (832,371)		$ (1,685,032)
BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE	$ (0.0075)		$ (0.0212)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	110,648,054		79,454,728

XML 16 R5.htm IDEA: XBRL DOCUMENT

Statement of Cash Flows (Unaudited) - USD ($)	9 Months Ended
Statement of Cash Flows (Unaudited) - USD ($)	Jun. 30, 2015	Jun. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (loss)		$ (561,751)
Adjustments to reconcile net Income to net cash
Preferred Stock issued for Expenses
Preferred Stock issued for interest
Common Stock issued for expenses
Preferred Stock issued pursuant to contractual obligations
Common Stock issued to Consultants
Preferred Stock issued to Consultants
Increase (Decrease) in Accounts Payable		117
(Increase) Decrease in Notes Receivable		(2,222)
(Increase) Decrease in Interest Receivable		(14)
Increase (Decrease) in Bank Overdraft
Increase (Decrease) in Accrued Expenses		7,343
Increase in issuance of stock below fair value
(Increase) Decrease in Prepaid Expenses
Net Cash Provided by (Used in) Operating Activities		(556,527)
CASH FLOWS FROM FINANCING ACTIVITIES
Common Stock issued for Cash		300,000
Increase in Contributed Capital		140,000
Increase (Decrease) in Notes Payable		50,000
Increase in Convertible Notes Payable
Net Cash Provided by (Used in) Financing Activities		490,000
Net Increase (Decrease) in Cash		(66,527)
Cash at Beginning of Period		115,922
Cash at End of Period		49,395
Supplemental Disclosure of Noncash investing and financing activities:
Common shares Issued for Debt
Preferred Shares Issued for Debt
Restated
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (loss)	$ (1,685,032)
Adjustments to reconcile net Income to net cash
Preferred Stock issued for Expenses	100
Preferred Stock issued for interest	891
Common Stock issued for expenses
Preferred Stock issued pursuant to contractual obligations	3,475
Common Stock issued to Consultants	226,177
Preferred Stock issued to Consultants	440
Increase (Decrease) in Accounts Payable	(2,115)
(Increase) Decrease in Notes Receivable	(1,629)
(Increase) Decrease in Interest Receivable	(848)
Increase (Decrease) in Bank Overdraft	(6,137)
Increase (Decrease) in Accrued Expenses	29,665
Increase in issuance of stock below fair value	(207,425)
(Increase) Decrease in Prepaid Expenses	(6,289)
Net Cash Provided by (Used in) Operating Activities	(853,686)
CASH FLOWS FROM FINANCING ACTIVITIES
Common Stock issued for Cash	0
Increase in Contributed Capital	70,000
Increase (Decrease) in Notes Payable	19,582
Increase in Convertible Notes Payable	972,686
Net Cash Provided by (Used in) Financing Activities	1,062,268
Net Increase (Decrease) in Cash	208,582
Cash at Beginning of Period	0
Cash at End of Period	208,582
Supplemental Disclosure of Noncash investing and financing activities:
Common shares Issued for Debt	1,002,686
Preferred Shares Issued for Debt	$ 6,000

XML 17 R6.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies

9 Months Ended

Jun. 30, 2015

Accounting Policies [Abstract]

Organization and Summary of Significant Accounting Policies

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company was organized April 24, 2012 under the laws of the State of Nevada. The Company is a majority owned subsidiary of Bio-Matrix Scientific Group, Inc, a Delaware corporation.

A. BASIS OF ACCOUNTING

B. USE OF ESTIMATES

C. CASH EQUIVALENTS

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

D. PROPERTY AND EQUIPMENT

E. FAIR VALUE OF FINANCIAL INSTRUMENTS

Level 1: Quoted prices in active markets for identical assets or liabilities

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

F. INCOME TAXES

The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established.

Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

G. BASIC EARNINGS (LOSS) PER SHARE

Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.

H. ADVERTISING

Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the three months ended June 30, 2015 and $0 for the three months ended June 30, 2014.

XML 18 R7.htm IDEA: XBRL DOCUMENT

Recent Accounting Pronouncements

9 Months Ended

Jun. 30, 2015

Accounting Changes and Error Corrections [Abstract]

Recent Accounting Pronouncements

NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS

The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors.

Any additional amounts the reporting entity expects to pay on behalf of its co-obligors.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6510796

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e725-108305

+ Details

XML 19 R8.htm IDEA: XBRL DOCUMENT

Going Concern

9 Months Ended

Jun. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Going Concern

NOTE 3. GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $ 11,873,041 during the period from April 24, 2012 (inception) through June 30, 2015. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

XML 20 R9.htm IDEA: XBRL DOCUMENT

Notes Payable and Convertible Notes Payable

9 Months Ended

Jun. 30, 2015

Debt Disclosure [Abstract]

Notes Payable and Convertible Notes Payable

NOTE 4. NOTES PAYABLE AND CONVERTIBLE NOTES PAYABLE

	June 30, 2015		September 30, 2014
Bio Matrix Scientific Group, Inc. (Note 7)		19,701		90,000
David Koos ( Notes7)		50		30,168
Bio Technology Partners Business Trust		84,000		0
Notes payable	$	103,751	$	120,168

$19,701 lent to the Company by Bio Matrix Scientific Group, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.

$50 lent to the Company by David Koos. is due and payable at the demand of the holder and bear simple interest at a rate of 15% per annum.

$84,000 lent to the Company by Bio Technology Partners Business Trust. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.

CONVERTIBLE NOTES PAYABLE

During the quarter ended March 31, 2015 the Company issued Convertible Notes ( “Notes”) with an aggregate face value of $882,686 . Consideration for these Notes consisted of:

(a)

$775,000 cash and

(b)

Satisfaction of $107,686 of existing indebtedness:

During the quarter ended June 30, 2015 the Company issued Convertible Notes ( “Notes”) with an aggregate face value of $90,000 . Consideration for these Notes consisted of $90,000.

All or part of the principal and accrued but unpaid interest is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent the lower of (1) a 65% discount to the lowest Trading Price (as defined below) for the Common Shares during the thirty (30) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the conversion date. “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by Regen and the Lender. “Trading Day” shall mean any day on which the Common Shares are tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Shares are then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by Regen relating to the Lender’s securities.

(2) $0.03 per share

Principal and interest may be prepaid in part or in full by Regen on not less than three Trading Days prior written notice to the Lender.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Notes Receivable

9 Months Ended

Jun. 30, 2015

Receivables [Abstract]

Notes Receivable

NOTE 5. NOTES RECEIVABLE

	June 30, 2015		September 30, 2014
Entest Biomedical, Inc. (Note 7)	$	12,051	$	10,422

Notes Receivable	$	12,051	$	10,422

$12,051 lent by the Company to Entest Biomedical, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.

XML 22 R11.htm IDEA: XBRL DOCUMENT

Income Taxes

9 Months Ended

Jun. 30, 2015

Income Tax Disclosure [Abstract]

Income Taxes

NOTE 6. INCOME TAXES

As of June 30, 2015

Deferred tax assets:
Net operating tax carry forwards	$	4,036,834
Other		-0-
Gross deferred tax assets		4,036,834
Valuation allowance		(4,036,834	)
Net deferred tax assets	$	-0-

As of June 30, 2015 the Company has a Deferred Tax Asset of $4,036,834 completely attributable to net operating loss carry forwards of approximately $11,873,041 (which expire 20 years from the date the loss was incurred).

Income tax is calculated at the 34% Federal Corporate Rate.

XML 23 R12.htm IDEA: XBRL DOCUMENT

Related Party Transactions

9 Months Ended

Jun. 30, 2015

Related Party Transactions

NOTE 7. RELATED PARTY TRANSACTIONS

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

XML 24 R13.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Jun. 30, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

NOTE 8. COMMITMENTS AND CONTINGENCIES

XML 25 R14.htm IDEA: XBRL DOCUMENT

Stockholders Equity

9 Months Ended

Jun. 30, 2015

Equity [Abstract]

Stockholders Equity

NOTE 9. STOCKHOLDERS' EQUITY

The stockholders' equity section of the Company contains the following classes of capital stock as June 30, 2015:

Common stock, $ 0.0001 par value; 500,000,000 shares authorized: 113,525,096 shares issued and outstanding.

Series AA Preferred Stock

Series A Preferred Stock

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

XML 26 R15.htm IDEA: XBRL DOCUMENT

Stock Transactions

9 Months Ended

Jun. 30, 2015

Notes to Financial Statements

Stock Transactions

NOTE 10. STOCK TRANSACTIONS

Common Stock

On April 14, 2015 the Company issued 1,428, 571 of its common shares in satisfaction of $40,000 of convertible indebtedness.

On May 12, 2015 the Company issued 500,000 of its common shares in satisfaction of $15,000 of indebtedness.

On May 18, 2015 the Company issued 500,000 of its common shares in satisfaction of $15,000 of indebtedness.

On May 19, 2015 the Company issued 1,785,714 of its common shares in satisfaction of $50,000 of convertible indebtedness.

Series A Preferred Stock

On April 14, 2015 the Company issued 1,428, 571 of its shares of Series A Preferred Stock in accordance with the terms and conditions of a $40,000 face value convertible note issued by the Company.

On May 19, 2015 the Company issued 200,000 of its shares of Series A Preferred Stock as consideration for services rendered by nonemployees.

On May 19, 2015 the Company issued 1,785,714 of its shares of Series A Preferred Stock in accordance with the terms and conditions of a $50,000 face value convertible note issued by the Company.

XML 27 R16.htm IDEA: XBRL DOCUMENT

Restatement of Previously Issued Financial Statements

9 Months Ended

Jun. 30, 2015

Accounting Changes and Error Corrections [Abstract]

Restatement of Previously Issued Financial Statements

NOTE 11. RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS

The following tables reflect the corrections:

REGEN BIOPHARMA , INC.
BALANCE SHEET

	As of			adjustments			As of
	June 30, 2015						June 30, 2015
	(unaudited)						(unaudited)
							restated
ASSETS
CURRENT ASSETS
Cash		208,582						208,582
Note Receivable		12,051						12,051
Prepaid Expenses		6,289						6,289
Accrued Interest Receivable		1,081						1,081
Total Current Assets		228,003						228,003


TOTAL ASSETS		228,003						228,003

LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable		1,190						1,190
Notes Payable		103,751						103,751
Accrued payroll taxes		6,692						6,692
Accrued Interest		18,147						18,147
Accrued Rent		5,000						5,000
Accrued Payroll		10,501						10,501
Total Current Liabilities		145,281						145,281
Total Liabilities		145,281						145,281

STOCKHOLDERS' EQUITY (DEFICIT)
Common Stock ($.0001 par value) 500,000,000 shares authorized; 113,525,096 issued and outstanding as of June 30, 2015 and 51,907,917 shares issued and outstanding September 30, 2014		11,353						11,353
Preferred Stock, 0.0001 par value, 100,000,000 authorized and Five Million authorized as of June 30, 2015 and September 30, 2014 respectively
Series A Preferred 90,000,000 Authorized and 0 authorized, 60,548,364 and 0 outstanding as of June 30, 2105 and September 30, 2014 respectively		6,055						6,055
Series AA Preferred $0.0001 par value 600,000 authorized and 30, 000 and 0 outstanding as of June 30, 2015 and September 30, 2014 respectively		3						3
Additional Paid in capital		11,209,694			(8,909,432	)		2,300,262
Contributed Capital		728,658						728,658
Retained Earnings (Deficit) accumulated during the development stage		(11,873,041	)		8,909,432			(2,963,609	)
Total Stockholders' Equity (Deficit)		82,722						82,722

TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)		228,003						228,003

REGEN BIOPHARMA , INC.
STATEMENT OF OPERATIONS

	Three months ended		adjustments	Three months ended		Nine Months Ended		adjustments	Nine Months Ended
	June 30, 2015			June 30, 2015		June 30, 2015			June 30, 2015
	(unaudited)			(unaudited)		(unaudited)			(unaudited)
				(as restated)					(as restated)
REVENUES	0			0		0			0

COST AND EXPENSES
Research and Development	68,081			68,081		93,287			93,287
General and Administrative	463,765			463,765		906,754			906,754
Consulting and Professional Fees	73,364			73,364		413,125			413,125
Rent	16,200			16,200		43,071			43,071
Total Costs and Expenses	621,410			621,410		1,456,238			1,456,238

OPERATING LOSS	(621,410	)		(621,410	)	(1,456,238	)		(1,456,238	)

OTHER INCOME & (EXPENSES)
Interest Income	297			297		848			848
Refunds of amounts previously paid
Interest Expense	(3,512	)		(3,512	)	(18,742	)		(18,742	)
Capital contribution tp parent	0			0		0			0
Loss on issuance of common shares for
less than fair value	(937,425	)	730,000	(207,425	)	(9,116,857	)	8,909,432	(207,425	)
Preferred shares issued pursuant to
contractual obligations	(321	)		(321	)	(3,475	)		(3,475	)

TOTAL OTHER INCOME (EXPENSE)	(940,961	)		(210,961	)	(9,138,226	)		(228,794	)

NET INCOME (LOSS)	(1,562,371	)		(832,371	)	(10,594,463	)		(1,685,032	)
BASIC AND FULLY DILUTED
EARNINGS (LOSS) PER SHARE	(0.0141	)		(0.0075	)	(0.1333	)		(0.0212	)
WEIGHTED AVERAGE NUMBER OF COMMON	110,648,054			110,648,054		79,454,728			79,454,728
SHARES OUTSTANDING


REGEN BIOPHARMA , INC.
STATEMENT OF CASH FLOWS
(unaudited)

	Nine Months Ended			Adjustments			Nine Months Ended
	June 30, 2015						June 30, 2015
							Restated
CASH FLOWS FROM OPERATING ACTIVITIES

Net Income (loss)	$	(10,594,463	)		8909432			(1,685,032	)
Adjustments to reconcile net Income to net cash

Preferred Stock issued for Expenses	$	100						100
Predrred Stock issued for interest	$	891						891
Common Stock issued for expenses
Preferred Stock issued pursuant to contractual obligations	$	3,475						3,475
Common Stock issued to Consultants	$	226,177						226,177
Preferred Stock issued to Consultants	$	440						440
Changes in operating assets and liabilities:
Increase (Decrease) in Accounts Payable	$	(2,115	)					(2,115	)
(Increase) Decrease in Notes Receivable	$	(1,629	)					(1,629	)
(Increase) Decrease in Interest Receivable	$	(848	)					(848	)
Increase ( Decrease) in Bank Overdraft	$	(6,137	)					(6,137	)
Increase (Decrease) in accrued Expenses	$	29,665						29,665
(Increase) Decrease in Prepaid Expenses	$	(6,289	)					(6,289	)
Increase in issuance of stock below fair value	$	9,116,857			(8,909,432	)		207,425
Increase in Additional Paid in Capital	$	380,191						380,191
Net Cash Provided by (Used in) Operating Acitivities	$	(853,686	)					(853,685	)
CASH FLOWS FROM FINANCING ACTIVITIES
Common Stock issued for Cash		0						0
Increase in Contributed Capital		70,000						70,000
Increase ( Decrease) in Notes Payable		19,582						19,582
Increase in Convertible Notes payable		972,686						972,686
Net Cash Provided by (Used in) Financing Activities		1,062,268						1,062,268

Net Increase (Decrease) in Cash	$	208,582						208,583

Cash at Beginning of Period		0						0

Cash at End of Period	$	208,582						208,583


Supplemental Disclosure of Noncash investing and financing activities:
Common Shares Issued for Debt	$	1,002,686
Preferred Shares issued for Debt	$	6,000

The Accompanying Notes are an Integral Part of These Financial Statements

XML 28 R17.htm IDEA: XBRL DOCUMENT

Subsequent Events

9 Months Ended

Jun. 30, 2015

Subsequent Events [Abstract]

Subsequent Events

NOTE 11. SUBSEQUENT EVENTS

On July 1, 2015 the Company issued 412,242 of its shares of common stock as consideration for services rendered by a nonemployee.

XML 29 R18.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
BASIS OF ACCOUNTING	A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.
USE OF ESTIMATES	B. USE OF ESTIMATES The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
CASH EQUIVALENTS	C. CASH EQUIVALENTS The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
PROPERTY AND EQUIPMENT	D. PROPERTY AND EQUIPMENT Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized.
FAIR VALUE OF FINANCIAL INSTRUMENTS	E. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value: Level 1: Quoted prices in active markets for identical assets or liabilities Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
INCOME TAXES	F. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of June 30, 2015 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.
BASIC EARNINGS (LOSS) PER SHARE	G. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.
ADVERTISING	H. ADVERTISING Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the three months ended June 30, 2015 and $0 for the three months ended June 30, 2014.

- Definition

Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.

+ References + Details

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References + Details

XML 30 R19.htm IDEA: XBRL DOCUMENT

Notes Payable and Convertible Notes Payable (Tables)

9 Months Ended

Jun. 30, 2015

Debt Disclosure [Abstract]

Notes Payable

	June 30, 2015		September 30, 2014
Bio Matrix Scientific Group, Inc. (Note 7)		19,701		90,000
David Koos ( Notes7)		50		30,168
Bio Technology Partners Business Trust		84,000		0
Notes payable	$	103,751	$	120,168

XML 31 R20.htm IDEA: XBRL DOCUMENT

Notes Receivable (Tables)

9 Months Ended

Jun. 30, 2015

Receivables [Abstract]

Notes Receivable

	June 30, 2015		September 30, 2014
Entest Biomedical, Inc. (Note 7)	$	12,051	$	10,422

Notes Receivable	$	12,051	$	10,422

XML 32 R21.htm IDEA: XBRL DOCUMENT

Income Taxes (Tables)

9 Months Ended

Jun. 30, 2015

Income Tax Disclosure [Abstract]

Deferred tax assets

Deferred tax assets:
Net operating tax carry forwards	$	4,036,834
Other		-0-
Gross deferred tax assets		4,036,834
Valuation allowance		(4,036,834	)
Net deferred tax assets	$	-0-

XML 33 R22.htm IDEA: XBRL DOCUMENT

Restatement of Previously Issued Financial Statements (Tables)

9 Months Ended

Jun. 30, 2015

Accounting Changes and Error Corrections [Abstract]

Restatement of Consolidated Balance Sheeet

REGEN BIOPHARMA , INC.
BALANCE SHEET

	As of			adjustments			As of
	June 30, 2015						June 30, 2015
	(unaudited)						(unaudited)
							restated
ASSETS
CURRENT ASSETS
Cash		208,582						208,582
Note Receivable		12,051						12,051
Prepaid Expenses		6,289						6,289
Accrued Interest Receivable		1,081						1,081
Total Current Assets		228,003						228,003


TOTAL ASSETS		228,003						228,003

LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable		1,190						1,190
Notes Payable		103,751						103,751
Accrued payroll taxes		6,692						6,692
Accrued Interest		18,147						18,147
Accrued Rent		5,000						5,000
Accrued Payroll		10,501						10,501
Total Current Liabilities		145,281						145,281
Total Liabilities		145,281						145,281

STOCKHOLDERS' EQUITY (DEFICIT)
Common Stock ($.0001 par value) 500,000,000 shares authorized; 113,525,096 issued and outstanding as of June 30, 2015 and 51,907,917 shares issued and outstanding September 30, 2014		11,353						11,353
Preferred Stock, 0.0001 par value, 100,000,000 authorized and Five Million authorized as of June 30, 2015 and September 30, 2014 respectively
Series A Preferred 90,000,000 Authorized and 0 authorized, 60,548,364 and 0 outstanding as of June 30, 2105 and September 30, 2014 respectively		6,055						6,055
Series AA Preferred $0.0001 par value 600,000 authorized and 30, 000 and 0 outstanding as of June 30, 2015 and September 30, 2014 respectively		3						3
Additional Paid in capital		11,209,694			(8,909,432	)		2,300,262
Contributed Capital		728,658						728,658
Retained Earnings (Deficit) accumulated during the development stage		(11,873,041	)		8,909,432			(2,963,609	)
Total Stockholders' Equity (Deficit)		82,722						82,722

TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)		228,003						228,003

Restatement of Statement of Operations

REGEN BIOPHARMA , INC.
STATEMENT OF OPERATIONS

	Three months ended		adjustments	Three months ended		Nine Months Ended		adjustments	Nine Months Ended
	June 30, 2015			June 30, 2015		June 30, 2015			June 30, 2015
	(unaudited)			(unaudited)		(unaudited)			(unaudited)
				(as restated)					(as restated)
REVENUES	0			0		0			0

COST AND EXPENSES
Research and Development	68,081			68,081		93,287			93,287
General and Administrative	463,765			463,765		906,754			906,754
Consulting and Professional Fees	73,364			73,364		413,125			413,125
Rent	16,200			16,200		43,071			43,071
Total Costs and Expenses	621,410			621,410		1,456,238			1,456,238

OPERATING LOSS	(621,410	)		(621,410	)	(1,456,238	)		(1,456,238	)

OTHER INCOME & (EXPENSES)
Interest Income	297			297		848			848
Refunds of amounts previously paid
Interest Expense	(3,512	)		(3,512	)	(18,742	)		(18,742	)
Capital contribution tp parent	0			0		0			0
Loss on issuance of common shares for
less than fair value	(937,425	)	730,000	(207,425	)	(9,116,857	)	8,909,432	(207,425	)
Preferred shares issued pursuant to
contractual obligations	(321	)		(321	)	(3,475	)		(3,475	)

TOTAL OTHER INCOME (EXPENSE)	(940,961	)		(210,961	)	(9,138,226	)		(228,794	)

NET INCOME (LOSS)	(1,562,371	)		(832,371	)	(10,594,463	)		(1,685,032	)
BASIC AND FULLY DILUTED
EARNINGS (LOSS) PER SHARE	(0.0141	)		(0.0075	)	(0.1333	)		(0.0212	)
WEIGHTED AVERAGE NUMBER OF COMMON	110,648,054			110,648,054		79,454,728			79,454,728
SHARES OUTSTANDING

Restatement of Statment of Cashflows


REGEN BIOPHARMA , INC.
STATEMENT OF CASH FLOWS
(unaudited)

	Nine Months Ended			Adjustments			Nine Months Ended
	June 30, 2015						June 30, 2015
							Restated
CASH FLOWS FROM OPERATING ACTIVITIES

Net Income (loss)	$	(10,594,463	)		8909432			(1,685,032	)
Adjustments to reconcile net Income to net cash

Preferred Stock issued for Expenses	$	100						100
Predrred Stock issued for interest	$	891						891
Common Stock issued for expenses
Preferred Stock issued pursuant to contractual obligations	$	3,475						3,475
Common Stock issued to Consultants	$	226,177						226,177
Preferred Stock issued to Consultants	$	440						440
Changes in operating assets and liabilities:
Increase (Decrease) in Accounts Payable	$	(2,115	)					(2,115	)
(Increase) Decrease in Notes Receivable	$	(1,629	)					(1,629	)
(Increase) Decrease in Interest Receivable	$	(848	)					(848	)
Increase ( Decrease) in Bank Overdraft	$	(6,137	)					(6,137	)
Increase (Decrease) in accrued Expenses	$	29,665						29,665
(Increase) Decrease in Prepaid Expenses	$	(6,289	)					(6,289	)
Increase in issuance of stock below fair value	$	9,116,857			(8,909,432	)		207,425
Increase in Additional Paid in Capital	$	380,191						380,191
Net Cash Provided by (Used in) Operating Acitivities	$	(853,686	)					(853,685	)
CASH FLOWS FROM FINANCING ACTIVITIES
Common Stock issued for Cash		0						0
Increase in Contributed Capital		70,000						70,000
Increase ( Decrease) in Notes Payable		19,582						19,582
Increase in Convertible Notes payable		972,686						972,686
Net Cash Provided by (Used in) Financing Activities		1,062,268						1,062,268

Net Increase (Decrease) in Cash	$	208,582						208,583

Cash at Beginning of Period		0						0

Cash at End of Period	$	208,582						208,583


Supplemental Disclosure of Noncash investing and financing activities:
Common Shares Issued for Debt	$	1,002,686
Preferred Shares issued for Debt	$	6,000

The Accompanying Notes are an Integral Part of These Financial Statements

XML 34 R23.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015
Accounting Policies [Abstract]
Advertising expenses	$ 0	$ 0
Valuation allowance			100.00%

XML 35 R24.htm IDEA: XBRL DOCUMENT

Going Concern (Details Narrative) - USD ($)	3 Months Ended			9 Months Ended	38 Months Ended
Going Concern (Details Narrative) - USD ($)	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss since inception		$ (8,812,901)	$ (166,021)	$ (561,751)	$ (11,873,041)
Issuance of convertible debt	$ 775,000	$ 775,000	$ 90,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 36 R25.htm IDEA: XBRL DOCUMENT

Notes Payable and Convertible Notes Payable - Notes Payable (Details) - USD ($)	Jun. 30, 2015	Sep. 30, 2014
Debt Disclosure [Abstract]
Bio Matrix Scientific Group, Inc. (Note 7)	$ 19,701	$ 90,000
David Koos ( Notes7)	50	30,168
Bio Technology Partners Business Trust	84,000	0
Notes payable	$ 103,751	$ 120,168

XML 37 R26.htm IDEA: XBRL DOCUMENT

Notes Payable and Convertible Notes Payable (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2014	Sep. 30, 2014
Lent by Bio Matrix Scientific Group, Inc.	$ 19,701			$ 90,000
Interest rate per annum	10.00%
Lent by David Koos	$ 50			30,168
Lent by Bio Technology Partners Business Trust	84,000			$ 0
Face value of convertible notes issued	882,686
Cash consideration for issued notes	775,000	$ 775,000	$ 90,000
Satisfaction of existing indebtedness	$ 107,686
Interest rate per annum payable quarerly	10.00%
Discount to lowest trading price	65.00%
Common shares issued upon conversion of notes payable	31,539,262
Series A preferred shares issued upon conversion of notes payable	31,538,862
Derivative liability	$ 2,368,685
Convertible notes, aggregate face value	$ 90,000
Price per share	$ .03
Shares issued in satisfaction of convertible notes payable	3,214,285
Aggregate derivative liability (Black-Scholes pricing)	$ 350,666
Series A Preferred Stock
Shares issued in satisfaction of convertible notes payable	3,214,285
Bio Matrix Scientific Group, Inc
Lent by Bio Matrix Scientific Group, Inc.	$ 19,701
Interest rate per annum	10.00%
David Koos
Interest rate per annum	15.00%
Lent by David Koos	$ 50
Bio Technology Partners Business Trust
Interest rate per annum	10.00%
Lent by Bio Technology Partners Business Trust	$ 84,000

XML 38 R27.htm IDEA: XBRL DOCUMENT

Notes Receivable - Notes Receivable (Details) - USD ($)	Jun. 30, 2015	Sep. 30, 2014
Receivables [Abstract]
Entest Biomedical, Inc. (Note 7)	$ 12,051	$ 10,422
Note Receivable	$ 12,051	$ 10,422

XML 39 R28.htm IDEA: XBRL DOCUMENT

Notes Receivable (Details Narrative) - USD ($)	9 Months Ended
Notes Receivable (Details Narrative) - USD ($)	Jun. 30, 2015	Sep. 30, 2014
Receivables [Abstract]
Entest Biomedical note receivable	$ 12,051	$ 10,422
Interest rate on note receivable	10.00%

XML 40 R29.htm IDEA: XBRL DOCUMENT

Income Taxes - Deferred tax assets (Details)	Jun. 30, 2015 USD ($)
Deferred tax assets:
Net operating tax carry forwards	$ 4,036,834
Other	0
Gross deferred tax assets	4,036,834
Valuation allowance	(4,036,834)
Net deferred tax assets	$ 0

XML 41 R30.htm IDEA: XBRL DOCUMENT

Income Taxes (Details Narrative)	9 Months Ended
Income Taxes (Details Narrative)	Jun. 30, 2015 USD ($)
Income Tax Disclosure [Abstract]
Deferred Tax Asset	$ 4,036,834
Net operating loss carry forwards	$ 11,873,041
Federal corporate rate	34.00%

XML 42 R31.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended	35 Months Ended
	Jun. 30, 2015	Jun. 30, 2015	Sep. 30, 2014
Related Party Transactions [Abstract]
Capital contributions from related party		$ 728,658
Common shares issued to BMSN		50,010,000
Value of shares issued to BMSN		$ 20,090
Monthly rent payable to Entest	$ 5,000
Amount due from related party (ENTB)	$ 12,052	12,052
Interest rate per annum	10.00%
Amount payable to related party (BMSN)	$ 19,701	19,701	$ 90,000
Amount due to company CEO	$ 50	$ 50

XML 43 R32.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Narrative) - USD ($)	9 Months Ended
	Jun. 30, 2015	Mar. 20, 2015
Commitments and Contingencies Disclosure [Abstract]
Sublease, rent payable		$ 5,000
Monthly sublease fee to HBRI		$ 400
Monthly research agreement fee	$ 2,700

XML 44 R33.htm IDEA: XBRL DOCUMENT

Stockholders Equity (Details Narrative) - $ / shares	3 Months Ended
Stockholders Equity (Details Narrative) - $ / shares	Jun. 30, 2015	Sep. 30, 2014
Common stock, Par value	$ 0.0001	$ 0.0001
Common stock, authorized	500,000,000	500,000,000
Common stock issued and outstanding	113,525,096	51,907,917
Preferred stock, par value	$ 0.0001	$ .0001
Preferred stock, authorized	100,000,000	5,000,000
Series A Preferred Stock
Preferred stock, par value	$ 0.0001
Preferred stock, authorized	90,000,000	0
Preferred stock, shares issued and outstanding		0
Preferred stock, shares outstanding	60,548,364	0
Preferred stock, non-cumulative cash dividends	$ .01
Series A Preferred Stock \| Restated
Preferred stock, shares issued and outstanding	60,548,364
Series AA Preferred Stock
Preferred stock, par value		$ 0.0001
Preferred stock, authorized		600,000
Preferred stock, shares issued and outstanding		0
Preferred stock, shares outstanding		0
Series AA Preferred Stock \| Restated
Preferred stock, par value	$ 0.0001
Preferred stock, authorized	600,000
Preferred stock, shares issued and outstanding	30,000
Preferred stock, shares outstanding	30,000

XML 45 R34.htm IDEA: XBRL DOCUMENT

Stock Transactions (Details Narrative) - USD ($)	May 19, 2015	May 18, 2015	May 12, 2015	Apr. 14, 2015
Common Stock
Shares issued	$ 1,785,714	$ 500,000	$ 500,000	$ 1,428,571
Total debt converted	50,000	$ 15,000	$ 15,000	40,000
Series A Preferred Stock
Shares issued	1,785,714			1,428,571
Total debt converted	$ 50,000			$ 40,000
Shares issued for services	200,000

XML 46 R35.htm IDEA: XBRL DOCUMENT

Restatement of Balance Sheets (Details) - USD ($)	Jun. 30, 2015	Sep. 30, 2014
CURRENT ASSETS
Cash		$ 0
Note Receivable		10,422
Accrued Interest Receivable		233
Total Current Assets		10,655
TOTAL ASSETS		10,655
Current Liabilities:
Accounts payable		3,305
Notes Payable		120,169
Accrued payroll taxes		8,463
Accrued Interest		2,212
Accrued Rent		0
Accrued Payroll		0
Total Current Liabilities		140,286
Total Liabilities		140,286
STOCKHOLDERS EQUITY (DEFICIT)
Common Stock, ($0.0001 par value) 500,000,000 shares authorized, 109,310,811 issued and outstanding as of March 31, 2015 and 51,907,917 shares issued and outstanding as of September 30, 2014		5,191
Preferred Stock, 0.0001 par value, 100,000,000 authorized and Five Million authorized as of June 30, 2015 and September 30, 2014 respectively
Additional Paid in capital		485,097
Contributed Capital		658,658
Retained Earnings (Deficit) accumulated during the development stage		(1,278,577)
Total Stockholders' Equity (Deficit)		(129,631)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)		10,655
Series A Preferred Stock
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock, 0.0001 par value, 100,000,000 authorized and Five Million authorized as of June 30, 2015 and September 30, 2014 respectively
Series AA Preferred Stock
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock, 0.0001 par value, 100,000,000 authorized and Five Million authorized as of June 30, 2015 and September 30, 2014 respectively
Original
CURRENT ASSETS
Cash	$ 208,582
Note Receivable	12,051
Accrued Interest Receivable	1,081
Total Current Assets	228,003
TOTAL ASSETS	228,003
Current Liabilities:
Accounts payable	1,190
Notes Payable	103,751
Accrued payroll taxes	6,692
Accrued Interest	18,147
Accrued Rent	5,000
Accrued Payroll	10,501
Total Current Liabilities	145,281
Total Liabilities	145,281
STOCKHOLDERS EQUITY (DEFICIT)
Common Stock, ($0.0001 par value) 500,000,000 shares authorized, 109,310,811 issued and outstanding as of March 31, 2015 and 51,907,917 shares issued and outstanding as of September 30, 2014	11,353
Additional Paid in capital	11,209,694
Contributed Capital	728,658
Retained Earnings (Deficit) accumulated during the development stage	(11,873,041)
Total Stockholders' Equity (Deficit)	82,722
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	228,003
Original \| Series A Preferred Stock
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock, 0.0001 par value, 100,000,000 authorized and Five Million authorized as of June 30, 2015 and September 30, 2014 respectively	6,055
Original \| Series AA Preferred Stock
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock, 0.0001 par value, 100,000,000 authorized and Five Million authorized as of June 30, 2015 and September 30, 2014 respectively	3
Adjustments
STOCKHOLDERS EQUITY (DEFICIT)
Additional Paid in capital	(8,909,432)
Retained Earnings (Deficit) accumulated during the development stage	8,909,432
Restated
CURRENT ASSETS
Cash	208,582
Note Receivable	12,051
Accrued Interest Receivable	1,081
Total Current Assets	228,003
TOTAL ASSETS	228,003
Current Liabilities:
Accounts payable	1,190
Notes Payable	103,751
Accrued payroll taxes	6,692
Accrued Interest	18,147
Accrued Rent	5,000
Accrued Payroll	10,501
Total Current Liabilities	145,281
Total Liabilities	145,281
STOCKHOLDERS EQUITY (DEFICIT)
Common Stock, ($0.0001 par value) 500,000,000 shares authorized, 109,310,811 issued and outstanding as of March 31, 2015 and 51,907,917 shares issued and outstanding as of September 30, 2014	11,353
Preferred Stock, 0.0001 par value, 100,000,000 authorized and Five Million authorized as of June 30, 2015 and September 30, 2014 respectively
Additional Paid in capital	2,300,262
Contributed Capital	728,658
Retained Earnings (Deficit) accumulated during the development stage	(2,963,609)
Total Stockholders' Equity (Deficit)	82,722
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	228,003
Restated \| Series A Preferred Stock
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock, 0.0001 par value, 100,000,000 authorized and Five Million authorized as of June 30, 2015 and September 30, 2014 respectively	6,055
Total Stockholders' Equity (Deficit)	6,055
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	6,055
Restated \| Series AA Preferred Stock
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock, 0.0001 par value, 100,000,000 authorized and Five Million authorized as of June 30, 2015 and September 30, 2014 respectively	3
Total Stockholders' Equity (Deficit)	3
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$ 3

XML 47 R36.htm IDEA: XBRL DOCUMENT

Restatment of Statements of Operations (Details) - USD ($)	3 Months Ended			9 Months Ended		38 Months Ended
	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015
REVENUES			$ 0		$ 0
COST AND EXPENSES
Research and Development			0		13,867
General and Administrative			127,580		389,961
Consulting and Professional Fees			30,287		109,917
Rent			0		0
Total Costs and Expenses			157,867		513,745
OPERATING LOSS			(157,867)		(513,745)
OTHER INCOME & (EXPENSES)
Interest Income			14		14
Interest Expense			0		0
Capital contribution to parent			(8,658)		(48,510)
Loss on issuance of common shares for less than fair value			0
Preferred shares issued pursuant to contractual obligations			0		0
TOTAL OTHER INCOME (EXPENSE)			(8,154)		(48,006)
NET INCOME (LOSS)		$ (8,812,901)	$ (166,021)		$ (561,751)	$ (11,873,041)
BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE			$ (.0032)		$ (.0152)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING			51,909,907		37,082,956
Original
REVENUES	$ 0			$ 0
COST AND EXPENSES
Research and Development	68,081			93,287
General and Administrative	463,765			906,754
Consulting and Professional Fees	73,364			413,125
Rent	16,200			43,071
Total Costs and Expenses	621,410			1,456,238
OPERATING LOSS	(621,410)			(1,456,238)
OTHER INCOME & (EXPENSES)
Interest Income	297			848
Interest Expense	(3,512)			(18,742)
Capital contribution to parent	0			0
Loss on issuance of common shares for less than fair value	(937,425)			(9,116,857)
Preferred shares issued pursuant to contractual obligations	(321)			(3,475)
TOTAL OTHER INCOME (EXPENSE)	(940,961)			(9,138,226)
NET INCOME (LOSS)	$ (1,562,371)			$ (10,594,463)
BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE	$ (0.0141)			$ (0.1333)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	110,648,054			79,454,728
Adjustments
OTHER INCOME & (EXPENSES)
Loss on issuance of common shares for less than fair value	$ 730,000			$ 8,909,432
NET INCOME (LOSS)				8,909,432
Restated
REVENUES	0			0
COST AND EXPENSES
Research and Development	68,081			93,287
General and Administrative	463,765			906,754
Consulting and Professional Fees	73,364			413,125
Rent	16,200			43,071
Total Costs and Expenses	621,410			1,456,238
OPERATING LOSS	(621,410)			(1,456,238)
OTHER INCOME & (EXPENSES)
Interest Income	297			848
Interest Expense	(3,512)			(18,742)
Capital contribution to parent	0			0
Loss on issuance of common shares for less than fair value	207,425			207,425
Preferred shares issued pursuant to contractual obligations	(321)			(3,475)
TOTAL OTHER INCOME (EXPENSE)	(210,961)			(228,794)
NET INCOME (LOSS)	$ (832,371)			$ (1,685,032)
BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE	$ (0.0075)			$ (0.0212)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	110,648,054			79,454,728

XML 48 R37.htm IDEA: XBRL DOCUMENT

Restatement of Cashflows (Details) - USD ($)	3 Months Ended			9 Months Ended		38 Months Ended
Restatement of Cashflows (Details) - USD ($)	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
NET INCOME (LOSS)		$ (8,812,901)	$ (166,021)		$ (561,751)	$ (11,873,041)
Adjustments to reconcile net Income to net cash
Preferred Stock issued for Expenses
Preferred Stock issued for interest
Common Stock issued for expenses
Preferred Stock issued pursuant to contractual obligations
Common Stock issued to Consultants
Preferred Stock issued to Consultants
Increase (Decrease) in Accounts Payable					117
(Increase) Decrease in Notes Receivable					(2,222)
(Increase) Decrease in Interest Receivable					(14)
Increase (Decrease) in Accrued Expenses					7,343
(Increase) Decrease in Prepaid Expenses
Increase in issuance of stock below fair value			0
Net Cash Provided by (Used in) Operating Activities					(556,527)
CASH FLOWS FROM FINANCING ACTIVITIES
Increase (Decrease) in Notes Payable					50,000
Increase in Convertible Notes Payable
Net Cash Provided by (Used in) Financing Activities					490,000
Net Increase (Decrease) in Cash					(66,527)
Cash at Beginning of Period					115,922
Cash at End of Period			$ 49,395		49,395
Supplemental Disclosure of Noncash investing and financing activities:
Common shares Issued for Debt
Preferred Shares Issued for Debt
Original
CASH FLOWS FROM OPERATING ACTIVITIES
NET INCOME (LOSS)	$ (1,562,371)			$ (10,594,463)
Adjustments to reconcile net Income to net cash
Preferred Stock issued for Expenses				100
Preferred Stock issued for interest				891
Common Stock issued for expenses
Preferred Stock issued pursuant to contractual obligations				3,475
Common Stock issued to Consultants				226,177
Preferred Stock issued to Consultants				440
Increase (Decrease) in Accounts Payable				(2,115)
(Increase) Decrease in Notes Receivable				(1,629)
(Increase) Decrease in Interest Receivable				$ (848)
Increase (Decrease) in Bank Overdraft				(6,137)
Increase (Decrease) in Accrued Expenses				$ 29,665
(Increase) Decrease in Prepaid Expenses				(6,289)
Increase in issuance of stock below fair value	937,425			9,116,857
Increase in Additional Paid in Capital				380,191
Net Cash Provided by (Used in) Operating Activities				(853,686)
CASH FLOWS FROM FINANCING ACTIVITIES
Common Stock issued for Cash				0
Increase in Contributed Capital				70,000
Increase (Decrease) in Notes Payable				19,582
Increase in Convertible Notes Payable				972,686
Net Cash Provided by (Used in) Financing Activities				1,062,268
Net Increase (Decrease) in Cash				208,582
Cash at Beginning of Period				0
Cash at End of Period	208,582			208,582		208,582
Supplemental Disclosure of Noncash investing and financing activities:
Common shares Issued for Debt				1,002,686
Preferred Shares Issued for Debt				6,000
Adjustments
CASH FLOWS FROM OPERATING ACTIVITIES
NET INCOME (LOSS)				8,909,432
Adjustments to reconcile net Income to net cash
Increase in issuance of stock below fair value	(730,000)			(8,909,432)
Restated
CASH FLOWS FROM OPERATING ACTIVITIES
NET INCOME (LOSS)	(832,371)			(1,685,032)
Adjustments to reconcile net Income to net cash
Preferred Stock issued for Expenses				100
Preferred Stock issued for interest				891
Common Stock issued for expenses
Preferred Stock issued pursuant to contractual obligations				3,475
Common Stock issued to Consultants				226,177
Preferred Stock issued to Consultants				440
Increase (Decrease) in Accounts Payable				(2,115)
(Increase) Decrease in Notes Receivable				(1,629)
(Increase) Decrease in Interest Receivable				$ (848)
Increase (Decrease) in Bank Overdraft				(6,137)
Increase (Decrease) in Accrued Expenses				$ 29,665
(Increase) Decrease in Prepaid Expenses				(6,289)
Increase in issuance of stock below fair value	(207,425)			(207,425)
Increase in Additional Paid in Capital				380,191
Net Cash Provided by (Used in) Operating Activities				(853,686)
CASH FLOWS FROM FINANCING ACTIVITIES
Common Stock issued for Cash				0
Increase in Contributed Capital				70,000
Increase (Decrease) in Notes Payable				19,582
Increase in Convertible Notes Payable				972,686
Net Cash Provided by (Used in) Financing Activities				1,062,268
Net Increase (Decrease) in Cash				208,582
Cash at Beginning of Period				0
Cash at End of Period	$ 208,582			208,582		$ 208,582
Supplemental Disclosure of Noncash investing and financing activities:
Common shares Issued for Debt				1,002,686
Preferred Shares Issued for Debt				$ 6,000

XML 49 R38.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative)	Jul. 01, 2015 shares
Subsequent Events [Abstract]
Common stock as consideration for services	412,242

EXCEL 50 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 51 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 52 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 54 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 45 158 1 false 9 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://regenbiopharma.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Balance Sheet (Unaudited) Sheet http://regenbiopharma.com/role/BalanceSheet Balance Sheet (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Balance Sheet (Parenthetical) Sheet http://regenbiopharma.com/role/BalanceSheetParenthetical Balance Sheet (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Statement of Operations (Unaudited) Sheet http://regenbiopharma.com/role/StatementOfOperations Statement of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Statement of Cash Flows (Unaudited) Sheet http://regenbiopharma.com/role/StatementOfCashFlows Statement of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - Organization and Summary of Significant Accounting Policies Sheet http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies Organization and Summary of Significant Accounting Policies Notes 6 false false R7.htm 00000007 - Disclosure - Recent Accounting Pronouncements Sheet http://regenbiopharma.com/role/RecentAccountingPronouncements Recent Accounting Pronouncements Notes 7 false false R8.htm 00000008 - Disclosure - Going Concern Sheet http://regenbiopharma.com/role/GoingConcern Going Concern Notes 8 false false R9.htm 00000009 - Disclosure - Notes Payable and Convertible Notes Payable Notes http://regenbiopharma.com/role/NotesPayableAndConvertibleNotesPayable Notes Payable and Convertible Notes Payable Notes 9 false false R10.htm 00000010 - Disclosure - Notes Receivable Notes http://regenbiopharma.com/role/NotesReceivable Notes Receivable Notes 10 false false R11.htm 00000011 - Disclosure - Income Taxes Sheet http://regenbiopharma.com/role/IncomeTaxes Income Taxes Notes 11 false false R12.htm 00000012 - Disclosure - Related Party Transactions Sheet http://regenbiopharma.com/role/RelatedPartyTransactions Related Party Transactions Notes 12 false false R13.htm 00000013 - Disclosure - Commitments and Contingencies Sheet http://regenbiopharma.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 13 false false R14.htm 00000014 - Disclosure - Stockholders Equity Sheet http://regenbiopharma.com/role/StockholdersEquity Stockholders Equity Notes 14 false false R15.htm 00000015 - Disclosure - Stock Transactions Sheet http://regenbiopharma.com/role/StockTransactions Stock Transactions Notes 15 false false R16.htm 00000016 - Disclosure - Restatement of Previously Issued Financial Statements Sheet http://regenbiopharma.com/role/RestatementOfPreviouslyIssuedFinancialStatements Restatement of Previously Issued Financial Statements Notes 16 false false R17.htm 00000017 - Disclosure - Subsequent Events Sheet http://regenbiopharma.com/role/SubsequentEvents Subsequent Events Notes 17 false false R18.htm 00000018 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) Sheet http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies Organization and Summary of Significant Accounting Policies (Policies) Policies http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies 18 false false R19.htm 00000019 - Disclosure - Notes Payable and Convertible Notes Payable (Tables) Notes http://regenbiopharma.com/role/NotesPayableAndConvertibleNotesPayableTables Notes Payable and Convertible Notes Payable (Tables) Tables http://regenbiopharma.com/role/NotesPayableAndConvertibleNotesPayable 19 false false R20.htm 00000020 - Disclosure - Notes Receivable (Tables) Notes http://regenbiopharma.com/role/NotesReceivableTables Notes Receivable (Tables) Tables http://regenbiopharma.com/role/NotesReceivable 20 false false R21.htm 00000021 - Disclosure - Income Taxes (Tables) Sheet http://regenbiopharma.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://regenbiopharma.com/role/IncomeTaxes 21 false false R22.htm 00000022 - Disclosure - Restatement of Previously Issued Financial Statements (Tables) Sheet http://regenbiopharma.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables Restatement of Previously Issued Financial Statements (Tables) Tables http://regenbiopharma.com/role/RestatementOfPreviouslyIssuedFinancialStatements 22 false false R23.htm 00000023 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative) Sheet http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative Organization and Summary of Significant Accounting Policies (Details Narrative) Details http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies 23 false false R24.htm 00000024 - Disclosure - Going Concern (Details Narrative) Sheet http://regenbiopharma.com/role/GoingConcernDetailsNarrative Going Concern (Details Narrative) Details http://regenbiopharma.com/role/GoingConcern 24 false false R25.htm 00000025 - Disclosure - Notes Payable and Convertible Notes Payable - Notes Payable (Details) Notes http://regenbiopharma.com/role/NotesPayableAndConvertibleNotesPayable-NotesPayableDetails Notes Payable and Convertible Notes Payable - Notes Payable (Details) Details 25 false false R26.htm 00000026 - Disclosure - Notes Payable and Convertible Notes Payable (Details Narrative) Notes http://regenbiopharma.com/role/NotesPayableAndConvertibleNotesPayableDetailsNarrative Notes Payable and Convertible Notes Payable (Details Narrative) Details http://regenbiopharma.com/role/NotesPayableAndConvertibleNotesPayableTables 26 false false R27.htm 00000027 - Disclosure - Notes Receivable - Notes Receivable (Details) Notes http://regenbiopharma.com/role/NotesReceivable-NotesReceivableDetails Notes Receivable - Notes Receivable (Details) Details 27 false false R28.htm 00000028 - Disclosure - Notes Receivable (Details Narrative) Notes http://regenbiopharma.com/role/NotesReceivableDetailsNarrative Notes Receivable (Details Narrative) Details http://regenbiopharma.com/role/NotesReceivableTables 28 false false R29.htm 00000029 - Disclosure - Income Taxes - Deferred tax assets (Details) Sheet http://regenbiopharma.com/role/IncomeTaxes-DeferredTaxAssetsDetails Income Taxes - Deferred tax assets (Details) Details 29 false false R30.htm 00000030 - Disclosure - Income Taxes (Details Narrative) Sheet http://regenbiopharma.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://regenbiopharma.com/role/IncomeTaxesTables 30 false false R31.htm 00000031 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://regenbiopharma.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://regenbiopharma.com/role/RelatedPartyTransactions 31 false false R32.htm 00000032 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://regenbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://regenbiopharma.com/role/CommitmentsAndContingencies 32 false false R33.htm 00000033 - Disclosure - Stockholders Equity (Details Narrative) Sheet http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative Stockholders Equity (Details Narrative) Details http://regenbiopharma.com/role/StockholdersEquity 33 false false R34.htm 00000034 - Disclosure - Stock Transactions (Details Narrative) Sheet http://regenbiopharma.com/role/StockTransactionsDetailsNarrative Stock Transactions (Details Narrative) Details http://regenbiopharma.com/role/StockTransactions 34 false false R35.htm 00000035 - Disclosure - Restatement of Balance Sheets (Details) Sheet http://regenbiopharma.com/role/RestatementOfBalanceSheetsDetails Restatement of Balance Sheets (Details) Details 35 false false R36.htm 00000036 - Disclosure - Restatment of Statements of Operations (Details) Sheet http://regenbiopharma.com/role/RestatmentOfStatementsOfOperationsDetails Restatment of Statements of Operations (Details) Details 36 false false R37.htm 00000037 - Disclosure - Restatement of Cashflows (Details) Sheet http://regenbiopharma.com/role/RestatementOfCashflowsDetails Restatement of Cashflows (Details) Details 37 false false R38.htm 00000038 - Disclosure - Subsequent Events (Details Narrative) Sheet http://regenbiopharma.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://regenbiopharma.com/role/SubsequentEvents 38 false false All Reports Book All Reports rgbp-20150630.xml rgbp-20150630.xsd rgbp-20150630_cal.xml rgbp-20150630_def.xml rgbp-20150630_lab.xml rgbp-20150630_pre.xml true true ZIP 56 0001607062-17-000161-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001607062-17-000161-xbrl.zip M4$L#!!0 ( (F!G$KO2)S^P80 .KG!P 1 X([ ;\4WWSM[ &'=SUL9>0\_NW!LW3LA0 MV-H1$BL)=_O\]2\SJR250& ! @36?LQ@D*JRLO*[,K/^\K]^3DSVPAW7L*W? M/F@7Q0^,6T-[9%A/OWWXWC]O]=O=[@?VO_[Z__X_#/[SE__O_)Q=&]PS&TDPW7MV?. MD =C.4^/TU)1JQ9KY>+8=B9:\=_ZQ<\Q+.)*]^!W^*W^:^FJ6(%_E!J#8O%S MJ?BY4O_?"2?S=&_F!I,5?Q;E?\3K?_GYZ)C&9_PG@XVPW,\_7>.W#\KZ?I0O M;.?I4ZE8U#[]\_:F/WSF$_W M/-DOG^ '>%ZKG!>U\[+F/^[P\5*0:Y_@5_]!P[4K):V^:GWB"?^%F7O^I.O3 MX(6Q[C[2P_('!*8:!09^<6R3N['OT"\Q+UFV93]SKEG^"A._MEZ(O/'R]O _>_JL.Q,=.&KRR6>-#SZQ(X%\=HD,'_B8 M$6U]?B:,(RN=^R]<_'1''^3/./%O'UP#I< ']LD?2A#_T+8\_M-CQNBW#]>. M/:'MU(J #\\6B*F=A_,'KW'+,[S7X-O@>V.$OXP-$#L$)8_@PZ>;=O=O'_X* M;*A5&TV ]R^?YE\.I_L4.Y^<;0JXM$>+4 !3.!X*D+^&R_%'"G];> TDG?^2 M7'#)+\7U)%$LB6YE$C22Y@-TB2 M' L;43DACI7+R1#'!I(QQ'/E^/%I7 --= 1$F!4 ^U.34N.+:$H*55.10/)Y61/ P%@]?/2R6AZN9P,X3FT MS\*24BM_R5#%/_5A\&XV[H'GYT[ M#A_U/7OXYRV?/'(G?&;(+1WF; V]F6Z*'P^&Y9!S^=.$*^@)?AH!,#^GIC$T M/ $K&QGPI AJRC5]QE@T.WV9Y<\N( MV;VWX0]DX!R6C\E+3T+D.1T?B YV&HB8$W9#8"![XI-!+NP4(L&0[^=5B,E% MW5&(N@0DGE/QZ0FZ,.*J*1'7,AX>'9<9/!]QU3:)N.*Z=^KOQD2V?;)3GE9(!R M]J6VWQ8D5_J+,?J;;;LGOO]SZ\Q%10)1D=/&.Q,&("0'?/ALV:;]]'H/5&EQ MQ[VS/<\ M4WO>W/6>1_1Y;@YFQ!P\B(YOYG20;3K8G3P(7<7:>:GINXI'F& W[T?AB2O6)%&OG+!.@; R+MS6"&SD]'AR])@]D^^- M@$=.@Z= @P<.A.1'NID\TMUYR? V+4!.5?"\OW8@&12"^R3^35I"O$/B/\GV M$.^!]&>6(>C^>_]J@3XG7'=G#O^K[&?]&9[Q!_-_BDZ!HRT9O_^L.]Q=.H7$ M%SVT\1P W_V2>4;&"S#&(F[QW1YVM\8>](O4N 8.YF&,&U69](I;]L2PWIKV M;;S,SQLWL/][! L)$'H/T[RQ95/XF'S#1MSXW"'B?^!/ANLY0+W8])Y)XGS MEN"K&GH_8+=Q=@G,2>W&6=<:_N73LE$79VT#YSFZV;5&_.??^&OB:54QNW0T M=;HK>TA%98/7:?+%P5=__]02,Z@#Q TL)%A'>).)9U!%R-+1U.E:\.L(G[@V M]:?$TWC.C(L)(N^K [=G(+WA:\,=ZN8?7'?67T9U7NMS"W7"ZN5%BZ%O@0>@K MPWKJTU42B6?[ X7,6Z,MSDK0M '=3[:3G*?Z$]W$BSZ"X>G*#]UZ54&(#!W' M!V++!?U>PW?)%_OW>XZ8*18O8R+"D02NUNYJ&ZQVM6 M(O/.];5D*'#I!ZD+V8@/#4"V^]N';N\:Q(Q6;I;KY7(CLMJ8:T^XO50M-8K%\J[!V4S.K@]:JGN2?(H=[<+V *2(]WE@+G7KS[L7[HP< M?;PYXFM:N1[.%!US_1FWWH=B4EA\G7"OOZ8@X\OE8G51WT3'WAR"[<6[UBSN M'[S-!/L&H))2!^5^8^N6_^C&@@2>JS5#".+&WG3^%-1TN:X:-OL ;D/UO#Z@ ML-?.C(_@5\U5FN6#@?F1ON[)<@WAOYH MF(9G$%'<><_<4;[:V- N:8M K9XJ-?BV9^V&5JEG#?K->'^+E= AEGSC80O. M!Q4R/]0Z4VR]F]5B<4<@;+0EJ\%9HFSQ:&YA[[:4R,M5^ZK94@8T!35<+<:$ M%[*SD@UU=EJK2H]>M$JQU*B%0*4U]_8D4*F6U C$K@';;$>W 7('6[;F;+O< MI)1 27M;%L+AX9$ 746^Z:94M:8RX?RHF\R:@D]:KI;W ].&CNA:\+5&(P,3 M873S7C=&7:NM3PU/-S?=L$JC6FRJ5E3\\%M L7W(JUPLEFJE?<*XJG9N%:CG MC6:Q62GO%=8MB:]4;-::E;4!)L,Z?'9+*JQ5&_"_$(CXT3>'86L:K)<. ^!& MF[H9L _E9JU<*S8/#_JF(FE!(AT:]QN1]+FF->KE8D7;9AVD5)]M<\0=M_/O MF>&];D'10!<*,(M#;S9Y:G=QKI2V1?4(*VW0M[Y9;^7YQQY0OBY,C5)=3;;8 M-5P;\<_:,$;#:.EQSMSYZ5O3I '6 7AJG\O:%[\=9*NV/1X_)-"I'*FONP#% M?;S7G3N'"CE&Y$G>/D])]8Z.:GVA*J1:3M!RK*C]X.3Q@;*57!0UT!D9AF M"VB2XT=K%NM-K;X],&^G]R;$3[%9Q@RU>"I_.[EW3;C2Q-0*L![X"[=F?$G& M==B.H1(GM)8?!/G#KC-=64GPWL-T:[?\W2$L:W?T/#!>-E*W>\#1[N!RN>X, MG\$LN()'3'N*$8'.SRFWW"6E-5NPSHJYM@9L72;3RHU:?5_ I>HMS02O5J M0Q$>;TR9 H3K"I!RH]FL:?N$,%TI4JS5JY5]@I^J**G4RO5:-6O8WTR>9'(G M-EK*EKMR[]AC[KITP'3-T['=R\6(M)Z?8A,0UC8UBLV(&Y,&#*G*@HI6UDK5 M= %,E=OKY7*MLG\$;L8#!T+F9J>\ZR'VANLN)M=A0J9N[L9-B)UC8T"V\+W3 M!21=ABT7Z]JN($V5<[5:J7A0G&[&PX?&[V9Y.!O@NFV[5&HL?TY%Y6K5>L2W MGI]C$QC6Y>.J5JY7JNG"D"H+:Y5JK51NI MANMYZ2:MHQ?VC<-,TU<.@TW4WDVQ-91A/76MH3WA-[:;"J.>SW-JS#P;@K(NOY[/,VQZH*3*MN<+A)8> MH*ER[_D\C>T7H1LF:!T6N9L!O0&B_180?G&9>#(5W:M8\_&S; [+VG[O#F%) ME:D;E<;N($V5JTMJFOTA<+I9XMBA\;M9%LWFN-Z-9SPW^@:3;^$-;S]YNN9S MHUXII0E=JFQ:KFJI K<[L_D0:-P(TD0HI:)A69K0!N )N04H[IV27L*:=%-AMX@2(M!G)YM#77W6<1R4HS9G#XO-TJEG1/* M#G5Z9<,-Z'$O[?/56JU84CN+JC.L/?WZ9ZHU+=K8=*OI2[CZ4B5R3\6:[1:V M P FU122*9^7M3?$<$,K-8NIS9_R03)8V$6UI\;6R$E1B#7*I7)]+XA+K27) M[O=VPS/M8K59B?3VW?U&;P@I'KXGWG6_98I?]GRIN\80RT<,<^;-%*%4G(99 M7SZM*%-O-HM*KL!:<*2^B-62:\DBRO5BH]2LUK*RB"UDVI(5@A]9K=1+C:RL M< MAM[3/1;$&/KX:>TH9NO-JW-71HAVS+Y?N4YX[KSI9LI5%P5 MOI[/N-X9O!MV.4\%=C];9E][NVJ^=!,WFZN"OCX8.X=WLZ3(]6%7?K^:.<#: MXO)1.HS:)?]N.N^V>WTPH))NZ-J<<3]S\'31&]B4V:+3XN\>3>-)IXOI]\6A MF\"1*N>^<;ST%GP'6^!FN8OI+-97_"D<[RXCF*13I)OU4ZII:F/G5>=V!SL0 M30+DTATN[8NO8R=*M_2XLLHD*>T.PLT*>9-!&Z85#QVLFKWBXM]=:^YBF53* M8K1(7<$;,Z8"8LJGLII6S>(*-HMZI[Z:N5N;TSG**Y5*I550SD^:#IAIGWB5 MFMEC!&W1LH J1!2M"AO/0!VL8!T26RNTNPXEK<9]>UX MJ8OWIZ5!?O5RI?R&L)V;-2U(T[58F[7:6TKC@.O8L-QQZS7UN-?6W>=[QT:" M&UV^?GG40[C[H-RC6+DZL7$D.U]29N%X=):WA)A,2]R4K&B:E$C:IWYTX8]Y?K21D1>9WUAFQGR.U]D"PC9<5Z!9I?>;EM. MLO-ZJ$ W!.U[Q"_S6U;+V0+\3ODQGUOPK;WB:RU MBH7C>OZXDU24!%.DG5E4(BJFU8HK=,OX;XI?M&W+M4UC1']@.B (!QC'Q<; ]-7,-2SNNE?< M'3K&%+_"EOWBX LS:^#E(=BE UCOI0G3)ES\A[_^3]/[,F6N]VKRWSY,=.?) ML#ZSXM3[\#^?O"_XXZ,)_D3_SAB_?F&/^O#/)P>6,SH?VJ;M?&8_G@V/ M!V \XH?>W:##M MV]_"UU>O^[]:@>]OB#W5VS?O=KKWO= M;;=Z ]9JM^^^]P;=WE=V?W?3;7<[?5K6XYX72%\:UHCC@,6+JF&]L6A],OWR M/[1:,2N[,'CFK&U/IKKURG[H+K,%_?*1V(&I8YBL5"DPH*X2L,J(.PQ</KC$R=.<5W[HT M[/-;W7.,GZP/U Z4/S:&["O .RT0$& L%V"0*PZ3BKLE'>!@XJ"+0VUU!08\ MXITV0(Q8(Y= \6S&K2?]B3/8;)C ,/%WVME1>"41[I3#G^AB$;Q*A$WXR!CJ M)M.G4Y!2,M8,LPV?V0\N)V P-OQ(M$( ;--;4/, MX\Z&0Q"+XYD)>SV9FAP'QQ_NG]&IZS(=AK8=_\\N&YJ&1< %8'L9OK8@VD" M8'[8,W/$N$&3ZY[')X!I ,WEIHGC2! E(+8;+!QH-;(\VP%"-&%LBW!@OL*? MHQ?L6D+H4IYEXYE#T\$T/I@+<.9R*CGUMB[89:O?[:,B"(5_CL'U^'\L@EY M@4'UKQ "SSJP]"/G%@@!/@4I.V)HG#P173^BZ8+\IP>F"1.2P 19 5_R*1:O M2:'Q'>PI^(NT KW5F@#P0] +WZ7Z@,%BAA3"WO%O;$1)[W"0]2/D0I=QW4'= M@:S/_33CZ#,>3>\!PH"CP\-YM-,?=&]; VF8Y>A+S*2" W6I] B2.+Y%?@-_ M8&P[$S2M?H!ZB^-*A6=!O\,@4TS8% M']R9Z>$A!EH1(P.6+D0$633"7@A0ELN*-8B]?<':K?XWUOG[]^[OK9M.;Y#+ MB@T->F D<*FX(W@4) ![-IZ>00Z8!C ZZF9,N!!L0I("G3)O)IPR9"N'@TD/ M8#^[9!&#^0TSH3DP=WMM7KM;NM&!(YZ_<'# M]]M@%W " 6R%C8#;"K01.^2B=56L\P,P6S7H7Q_-.8 _3R#.7F-Y^=+DCLM0-:SKS8(= MK0++ZR^Z8>+WPB4=VZ9I_T#K$ZQM#,+]-\D3+C6SB?$HLF/%*"H4@--7>I0: M#^C.2*#;4ZR#&=JZ"*%8KK*PS^^6,>B_(HR[-H?!]$\ MN6=(B!@J)0)TB4NP(L 3@5/A\%#\,?!W#K'24]N7TOR^W,TSH8Q# Y]83.ZE MOVON#!2][K)_1_82=\X%YC;!'(C=MR]S+QB^V%&=9N \R_9\JH !!!@2IN 9 M16; ,T/=(KO;=AS[$8\]!,,K#TGY!O)+%X#.'E$4> 8% @*/>09.@<>=B7]L MXW"3!HM=ST[,D/=&B.5Y0OQN+>B#<-O=V52&+1[1;?,\L?^6[6^P+A(57V6< MPW\-H,(3,UU$<'!G%;VEA$SVM\]'L;V;&$87K-MKW]UVV*#USSRNN6FL0D8D MA60DG2@NF?/TGW@F&!P[A$;AA'O/-LI62I1X%"S2ZK=9O5(L^"9;I?Y%WE8W MP($N_*\;7]2#!S%4@8UD.@?.JK+'0OS1P=- E)L&'C\\4BA$6H\B%LC1V_-M M32]RR!+&%(EE]9_T_HH0*4$B, >ZM 3\#&'HK'"BC9 C#^B]&!*%S*X:T*1SJN#QZ'B)\91E"(@$B@M ZVJ;"J;4!]C$:^2K^_,48XRA^?E"G M+%JM;^TR3C610UY@X!W@?M@./S>-/[GY>H[Z^!PU)*Z4H'!Q.PF'-I C.AFF M6? 56!P(A!X<@KP3Z5+3(B6V #3U/;D9; A3/Q%60WP;OID]M)\H)0+M DFK M*$6Q4:SOKE#(6.P0/&'.1M)\IUT,W8L\76$SB8$'ZS(E17B']HOABB/YL2\( M, ^J&A$'8285NX8-^PYDYW@8_7EE78NIPB*4%07)0%-1+N"R(=A\I%^)%:31 MY"=.2& P6P$IT :N1P83$=9P=A1R,W]VHK"I[1HBIT A+_C-GCFQA[07K#4; MH3]-A(9O36 H L.>@MS!&3###78"YS1]A]";B7,3$XQ73V8QX+'G%/E%70B#E*DPZX'14"^U2(WV]^*VA=7 MT0#S:@+P 70AC/5P))J'0'E$LQBD-F)Q^?C^T0XZZF'!I AFO,J%_'NF@U&& ML07ZVL(C(;DL$G8%7!#&%@IL-I6"3XXKMF=A;'Q"C!V<-!$(_SFS."L7*=>J M&O'?G_41VH%+2*A 6H0DGSA/FY&@YD* \V!KPM=#ZI/R:SS#"&8NGC833S(K M2HH%/:J8AO#!0)4& ST],PL#9/Y-U4*'##%Y&RGCA^Z,U C4-_L'JFE,?HM3 MQD R6K'X*_$SI6Y@2_='TW"?#QA&/L*M#-H0(AN!,-7-P!2S!:O!AF(BKH7) MN',"&Z6\,Z+](*G?:O=5R>_'Y(0%!KK$=4&91$P)887$#=5O$Q #>VH,0PUW MKC5SKVV-[?VJLA3FD+59I_70Z_:^]@FDLYN[?O\CN^\\L/ZWUD,GQ^UZ4O Z M,%=">XO@Z0>T?VEC6/KLNM6__ AF->;.*P^S\,&V/0IMK3-@@(^L5 MLNG+E MB]^:G-V#0T2P\ND #9R8,E0(YD7X"_GQ&BHRHBV-R5)G< MG^X,)?5'5-C,Q5G%KWX>*['K= :R=PAVPC,WT>3!2^Q@-^SAGQ<$!9JIL)@P M]488CPHT-OE/P.O+IQ4 BV;Q2Y]:FN6VPH!&R(2+A+%)2FT!^<2G>9;UFOEO MM(&HY4FW3V6ND-P]F8]DN$S0I(ADC+!1D!_UL.A,BS2#/-?Y(1M.@Q=-':>9 M12VG1?Z4H#+J/0W.0]!\.M<0:^S9-[# KW[O/ RZ_3RG>+T,+MOU%CQ?_Z@6 MG V#0EED^@")/HG8DTRRD":03*1H*<\'Z7D_\*3TEV+@-472E+B%:1U1IPG% MHW@^$'5OO%.)YY1XI"ZOI%*N/=ME =AB#X8?RM..;=GHY)'^PC)1"FJY02]% M>L9/ 7T/166E"Z4H+.2="!?1CP^=-J9=D9I6*LL>[GKPN=T)4T@R7U_FKVA. M5.P;[M7^EN! I+-"8*3%F9%LWH1<93M^GU*2<,^^8)*"?8N08Z#*(OGD1T!B M8O1J3H6P (6"!2,*;;QI4$ JS_!]-RXP0*^4:JD^9JFPCC00@T?8F7#FFEKU MH[#2='A\%.1STQ%%J_]=V S&9&H"-B-E%S-#>(B/&*Z?@!6'\M4T49(*L&%) M<0<0"Z:M6MOE$K2^.3L/F$PI=?'48#0;/_Z(\ M<5O$ PLR+#@DM0%+\'&2$\WNL% [_#%+D_:I$7#,)U(# 9 M&E7WDDR_B>%Y07;4JQ\]G,\T9Q3;Q&#EQ/\&WP@/.SQRCT1"Y*<! MCA2!H'A =.X"1B]H'"?8%=Q"X5YQ)NH.PSU1TY<"KEA>H$.LX8=31)&- M"!_XERK(\$@;Y@1QZTCU(NMQ_&@J280@@5&4%[FDV'P1$^91$2$.HZ,/_=$+ MX#V@)B!AYFM[P/A$SFL!QE;.'1@+,O\R3"@]AR<("MABF,YY/9>AIF'LB(&J M%I0O.8%];;7N_;QS4Z=<,<\OR0@*M,[%.3KH&L=&!2-TH6"8T%19F/."W0MQ M'\AE/8QJD>]%+"M5[0HDB./$J)K"0P:@*8ND"!98$Q17("DH&J%5R9^J"1WJ MZS.J((M7>X1?A]-04L$&V@7U)XJ:J Z=1A='&TI J/I"2!@^4BNR4;D!M4HQ M1D,7_,HR?U^P;K2 IWV^:><%20.RTP'J=-7%*K!G<4 CB *%HFG WVZ0@.OP M(%^#TKCD@628BD Q(LYY>SWP.)!,=:WD ]:B=0Z./9"_4OI5]6^,&JI$OU5 MVLEUK?&QH)K[2 84]CV_) ZYUU^%!?2/9VX%/O\ R$8D=EBLA:=J3';_ XK! MM#F,'I,A@NPYP,"$!]/C&?4E$,KP&7=Q)+L(X'@/R$&@=3CB[P4SVN_]DULD MT6 HCX:2,@*F(4M2\O)40,J4^DF7R2ZX84;?T$^2UQ>A< (H7 F%M!;=Y_ M MPI2,])+=B?TW5!B!W$3'32F7DL;A82L*:^P@'6KK4E"AFBX(<2J0+=G;X6-3 MI"1) UW642KI!MCR8P2F[Y.CRR0:);WQ(@H0NA61X@1Y3B>.\EY4-*(XC&*Q M@.E+(B<)N/R19$:02!^/0)^W_;T2&B:0^S!2$%$/]T/-(%@0J2!%62!1@XA6 MU#D0&H\0)LQJ=< X01H(47$.,6]@OV^!N>- 1VOV!$^&PE.L_.THQKSPK(($ M4ZO"E5.W?N@&^AP)P'ZU<5RPP< & A;NSQX]DJBE8O6\4OPHW+>K2#%VF!]% MEL.C/<,C<1'$0.^S)7-QP(QH^WDF)%XB<_EM'I*6HHLS6+2*0-++_)5@E;IB M-@/L0CR<0H_X^5-A(Y"PZY,Z9DQ3D)@DA@CA8OJ,; MZ-*&!14$Q,B&14D&B9"*'G+(,,(AD7V\P.Q#(;Q!F\]\MW7%ED3RNA[]>KR% M[7F36@KL48(<$W:4DB.>$;D^80:A'?4T$Z(&H>;'&OV5!Q3 M_>N+R&I<$@*5L%#60#,N:%G?.%'Z=(QL[LH<9U*?,NU8V)VHK2?< M\Q6ECW/9"XNV-HC*4KPFENP(64%G=B5%(C]77D/_WX'OI /%.:^LK!$ME@N! MCQ+O2BU: O\'R./_,M':&08A66/".VW*2W[U(^?]H3TE+1[J=%^'WU'&/HW> MHBSY0-LI=\K,VZX6V7]R6L&B[GR(/D@?I;6\[4C\'_%':KP$F4/W3'EJ:M*+5;5 7 M24Z5[%"G;+-E_R"X)X1L/__<6XJ[@K)I$GN/ N\R5X5CDFJXBOFYAB87DM&) M. QDR(B5S5EM81NN%]M\\0%\-,8S9TA6/ KL$:X>I"-L#(I[U^\'YG<@8?J3 MP[E<@*Q?84M^IF,"2)L/"OJ"TR^.RG'(9;FFBVK*DLC5'0=/Z>6IE%)F&BS'3Q\+ MMU+U+%7%MBIDA]:6(U6D+Y5\H934RQ2&A^]IDN[V_4S?X4,PI;6EUAM1S%8/ M/;IHI/_03MRQ'_& HKGFCP[M::F1AJ:I* ).O;[Y@6(YY$UAC/\_J64G4D\? M&1(V\"8HV6@IA!V$/_X1'&H.;#RJ;E%&G!_L"6=B71<\@Y]A6[^'@+2OJ$]# M5#-45,T AHM?\Z$(4I%DL)FB IJH*@BYF>MI)D5 G-13FB[8(1J5L%B 2O^L MXE\!2EV)TK *)B(K?!V"3@&B4H^@,IP-V7$L4!FT[(TF/>#N%WR7$]Q3_ZG@ MU/!@72)V=(B6*HRE-V'TCRGD#D4V( AKH+@GNIV"4RHC78$+9R!9AYN/>TU^ MQ3EML^VH)3TXQ>?QL : MX4@(6T3OE0P;8!,UQAXXY 7UD#!(W"K,*0(W0YK*CO&A] ME.IJAV>9\P$IA;AB L@)/.4ETCOJ)4DY +*M6-8UH!Q3P M@:\WTF4$;/6IU:I#XA6BO)Y E(N _";B/";'+RLGN2WV DS/1;-<;.0)^RO3 M"F07KQ]X4#2U/4['1"M*@.<2(EUO-GK%#,H@]\J/NME*(8E@((0!.Q\Z_&D& M+&,[TFA]$I7)%W$E#E?BT(C<1,%(+Z**$#A+9+HYK\S"5L"R6112KK_"$/;" MLHU4SB6>=2$9D$"4ECF^; HLG$#V4ON&$#U!YH;:N0&MZ>3AH&38PO P'9;+L_+W4(,#5N_7.ZRF:=_UVIV'WN'+:#+JLKZ5PXTB MA=@ODLL06PD0O* M%4WMJN_7,Z 3,G>9U%E0LO$QZ(X1J>;#V2E'PL^WHM-X5SV.9\I1?* #);QK MG,*3%:A[UB,%^90XP]B_ MAQBGD@D)@4E *2DFY<3YCJ G.KB0X29GE2UDEY'$R!;)#Z(OE:A$":_@%E0Q MH4Y=LD./O-B 8T&QZ'8E@_M!!QF8\\2FCH=-PIH7V24J+=P6# MHO\R054LVY O/DR 7K"KD*]E5R194'N+K9'],^YHZR)Z=<1^J=>KA6*Q&' Z M/N/7&OG1!& P*@)&AV>$=SV2U[!LTN7MDOPYF\6E4[*8Z40F&NN!$<;H7+!\-]]=M_ZHW5YTQ'AB-X5VA!4IP_?S3UQ<*LB ME7"K1\[^$!QC=ZJC4L!K2.GO*8H)^??:"_EAC+SGS]0MZ@L>AH/C@="9^M3E MGYG_Z4,(#X+B^/,0DPQUTU__H^UY]N2-I>(P2,4TU,@?:EE$:@XSWBAFC*3/ MX7H >]9O'\H!JN2:!>2P A- 9QH@CA*)H]N+E6_<":@2L:QB_-PU_IM_EA$V M$SR<\V?JSP%?:=5?H\0<$5%S)(IC!7^!.V%<[0!W M*?&I:Y@OOE2+!^9@S'FEOQ@C]C?;=IDP-UU@PR@NTM,.ZQ),JD1234H@::_F MH*L&W:?5&ENO?%\*ZZ!*:L"'SQ8 ^O3*[L&[L[CC,K\M$ALX,/6:(D:=N^0[ M.6M0PK;OITI)C'O,/KJ119D;00YC*A YJV?Y+()]D&^E_6 MW.1UO*/MCL(&N5B)PT&V\L9V5M1E-7>GF=/ M$YP0E.K3GYO&]9>#LS?1>:67G MQ+A#8GP\,#'V06RZ8WEM. I6K5@GP8H-?K$81C2WP201/D)[Z//AJ?7DS-0. M-KJD0TF9KTZ )#(W;SCE4J-5"P MF]',FNK&*'0M1,9H8&9%:&(%[<#[@5^+5ZKTY94J8_; GV1K2?)'Z8)OY48> MU8(3]AW>J\/N\3'5F,.43K#<) 7JK ;^+%;$B))@,3>V6X(E#!R=&E30&.Q, M=^D",KI^EL,C'U7[;@Y>)5O.>S8<[Y6=E8L?@Q&O]->8\?PL7=D70U9M8%&. MZ_FW0_+(&&$IHH1\&*Z<+CI5D!)9C7(I[X13*B2^;-K48N/1D/>G^R#F7V&PX2PW W:?[]4=X7*C\)K MM['?')8MF6K-K]\G\BP<)RSED0U!U3%''._D#NX#E+?X2#H[,RX .Y>F;6.: MS!.V8:?.D[1%E!E%YA6A'L@GXU[\K MP;\:P0HY@]@]*>V*VPN4'^7"5\,B1 @6=CYRV2)HQ$=QB_[=-F<3'K]N'#J\ MHTM>SN4SA]Q.59K."2'\G0!9D#)^I4)4RX2[3+=5 "K]!'^?H*@[KPMR$EL4 MB;_HSC&LMRV(0Q8WR!5WL0WGY)&NY<"R!1&GXS(Y7!:D80 MT8/66Z#MP8DR*5][D2#OY, /EH%4J9Z./*/@F,_.) M)&;8_K(?,GMK2-:CUBR7"W+#@\Z*6%R#Q!*Q_P25(R-Q<:\.P",^(Q'+'F$( MKT6 I!GVJ?:Q^!2;,GCU#.4BFBX+'H*#2-77+>RK!H!"VP("'*!"N)B&<*' MZ&NA!R)Q'*(*2[\I2$AUX0JH0GR)E8Q\5:4$_/'/F+N]C9\$@MB&J,^T^+2. MRAFK4. [F,3?H&#[Y.W6.7NLT3$ZXI-(/\:=\X#(5?%5%PESWTN13=Z$W(*' MM$81%; ;5G1%*4[$AM4IA2H1_1&YH/9GT0Y/REW_:FM<+'<5Q=A2=&$ E4IU MXCY5-&WDB-$UR#E' 8.$G).3T)H.M(CXTTT^J/7$(:VD)KZBI"IZ@G&!GZKE M9J%4*\W?-.H3',TA3S<"!SIZR"'. H-&F^Y/#C3F8/LX(45\GAO!)H4:DOHD%/R9D[K%BW[S*^#A_3Z MW\H-Q$K 8,R5]@/^<96X\<9O!JKV4XAT4?8OL>BWL1DG]LD/)=)5V$N4]O0; M'SVA-QK(*>'_8(UAZ/<$-=)!2](82,,>V=$;W76EK=(H:+P 7I=0QQ9I4;S2 M$_MS3 S/+P2-=QBH+]2(F[ ZO.-IA,VAQ!=% (MC+Y?#)# / I6E$NG=8]% M-T#X7?(M\LB4SJRB9Q2UN.?F:WC!"/,O%['BFK=2;:)."#66]@"9K[\,6[K$ MC8AQ/=UQ##X*N^.)7L&B7RTL2[T8I&5AAPWPPTV\ 81)QQ#=@. A:D*C;#UV MOM*EZR6;-D[4%MS4.@R[V_N;C:$QVU+V0M[;'+:O\9UG/;PA%Q=!)?Q^O\:8 MQ0A9Z89>G+38Q"IR(;2A$*)==P..BZ.RL-?O)>8EGO>'H"]$\R.JT9_8P)#R M5BOE7%X9(90 >)!4*I1KC4*M464_='?^2IJH62[;'83OXQO*U:6!54>PAP'L M&,X"=QGT5Z#FZ5\DN4%[CM* M)Y'U\NMFD_@O9F#GW\\1DCPM(H/A3/NXYH&2.%J-'@+M^T!):/OY0R5VF ,E M B;N4&G^$.0 !TIRL_Q#)7:8 R6?A^(.WZ@E-T#I8-;+=FR M5X_9YV>$<'I!L82NGNWW0W5GI(_NE>%$LA_['X2'+%OIR0MP'(<:G M<$C#>E]I' ?(T#WZC)2\(@JHBY%'Q5KL5;@(A3XIR> MCN<,M%PM%FJUVMLGH$@JL-\6%Y1)I.(?2LWU:[;4?D4^Y2=K%3U_SDJ ;'[6 MBJ(,2^T=1I]ZM>TG5ZOCGUC:U;+IT)HLW-6];H#@.E#^$- MRZFUK@Z9Y9.%5\V;N^ZKD '6#9HB8$N'4+!4+Y0>#P^==J?[>S;:/&2N=CJ= M9M>K"JBWZ6D]W^+-;XJEK=,V;V_MGZ,4N5USZV->^2ZZ7$=GV&]+Z[=;$$J> MJC;VT=-:5(-;E"QP:=@3/L)E9*1M=0+0UVV(Y\^@;=JB67:Z*Q03=QG,4"_K M["*T6*B42CM :$IS90;G M;IJ9BFY"(D-L>H1!-%8XJ9L MT]_ORC^1\O2?\H;ZY1W\4H%SK>A5Z<.26;3%6=28U08VVC;@[SO:U-24:--. MZ:.'>=S!C?1()%2EB>?=/_!J\DV# &N#OTD8)4OKP M5@K%(U$[)>FOCNU2]>*\?9 9,M]2>NYOIOW*Z0R1R+SS:!;?IAZ6L(>S?PLB_ILT&HZ,?1W:PSEW?Z3->F(1.U$ M#I&?E.I'Y9\IFS((W@R 8UO(L915&DC4H*$$=>$7%<*B-X.G7LG\:$.EP1$+]H6J%1+Q>*%2U$W)DH\Z8B"@X T\4"2EX^U=.+IALP M#2:4&M9PAI!_S.^92TX8#SRH"6U((Y 9M.Q#)]R6J=LC38;CPVZ39"- M9]2F#1Z7'2"H+9>2'BSK<*C89\1'LZ'(PO7X9&H[HM8Y-92]XXAJ"(: MH?X?]RBCQ>\X^%"!2+S+3C-.,N(R]MO4Y=N(5AUJ$0>I7 MY[?A$ =]XMBP7/F577/LKF3"/CE(<" X'K#)S1OKB5]9DF3N58=M\P=S#YQ MQCL 7P>.;KFB4"2]/.ZC.*>K7["'SDUKT+DB>.Y;#X,_V."AU>NWVH/N72\_ MM=NIV@]*R627$**TL/D'*=VW;I%5^RM=WO9[:INF K5O%,P7M!$E2&2U%,UG MFV&]4MC)="0;ODQ!SW/\GVRA\R_;D24O^/>+33;'U&_2I=28VC//]739&\OO M@$NCB^-+S\:^*/#C+_52HU"K-FA21(LL=*D6"T5-U,5$B[M 7N-*1;5I4)D3 M[9A*;0GAY6;1[_XB%V:Z-@/\8L-,V;M&-8Q8J5"&^5PL-^%LS(499J/.A85- ML9,<"+A*'9[I3TG1]CT'G@*RF<'NPW97"NQ&9[?8$VM6=&P M4M7DNJNV$8[<+QNF9]Q&TC-0G\F:8WA1?'C470/K9X%*+03D;NC9F*TM^AI7 MY+)!!8]9YR8P6_7Y;>.Q9OJ*+'I M@L5D.+&WLYM\.MI9AE-^7?-.5.0WW<%MIS<0=:>MWA5\UQMT>U\[O7;W6!(9 MS>Q?,ZZ:Y;E%GEODN46>=O=%2]YU4U*5YQS*Y5[HX$8+)O#WFFG-YCS;F?HC MQA)LYU6R'N@#<8&&QZIEK<@ZNNN1-WZKF[#-?=UB5P9_L@NLW6+-DE;21'@9 M(QO?9K!>XBS;Y!A"=( <7$X0=RU8GS?S(NVC^SYD+006U942[+A@]['WW$C* MCWEW.3)^&*:)!"PHF-S0AI@#"JYD2 _* Y+:%*;&/3 M;X=CL[ XNR&_/%/[;M5DUZV/(I"#R]%G'M 7'66;M#"@.,QTXW2'M!_T%T#H M$^X/01"RF46]Y^:ZRQE*! MX&5=(D22PNFJRGU/0YX,FU,T+!D1)!IV\?FE> M A1"F2>:*A-Y8>N= #44K$J$_UQ8[$)8,#K&IF9W=,=S@/> M>06$3T@B0%! MT!^AD)$]N.G$QC&X""C"EV,@,^H+7F!NX*4%+IG'A\\6A1!D^M@&_-7 MK%C;J=.6N+T'>53-"]8?W+7_]NWNYJKST/\/UOG[]^[@CSEG))+/DE&!G63I M4:%^@%5MNX*!+!EU%;KZ#]$@_Q7;R:O-]'S?3=Z"YLJ;)_# M?[PE6N6!JQ()Z<04*;UG$OBD%2FM+.GBX+]:PJX7I77X6#2]#*FAP'X!)($W MIJ'/*%KL?6'5(IW0D9N60M:,XK3/0JFAD>$ M%UE 5V+<_ .T!0$%"\+<&.H[2WUP=0\5+]BJ$]2L9.OH>$HJ[F]1N"KDHN!\ M5O;2E2'%^;ZCX745H"(\D\869[G@:[3,JK7!4&0Z+DV%W>1RPWWF02QC4$I MO&!,D(\?QUV0[^B?D0.#-"+:6XL+L\+7;#8V?N)D\+PO^0@FF(-N\N4C$9Z9 MS$S/P&,N^&'LB',F=-GA3\OVC0E*J?_TET!_$4?Z1*.H<.% MJ3<&A"P M^],"DQJULW*@L=AO(N&,4W;=ZV$L@^ M4*BN%K5L?5VVC (*H67LV\H7#!U8)IW7P*Y(WX%="M2B-^M#D9HWNWSNY:ZM M (*CXV3/7.3:,Y&!_/&"=7X.0:B1>8W&Q@_#Y6%-B[#05 ]0]?X*P;V:OKP( M09(F9Y#,&"(SD!QO89%VAZK(\$X#/+W T!L313!R1]WHEI+%JFQF-F1#*9<- M"_9.)LV=K&S4)TT[6"3I/W5KAH:%-'"J&QHXYL,"T\?,'#F+> ML,"T$>+*-TH Y&4!C>"!!+9-DF&V"40>@'PV5_S-A:C6G.[/HNH_H.9?5_%C M..4 >IZ%.CY>Y&= S1^$4[X)H-7\J*5;2^D0T<,1%D3:?SQS1+.0>P:66P/J MG' W'GU6'"UA10+A#+]0BNWP)=7_E/'\,>C#N' ^Y65@^D&!6;9U/IQ-9C)$ M!83_'-XL3ND0P*P:)9SY]QZQKA7$[^DB<'%-?/ 2!OR#9>'5>GBGJ+P47A!E MY"C!D)<\^F<;H4A0(JCAZ47D?"/0-\OV0@_0)RJS1=. (&P9XEV(0+IKG0*$ M=;P(:_+F\)R%U%94L4GJ;-[:YDV6%H;2JA\V* M1608[F2]10XBD90S\>6'LJ'<08DS$K?^Z:;"K'.2I!4^<^4_HPH6O(!.5+"< M@20C9C9":0#L,Q%)%NYS 7,T_+ME@8L$YXO<.._U8YA7K53%G(F;B67VAC,) M[HI5)-+\020J:46'BN,1>V:.A,T2))$]ZZ.YJS17"O%'SJW(79X+DJ@@IHW% MF#0C\$YEF7LNY(9(?X/O*-&+9)',EH]\YR?+J=,=E[[$.XN#0^YE9]F%98?9 MHC2;^12V])#\#/LF8R;0"S=?\=0Y).2;<$Z%?D4@XY%TG]1:JFQW@FT(F$G< M/VP+Y:766<6D*:@J;JG#(BO.H^,DMU 5IO:U_,+)^B(&B5+E,_Y!KB1L#Q3,W?=4^.2[.Z8X%A5"+':2G&Y5[ENYU2"F&I33F MP?QF75@XBSL!P]E/@D#([%(W0,"P=!/\>^&1,_#<>!4I$]26O%[3PUY.V"7J MC54$C.D?6P"?/<6EML3-)Y)/J'H;%8[MJ#DKXFB;$$#]&X1'![^\,J$W0E_K MD?NF*$D88?'ZC!@>)BLRQ/5/;TENX/6J:%"3V IT'_/T/P$?H+>PEF"L&[Y? M?*9C%H9($Q87N#_9]@B?\)[52S3(5OU(TO/1QKO.94DH-Z-9D?1< NK?/&,X M<V6?N.93/[59P!C*I:SA*4QW.# M]1WHB*ECF$RK+"UVIR"25JB4&@56K6N);S__I1)[P[1?.F]QU\W ;>-A)=(K M^*9A7%VF+4:0(#./DV- JP;/9WC5C7>YZN;J56N%>J-:J&N5Y.NN'@.]'X]L M"L3\HND7AD..0^P?@5+=0A,D. 8!=M&'&)BE]IC!N:*HEZ8^H+8EXBOR9% J M#Q%NPK)O83JKC&7AX<3\&8=L)7!PG!X/FR64AZ6H%DBPY_I\A29%W?TJ6@=; MS,H#$N[["^X7&K^.=I,E/K M@EVV^MT^YE:UVNV[[]2GZU!9<PQ"S:'APLOC=,JC(#2>@MUH3 'ZH M7\ OE(7SC*VS%H<4<7D'4QYFHN!-:??NTMF)# MCEWK+77A&1&FIF,LT]$?# M%(>CHD!2W%P0[1!,]S&,; )>#_MR$!QE<1_".?!^VFR>C'OG>?Z[R^_&'=CG M">'UE'C[$DBC3UF3G?Z@>]L:R-9[.6,G9FS!M;J,B0CW+8;7Z,HLVR!](@XA M?A5E'$BA+%*%CG+MAGB)T$3]>RY8:^CA<:ZXRP*Y%$^\Q.4; @9QNXKM*BA+ M6[Y$)<5"!U#=?<;V,_"O3I!CZ9ZRZ="^8.U6_QOUH_F]=1/8W+EX6;MYIV\E MR^Z=>#1M/&%S)Y&#@MDC0-:"LTBXZ)BM.@OO$7 XE_VMJ-28.E/AZ?5TY@R? M_>:U.W/'B[XW<).V7NN;I@]P]W]QV\+P0[ MY"(7W6/3W)R'DB/1IQRA27RR$4PT9\,.;=>[8+J:A?=4H8D:B,5\,H#2>3&C"^H2T MN3$I8\TSY#7@!.\)!7UW[2MW[-[FS"8A.Y\4-W8NV'6K^\! CWTGB_FZVVOU MVMW6#4'4[?4'#]]OH9LO 6I7EA?A0&1\?8%CZP5X,[,*2A+7I:3$ (".DP>@&6 &O;GJ'= M[?P)LV&(&+,I00^#YO7"@"M,Y?U 'UX^"!Z!9^"89,^*:29<1T,Z2(:]8.%N MM-1LJ6<#O )0RJ_2+9>V/\Q,*5JOPO3_:4Q (-#(,Y@:(]M?KK*PS^^6,>B_E>4-Y%9!=H/;P;3/ I S+_/;/29B.9=<79!=2Z" M $7/5LQMI+ZE04ZBHWIKAUCIJ>U+:7Y?[N:94*9- Y]83.ZEOVLR>9G].[*7 M% $'YL;.J+'[]F7N!<,7.ZK+[]#ADT\509F"A"EX1I$9\,Q0M\@%L!W'IB;D M@N&5AZ1\ _FERYJB1Q0%GD%AC,#?IPQ:I:VL(^[-B%_/3@Y WQLAEN<)\;NU MH _";7=G4QETP6)+P_/$_ENVO\%$-X:T1L/7 "HJH@YK0Q6]I01\UMCGS6W7 M1#;HO.$:W%]YRI[C]07K]MIWMQTV:/TS#^EN&G.1P5@A5DFA!I>RPO3A*4UH M44ZX]VRC8.;NT#$>!7^U^FU6KQ0+2O&(O-UU@ -=A'4CZCF-&*H0N4Q7Y:V% MT"L5IP8Y]H\4TI&F9W@'<6"H>I$SJ3"<2ORN_Z3W5T2'"1*! ?"5Q<7%\)9# M@6AA@AM^U0;C(OZ\S&F.7I$\=Q/CX37+D-AL?<1PYOV>(P>0MQE MQ,8XBI\?= <\K38H)>94&C+D!0:N!>Z'[?!ST_B3FZ_GJ,S/4;WB2@D*%[=3 MUF-0_0)=S>$7^<6 0.C!(P8=_].[I!HG0MI@J+4%84_+MCQ2T/+G8J M<(+^CK[%)2"QI9]K#S'L"Q1H ]\I%?@?PM $[@7.:OC=)5[D CM2.*7A*/$5^ MD9R!5]N:W,\^EJ,$$8"I$5Y+NWS00);K[ DL8Y 9"KCRU$B<(4EO7Q\A%?A' M;FJ_ J7O::@!YM4$X,.2O3"4D6@> H4JJD!J&V'-<,SX_JD6>OE3F2KCRDC( MJUR([&)@OHIZ30M/P^2R2-A1;1L&)@KBEGMAE].X8GL6QL8GQ-C!(5M,P]UH M-Y41&I%+2*@0WI0CCA)G)*BY$.!!I;7R>DA]?O$TW6N?BZ?-Q),X< XJ#Z.* M:0@?#%1I,-#3,Y4R2GH P4 Z9*@[#E'X#RR_4\)7W^P?J*8++%X9VV-JY$#\ M3)DN2IN*?"N3;V4WN/ 2;\T$C6T&II@M6 TVE.IC\6:3.8$]G]O::O=5R>\' M](0%1EUO0)E$3 EAA<0-U6\3$ -[:@Q##7>N-=-V^99Y;_->7D>6>]]SIX^) MAZ?L['U5.1$S]=JLTWKH=7M?Q>6:9S=W_?Y'=M]Y8/UOK8=.[@VN)SR#V (+ MS32"IQ^PC.BQ?4_ MY3!T1P>&<4760)CI2T".T,!_U'I M@4"_XG$#3D14$M"-0L7G'Y-UJWL)@P64G8G HT-KE=("*63RL M-K$Z?OE32W,)5]C=")GPK# >2LE (-;X-+R@(==!B3(&:0/1.""38"JSJ^3N MR0PN@XH'IS,98*0V"WZPQ*)S-%(H\BQ)>-^H:L"&T)_4?G/1$L2%JVS24RQO M*(QY_=(:48D'QC_:MGO:25S?P.R_^AU[;/;SO._UTM^0-.;=;?]PV:@M3(?\@6>[OQ0#5RV2XX65$Z.8JU'$\X&@?..=2MI\ M]@;C+)0K#<%%F)G\;GS%'[T!!N;VQ&1K];A+3DZ1OG:/E$F =&/J4Y=_9OZG M^49Y_CR$NZ%N^E3X:'N>/7F#*W"8Q=YT2SOY1)E(=I"+CI'T.5P/8,_Z[4,Y M0)5X[QD_6#VW;95UC)5%Z?>H:MA5C]8T)BG%M=X]?$ M?#O?7'/S-Q&C*O:HY?4V6-*:A7I1VPP#FZ_C-' G6E;O ':6#9\+^9MO@9#)D0Q?8\.V&JIMIAW4))E4BJ28ED+17<]!5@^[3:HVM M5[XOA750)37 B]\!T*=7=J\[GH6M""_QB!_/# <.3+VFB%'G+L5W*][I^ZE2 M4J.R@9 ]- 8RA<'=(>_P>BI%5B0MY'=73ML_2>23; /]+VMN\CK>T?9&9K%< MJ%>36IF[4G#O%?FEG>GB^6;VFX>G5L6;EL>FY%&/2ZQ[8^N6V[)&\MC(>GJ@ MPI4\=!4GAG<5H9H7V#Z):^LHP;T%<](,51WSRG<1LSID@.IM@T+R5+6QCPB5 M*&.$K7$]!@;_A(]P&1D)0B4 ?5WUYL^@;1IPD7JK4$QL,V0H,I5=A!8+E5)I M!P@](B\]>_&5 T"4!9,>7V5P!I(') M?#?2TA[K87)/'N;:7N.JY B1QSW0?[:HO A&N@F+M?*\B?25OR/"&\6+QA;W M(BT]EEHL&/N\(S;!OQ]>W%-3?'B=DH?O4AM M!A5OJ*49[J;&]=K@;^*>))ED^T28#7V;ZE+PYHXCTH:W4BB6:X5&N;(9W*64 M]F[?/M1.V>0.6UX<7FZNM(GH'CYI%:W'%P><>K/M."^>'V S]N[A[92DOSJ8 M=1]34)X9,M]2>NYOIOW*Z0R1%W+ZK/]D3FFT&W_)#BM(1] M+[Y]RU$*8U9DP96$!>\RU@FT7X3Q: E9C]KR$PFSWY MKTO#%M4=87$'U7;<4B+#X?$O7@#^Z]FBFG!S>JDFPW_,C.G#FX1DRD6MUL@. MR'.$0Z4'6'F0@%+2PSR%1-0A-B6&1B7"CPOC;C1QDEU-?=)%A@XSX?U$>#\/ MGM+@$VS8NMA1?PO:6H:WS6\LX8OE>G6)B(F9)@6HDNR@5EK.F$FAZE*3#2T- MRZ#1*-4:M3EPY/@Q]U ,.1^Y.%4[O.<1DT73 *5>KT;H9L5T6T*VKNTRIWYW M!QB@25-05CXO:[M"6>*S5E O*Z"V^U=@[K4JN5FJ58*05X/$'\9="/IFZ\&MZ_N M;C&-!BYF&W!BF@<[7'>!FL2_N]85=XP7'7O**/Y-&N13*@/U-*J1UE=)YHZ5 MEF$R0=1BV%BOE(H+:F79'%L#E$BE%"NETH8 A<^Y::K>*(I63[(]2!L@:3V0 M%ESZ.__\^<9VW38>/_NGSYNBK%($FB]75/F3>,ZWP:7V]QM"5EP%$P[\YO3B MW&9GB*'AWP0B"+FW@M:,.X-H<:XWP<-PYPXV"(9-,O66P92W,1+.L>"FI,Y* MFM:HEXL510 E9QW5@O+]GV=C"DK34X]:57]?VPY>,Q=K5:P&=XE5 ::F)@SA=4%( CI) MX,AKB_?DI8'Y4K'8?&,)24")+.D&31)XY@&;_9DRIIF*>U8-\1T_R0)SSSA. ME9ZEHUK$<6/' #"P[\9C8P@D?.<0BI]M$R]OW%+(J'&@MV=9SR"/\7Q"R"KG M6N6_Y,S_U::F?#1A@E!(16&8A$"D"'CU7"MM"+A6/3#@C6,%O+DAX-6#DDJ$ MQC'MF+NMT"T\%FIO;KV$+78AN.,5E;9.%S+?/9K&D[Y@-(0PE\]+;UE6BM2+ M'7G1@E&7#%(:Q2,*;%)K?HO/Q$+X?HDU4+P 1&FJ!9-DVO2 C?7YE@%[8%CG M@NR2-F.),R3@(;=TL$;$S=YQE)OQG4FRVN-8D+]]:\N6?2Y(3-6:><^V0UWO M$S'X$@#)SI\/>J^:;7O8%OEYN1MR$,C6W/YE6[\_N'<@=98LJG:@'5E/PF0$ M^,VDR1+@F]OS*5X2++W)+;-4HE LCKOQY LH>U,WSD%6*S6:ZP.W@$<1$]AR M4[?FM6JE4:Y55N^X@'2[->U3[J4![_[D7?EMEDMS U(1Q?>0W!HJE% M20'R3-%/NDO;)R7M9E-2(:=DLC-F 10.@)%GU@C $FZ_>X]W\-DSUWR]!VV2 M1I[)>24(3:^>;$NXRDK!>Y;@BBG$7TOG_W2-SY9A_O;!U!"U3#;UCO17M'=(ES1_4H;QC10Y<=[)1VU] M:GBZF8;XTBHK\_?F9MP>OE29I;X)["3P%FE120E4TT[C/*_MQ4UJ,*2*SF9= MY+MN!-U!EK:16$IEF7$TAWX"AAG_57 MNJ;P;GRI6W_>P5Z-''T0IVP5:N1Z/P^50Q>4/AR=T_J6QJ+'4 M%(_UJ< KUV8=5S+6EXVM&P=U4RN8X,RFP-LE#B#@K>P MX!>OIDQTI+05H/-31M,##)>:Q@WL&_L'O#!P='32[QTC:2[G$MAJ5?_$?\4, M,ZEA78U6R8$W\QVBE:S)9PLMN[U@;M<=X:8 MN7O%7[AI3_'Q]2)$J_.(ZPLUKBOG7$NV!,G'("]>0(XN*ZJJG9>:/L1U@/YM M&5+12J5**:$(60!C=4#_"F^ZYM8("0>&N<*^I,Y:-87II=A<+,^O60'FDFS$ MO:0*DVRO:PNYA\F3)O>2&%PMQF9([@C*3;. ]POEIBF_6AUWO+(7,%-)\-TS MC6Z?SKLIAM<3B\NLZPV6L$27_3ZK4&=P]_L-[=H/.9VF(I%_C$-"'?,4B#;]T^:]UV>E?P_P% =5%B M@SOVT/G:Z;'+[MW]M];#;:M X'1[;=&*JU'2ZE_Z[&SPK*_>?W7B>X((J=*8.IG^\> MNE^[O=8-N^[>='M?(Q-T^P3;90=^P-]AT/[=3>?F#UP&+8QFO;Z[N;G[!SYS M?_FBX 5?4.%Y((I?L776ONT#,P#7?[Z]:@\X5@7/5[;=O M[OK?'SI]=@__ $J$A[J]!5)^B"/E NO\L]VY'S"8I=N[ZK9Q7-:ZO/N]<\%: M[?;=PQ4\=?,'K"8J%Z[N.@07P?#0N;[IM >L\SO\!'S4;G]_>$!&:5T/.F)> M!'@9.[6 )?WQQ#K_"%<);]SUX7UEF:WK:Y@-X+S\@_6_7_8[?_\.\Q(D @)U M5?W[3AL0UV[=@ 0 0#L/G5X;WOT&'[J]"U@U2J062@":7QT<@258#>!Z7[OWGWO WEU^_WO0!37L+&]=A7_WN&I^N>S;QG3H#8C@$CZB8SY,DKL\?L@3]Q2S%&7/;OF0Y^@&.^ MLK&X=P;>)T$C@C_=SAGX-5YSVPJ#GN POF(1:ZJI$?!^YOJUBN8 MHC#NQ+#XB.#QGG6/_5*'1\&&1UBX" FY#(C=?K*H4F!$ECP-(P&+G08L_)E) M%U^,@17H\6"5"+&)]Y7#A!8;ZX;#7K" 2"!E#(R$SBESR4]@!GS2/<,=ZX+A M&#T11/*91;=I&2([^?$ULD#WV9Z9(WR$/>LOG#UR;BF+N<@(>1Q .JX&:/", MNX294.+J$FP_0[" 4VB"X",D#T,A^#DC<+^-R$UN/BIEZ-I=Y7J?!'V-Z9DY MCX>!J=IK7R3L:YRXVW3,;;3J]NWF$D-UUL.,O4$O\[3V];(%+G>[P_K?.IU! MOIV[V\X5[;Y7[? :/=JW'29FMY;UT=]\%_<.[ E EE/:1I>-M]#*6[/S_G&L M3!^A(4.6^TFN;YV=RYEC(Q1''*WC(Z)\/W+2WQ359S-+GXW VQLMOUWH6$R# M4\=\3N+'(?NR"]E6!(M)D)BCO1MJ#:ZIVN!6LE7X2V)A]?L=&8;/H/C+'E5)0 ::5BHU!ME-+%6_JK//:= MR#+S+R$F!'*Q6*5>T$D7(Z)LXQ#7-LI)@! M\W$+T2;;8S%9);GOP[NL$U2M4&HT3Q GN6C+%+JR28E';;.UAD,',V?]Q@&Y M_;94:1:*C=Q\RV7%,@3?AK8V#33;XG8HAZA)\C[6X5*2HU"L5@^ M0:SD$C%3Z,HJ+1[:[LO6]N5,DZ,K\\-D %T'MZ2RM2.GL[''-$R.KF-#5S:, MC02FV.!NT+IYAVE>6;52CVF8#/#9,0US=+28VSXYUQQ\F!Q=QX:N0]L^6\6> M;[JMR^Y-=]#%AE^]*]8?W+7_]NWNYJKST/\/UOG[]^[@CQ.T"#) -LTZ;I/_-JF(4:A%HSG1+2;.$DEV^90EN)6+M2AJJGCCR0GB))=JF4)7-BGQ- RV>^&/GB 3;Q?? M*%2+>:@MEVSODQ2/VEZ+EB KB1HGR,Y;$5:E6BCEG1ER(?=>:?&X#3@AYG+Q MEBF2.J9AQH>O0%LMVE4'V9&);K._9PS_9V2\7Q6)1@_$<]J*;,_Z1 M58M%/*/ _S/W67>XR_29]VP[,,Q(6;:FE0O54K50;-:8X;H8H]>M$;-GGNO! M![Q87L?+0EGX2N0F17JZJA6:Q7JAJ=7]N98,U>=3CT\>N:/@/?@DAZR\)UF: MQ)K7"N5JWHTBRY+DF(8Y-E(\N(6X;4/Z,7<<$(4DJ0NL.">I"_!L**E#$4VB M\]IXX>S6,$T#1+WZ&TGD13DV@2Q&FMHHFS$C,88D;I$ M^N;6YY8$GGOTN9A]=U1XU-9L"][TP!/737:/E\P9%AOJ4\/3\W3FA3!1J=@L MU)JG&,K- '[/&H4FX+=23K-F-,&\[^J4,P$^2H4RF%.E6EZZN];!E>4YQN/, M ].SG8O/& S52XU"K=HX0:SD]F&FT)556CQJ*_&!>[IA@7#KZ(X%8[CL[(J/ MC:'A?63Z<#B;S$P=9=]HYJ S[3US-N+@']O3":>1]:>\%=6+A0K M:>:TY@;/VANQ"[LS*WC) 'K/2H5FK5RH%=.\&3E%,C]NPU-4L- Q_+-MCKCC M_@?K_'MF>*^AA#Y!NMZ*WTN%>BEG]MP0?9^D>&@[-%N[E_-,CJ[,#Y,!=!W< M2DIN$=$=@.K--P+N+N(!5.?ND K_J=A]:@>]=+?*7QP5&7CYV0G+*OTI6UK:/>AQR;6.?0YM!F'=H3@.SD MA,[^W1&52I,$&9X=SMD$?GEV&;=&?#0'T+9.R@YYZ-2&3K!=^@@]*$Q%2*?# MVZFA,&>F?.C$V]4S+,YNQ6YU\MW*^&[EHB_+NY-I7MJU67EJ^WU84HJ4+AZ> M>/*A\Z%S7GB/0^?[DP^=#WVLO) ;?9D9.@'QG,TL?38R/#Y*)WOIU%"8#WT2 M0^>>IZ>#:&8#YT/G0]][$,? M1.[LRO#R9TVQ&8PLIJ@4?TV,KX?.[YW>]T[B-/1D$)1^38T6_ *1U$>L_;I- M\5(Q782EO[PCWX(L@WWDJ,VI.]^"? NR#/:1HS;3U)V:E;9=TX.L5$SLQ&;/ MR^9S=.7HRM%U',/DZ#HV=!TZTI+8S&G?]0>LU;MBG7_>=WK]E,(L.3T<\3 Y MNG)TY>C*R# YNHX-70=WW[=LN>]RW1D^TRUT5V$S_?=D%B1 4ZU1*#;2[*"? M%:2<#A\>TS Y*683M\URH=2HY[C-V?Q=DN*AHQA;63)?N<4=W21#IC6:&);A M>HZ.]^>>(#]O0UF56KE0K^57E>=2+J?%S ^SE0HIU@KU:GZ1;,[H[Y06CSLT MT[8M=V9Z>-,AVC3WCCWFKBLNT;[F/)U&6Z=#8?5RH5S+A5TN[')2S/HP6UF, M6KF@E7*+,>?S=TJ+1QVD>7F(9CYU(225JAHN0+)A5Q.BYD? M9BM#L5"I@JU8;N3HS5G]O5+CH0,QV=K G&UR=&5^F!Q=.;IR=&5DF R@Z^!1 MB<0VCKR>N_>5W=SUWU71;@+DG*7O["68=<_-_-X+3Q[3,#G1'OTN[,)YS/)D=7CJX<71D9)D?7L:'KB&(C@V^=!];MM>]N.TR 7&Y\ M86=^B[/=>;HRM&5^6%R=.7H.FET'=J=WRIYLXO7]7#78UUK:$_R;B!1 M[)2:>;^C++/>,0V3TV$&$=NHY%F:.8._0SH\> !CRTK9,8#@,GO,] E X[EL MZO 7PYZYYBL,;(Q.D*MS=LS1E:,K(\/DZ,K1==+H.HVHAJQ%?4_60 +TG)4+ M5:V4(E(2S)F?,QWO.G.2/7V23;('6J-0K^2;D,N-C*#KV&GVN(,P;7UJ8.>/ M(?SF&(\SS[ MYDUA2"=O9+:;&Y2SA8]<&F8*73D5YFC-W# Y) WMR02^=8N-=<-A+[HYRP^2YJ)KS7*]4$FUR7^"6=]52#@!/NKE M8J&8MR;?$8F7BCF)'WX7F@5-JQ4:U33SH/-]6'L?&H5FL5FHE-,\4,D*7C* MWFP+F]3,N4-$?.X=/N:.PT=^@ =#/_#7=.9@",ACGGV"-)T!)^"8ALG1E:,K M1U=&ALG1=6SH2LU .$B\A_)8]*$WTTUF/\*P.F:TY-?8S"=BEM*\'2GWP7+9 MEA/LJ>] H5+/J$][$GN0%0"S-O0P^3HRM&5HRLC MP^3H.C9T'4^NYIG@)C'M,P6Y%MHYP3 M[>%W02L6JLU*H5(KYQN12X]LH"N9TJLUJH5BJN52)Q[ZMY\'W2NNAU>U_[,KK" M[CL/K/^M]=!Y3S9 $I.S>%'4*KF_>@K<>4S#;$NSQ:QFV[^C3=#*Y3R^D@N. MC* KH> H9?56D*,)KORCT_WZ;="Y8JW?.P^MKQW6^WY[">;5W35KW]W>WO7> M$Y,FP)>F%0NU2J-0K*:9^)05S.12,%/HRNGQ\ BN-PN5:J50+^5W1>?\_G[) M,36#9N?!(@H,]=G=]T%_T.I==7M?3Y!Q31[Z:JOI:J&HV,";<93W^@SW8$]TJB"\*K,\=8_R%373GR0!(BU^8-!P< M/HH#>!K.%/>/+61 QN% VY*;I3O6A83W]]J'X@?Z6C>CH[^CDI;$L_CK%]@I9\0=-)Y,?>J"G>-_^A#!<&AQK=KJI+NZV7,(&B#"^NU# M.07*RMK8*\W<-9&>P(I]Z'SM]-AE]^X>S-G;%BM@@OE%0DOV>+!Z0CL&WL:@ M<]OI#2AVVNI_8]'^])P)(]P^+*M,&G6WCVV64=:\1'"7GU+6CVO[C6Z%\SUYO 2^LV M%L[.&K;:H)1H. VL9 ZQ_SFS."L7"ZQ4U-9-A]G3*DX8K^^6,G.(4J&R!^YZ MNI>NZ /O?XWCDZ20AJX)NWZXNV5W]YV'UJ#;^\I:[4'W]^Z@VTG;:=EF6]<+ M>!WJN1SRE$S6.)I?F@-UBCC+(3]:.GW[:%N&=BNU7Y/;V]QC76MH3S@[,VW7 M73=K5DY9_75MY>K'H9/#^LMFL&G:KXVPSH_I]QR>=+@]5KHVH%YN456?;%X M(,V4!2(]*.1[VIV=:XQT.'$4SX@&QB:YZYT$S::2:O9,TK.)\V(:>S.$6C$ MMCV9V-8B%_(=JL/W3'GO%/(C44EQQN%TYK@S'5X%UWZ[FY2/5U6M[U5RKJ/'4==58J:(F3 MKY,.FG9M41:(.NOJ;,\;>02:[\SG\8_,YW%D\9[M@3I\X$-NO+P/%M<*M5(S M9_'C9_'];N0QJ/$E/-[U3PO#?0D^O2?.;U22-LW*^3[#?+_/;3P"Q1[:[BQB MO%_JUI_L#F <.?KX]#,%SFH%K;Q6/#'G[VSR]WXW\ACT^A+W7!\.'0PDOYNT MO%*S4*OE9ZS9Y=V4-N@(M.X24_O^_V_O:IO31K+U]ZF:_]!%;6J=JO:D)4! M$J=*QK+#7ANX0&;O?MIJBR9H1TBL7IS)O[_= FSLL9/&"-0MG0]) 8:CH^>\ M]M'ITQ%;4J]")LF]M=F&Y;3^IGMD06H5=KEABV>V-' 9"F?$^(I[BWSPV]H M1KT(W5$_+?_ZN8,-P\+MIN9M%3*VT,8=TL'RVQ\U=VPRD9VT<,.L1&C?-GN; M4Q'MB]1'0Q'7^4==NO02ZI?>W.MM@@UHOU?8)O.2T,%CL>P-B5D'71K/>1H= MWGE3OK2]_8Y.OL1,&-Y;-+COV+!=;I5W69M&Z>WPI-VL8ZMM52,4E=I@UZ(L MSW-I60Z?SIRZ[/7M?A=F3@'G96FW,O/84-95=B*&Q$U!=V^997/H2)*#56VO MV[K\[Y%WFR;*ZMZ+ZS\("=PT>1K='! MS?9.94#U5+C4QI>3@/2+;QE3X@"BE:$M-3>T3LO:BBG 171^RL)&U8YR@='%82DIUP#J&A-+I14WM[?H7(KVXIJF[ZH]M-Q>L-ORST8Q,"'07:$KYZH$FZTQUBLS\BIF1A;TX6K*^2M,")8/ MP+E"ZKA;LRG_0KRDP5G-J-=>[CQ]?.BQR\282&EG.)FS;#[T@E_GNUA'K-I0 M>6#@ZXMLY.37*-LU'R5B%<*_'K--2QW_?)S0)%NOO-Q2]PQ*[Y*LQW7[H^4V MDRO^T,1;<%;Z[!L:A0L:X-4'&(U9Y,T^H 6-OGK\CLEC ,3!Q=[L^T^0?BS0 MI?CLX[LT/OU*Z?+]>F VAV,]:-X.IDX4A5$WY('3S0Y"FO!+GONA^\>G7W\1 M(OLXNCH?OA^[,Y;$$P',/>GL M$";^9L1F9[7+*%R8Q&B<&N24&$G(7S=/B75:)[5/F;Z(GW+Q^T)GQ)+PK$9J MV?NURF3O'Z-L_ASES>G6A+SAD(;1E$4"3I\N8ZY'FU>UG:S@Q\IN2BOOR+ER M^NB\-QA^MDWKUH,[9R"[6OD>FY?V_VN@\:? M'6<"XCR<.'\0,'\DX1WB[KYDGI'62Y'U]5(\.K,EX PT[57YEAWS-&K'I:X> M=T8?4II2WM\ND@/C>!7$_T@#ANH$(Y';ZJ=$( ]0_=="?9(&-)WRY>E4=J*3 MNJE!V9$'%=?#]ZG+V5X**\Z H5Q=#Z.MFRN_9B+%C_"3R;#&8VUS M,++\+F=)CIIO$RGSKCJT&6EYT/K>7 M7Q5=$;L?KUN*,"R!CF%BTI0=8*\3*.5)<70BHYLJ*I ^[N':7GG66544:I?S MM'3"!%R;4G"IJ8E:YVSV^ES5S;GID+^]�Q:4/Z!CZNDIJH=_:VQ;GDJTDH M-A=WTRABG+0=Q^SH#5NJ:Z%IMC$AL@,[=$(%/*)2<*FJBT7G?6J)#XP&X%*> MC )P%9Y)J261\@A6)S( EVYPJ9%L2*1BD\'$OJY@FY>J6:I.9!2P,YW(:*>+ MD/N U11.!N#2#:ZB[H=IH16O%>\;&.CT2HA*.#:E()+454L1>8V8@&XM+3N+4$A\8#<"E/!D%X"H\*9)VJL]M M"$(G%\YEK]N;'/N9AQ,E,MV[;,.JX:38QZ5C(BV-1HZ?! M%(5I$B?\!><.47%8*'KXR:.3%+-O-PW<(2W<,5J;:[U :LR6"5OP/4F3*-0V9/H1$8W52P\0]QW(/V,11%WA9FGQH@\\=28?_?! M4S^XZ,QU7GIW#-UXON]Q5[_]M\PC_]4/W[O7S<<-Q)WQDKD))^1_+Z$/ >,' MN$H-E]9)ZIA%'D\&;?3@!CL/SLY^[.RVO1]&%L'-1AO7K<;ZCW_)2)]+(1]< MHD' )>X>X"U,FL<^K%XC,@KX YW(:*:)>F>:&U^[[6S_]C3;Y&[UV413^$;1 MT?B,2WW!^T+VN:>"PXH>W&SEM%#K;-;FOTSX2ISZ:"@.F?,"Y-*EEU!H9_Y+ MF<@D'6QUREC*50#?DS;N<'P;]3SWC$I=ZR5M$73==I#X5OF^:1F(QGLGW!P]=0KW>R]Y-W#+!V"$1K:8J%IV'JB4]L!F 2WDR"L!5>)8DGQ%E M9P!NGWRSXKO>_O#L^3?5W.XB 22<&*B^6>I$1CM=W,GGO4NR<>O\HX_O1E?G MP_=C=\ZFJ<\&,R>*PJ@;1I%H&@F#V ZFP\@+HR'C_T_MZ7_2.!%ELOB<^C1P MV7C.6!)/!+T)1^S55[A/Q#M/F1O)]H""?%&0_.:BWY&JASY?31>6\P_&R/;FR$ M4:_?_4U6)>\O6,]!_X!V/K1_F+L<5IO&$WOBW#C]"1IH(\X@QM.!_ MF<>(!5,V?<+0ONN0 ]I0V4A+B(L^K'5 .LI)!XQ)'=(2XNI[ 4,W*VDY("W% MI06N3V7I*&U+ATXKRR;O8E7IT>[$XI4'2 -IL(4JD@;Y &D@K:LM0-*G#&D) MY3E) YI.O81-\VE0*AN$0+H4I,$25"8-T@'20%I'2X!D#T@#:2!=L$NDL1B; M)YJ057"*0!I( VG=21?B=PZ5>&VNFN.\E_5FB@9Y(XW7R/G=Z7]QI-O0Y3@P MW^2F"YL-(KE3M-[LLS^)Y M8_K>GN0A49EMS:$&[000@ I79UAQ:I;4[MRQM MO[D&JNR8.$C.#COC 2Z "^#2@PS I1M<15=:I-.<[F \07;_ CG_-W3ZXYS* M+* /&I,!N N@$L1,@"7;G 5OGS?YN57*2V0@,EJ8]+. MJ<[$O&\AFT51X-:]5QW0)G!\X.5%%U,GMEC$8=&R9D MC&#G%=5%K8LT(WBT]!02P\(FR:?[6"U0P)\I!1>H8K&QHHY)"Q[;@9E74Q7U M+L6LCCCOAG$29[48Y\\E"V(HP3QM33 -W# @@("3 UU4GLQ>B2)N-'FN6&\# MO&#J5=7&H@LQ:@D0S ;@4IX,P 5P 5R*D%$ KL*K$M(YSOIX[OX5NAZ,*[5I M5P*Q)7/?(POZK8I$YD0&FUE\(A%H\@!W >U59;J(V ?15-!N "N N M1<@ 7+K!I5%M9/+9&:%>OSNX<="*Y7K[ SK9C#B#7%O?^P2X "[ER0!< %>I MX2IZ.;]7\V9/'-?#X@3U C=P-ASI^R,LQ"C<(;H@G.3Q&@9L3LO3&/_.R?L34MHU6". !? I0@9@ O@ M*C5B5BD;D(#GI(Z;AIDC*!+7A.=,^MXGJ&SY559&!D8;MQH@!/ ; MBL"EN\[J783ITJ4G)G^X_&^1=YLF7AB@9,E)1C#([# G**N%!WA#I> "+018 ME2,#QEU6+2FB0'0=QC'BZ8H7QRD-7":>)+GA8L$_BN<\?XG1+(Q*:-5@ MC@ 7P*4(&8 +X"HU7'K7-WS&X M:J5*PA)XM.H$$QA-?B 5-PFH>/%2Z&##L'"[F6YP,5 M57!1 %ZUG4UNZ5P1%9]AQ&8LBMAT4^ 1I1_^;IE&H@24H"0LH4XKL C0B0S M!7 !7(J0 ;AT@RNW!*&0>D_6QT+=)*4^"F\Y62HZ6N 8FZ>-F&:>IR/!&@Q\ M&RALV26 &RU%U[2ED($J#*I%IJPJ6W091BTI@VT!7,J3 ;@ +H!+$3(*P%5X MH40Z*9D,)O8U>C1$=C,ZME(IMDS.V&D0W+%@L5D&"]6)S'Y/G U0VN*ET,%& MO8U-TP(Y@/-0 RXIYV&V<:O34%-IH4X"UE4T&8 +X *X%"$#<.D&ESYUDKXS MN:^/B$.(*Y59RZ2*!FY:)JZW8*59!L/4B:MNN@](6+P6#X&:G@1M6'00! MWD,-N.2"GM5N8I+K=JG254@D;NC<'O>ZR.Y?H,LOU]?_0A>]ZR\3YP*L4]O[ M!+@ +N7) %P 5ZGATJ>^XMBC?J]_-5Y75]#0&:'Q9WOD5"D'D$DYR6_$:,!Z MM0S6J1.9?766J-IM7R$A&/4ZU%? <2@"EZ3C,%4]%42;XLH_G=[5YXES@>S? MG9%]Y:#^EYMSGEX-+E%W<',SZ%?)2"7P,@R"K48;DV:>C4^J( ->4"FX0!^+ M![C5P8UF [=,."L:[+VZZIA;0G/P8E%6&!JCP9?)>&+W+WK]JQ(:+E@
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ɻ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end